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1. General introduction
Parts of this chapter were published in: Veltman JA and Vrijenhoek T 
(2007) Identification of Disease Genes by CGH Microarrays. Encyclo­
pedia of life sciences 2007, John Wiley & Sons, ltd.
DNA
genetic blueprint 
with the
instructions used 
in the development 
and functioning  
o f all known living 
organisms
1 m Introduction
L’A D N  f a it  n ’im p o rte  q u o i  (DNA does w hatever) w as topic o f discussion 
in the Science Bar at the 2005 edition o f the Science Festival in Paris. The them e 
prim arily  reflects how  com plex and unpredictable our genetic m aterial is, and how 
m uch d ifficulties geneticists have to fu lly  com prehend it. D eo xyribon u cleic acid  
(DNA) is highly plastic, g iving rise to a plethora o f genetic variation. W hile  m any 
years o f research have significantly  increased insight in the w orking s o f DNA, it has 
not brought us m uch closer to fu ll com prehension. Each step closer to unravelling 
the m echanism s und erlying  genetic variation opens up new  areas
7
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Figure 1.1. Schematic 
o ve rvie w  o f genetic 
variation in the 
hum an genom e. The
grey area indicates the 
primary focus o f this 
thesis.
of research w ith  unforeseen questions, resetting hypotheses on the architecture, 
content and function of our genom e. As the full w o rkin g  potential of our DNA 
rem ains unclear, I ’A D N  f a it  n ’im p o rte  q u o i m ay also reflect the DNA’s potential to 
do alm ost anything, and provide unlim ited possibilities for disease prevention and 
treatm ent. The potential im pact o f DNA-based applications on general health care 
has increased the dem and for a com prehensive overview  o f all genetic variation in 
hum ans.
M odern history of genetic research started in the nineteenth century, w hen 
geneticists avant-la-lettre  Charles D arw in and Gregor M endel published their land­
m ark papers. D arw in developed his fam ous theo ry on natural selection from  the 
enorm ous variety of species he observed on his jo u rn ey  to, am ong others, the G ala­
pagos islands [1]. M endel perform ed experim ents w ith 2 9 ,000 Pisum sativum  (pea) 
plants, from  w hich he deduced his tw o  law s of heredity, w hich state that alleles 
segregate and assort independently ('M endelian inh eritance’). W hile  controversial 
at the tim e, both theories have been the basis for groundbreaking discoveries on 
the m olecular structure [3], the chrom osom al organisation [4,5], and the base pair 
sequence [6 -10 ] o f the genetic source und erlying phenotypic variation; our DNA. 
The ultim ate v ie w  on hum an DNA -  the draft haploid sequence o f its nucleotides 
[6,7] -  w as published in 2001, w hich reinforced expectations about diagnosis, 
treatm ent, and prevention of disease [11,12]. Represented in haploid form at, the 
reference genom e gave no insight in genetic variation am ong hum ans, w hich is 
required to elucidate the genetic background of disease. The first challenge w as
Mendelian
inheritance
the typical 
transmission process 
o f hereditary 
characteristics 
from  parents to 
their offspring.
Also referred to as 
Mendelian genetics.
Box 1.1. A detailed understanding of heritable variation: 
the reference genome, HapMap and GWA studies.
The human reference genome is a blueprint of human DNA. It has been compiled from DNA of 5-6 individuals. 
While its publication represented a milestone in the history of human genetics, it did not provide insight in 
variation among individuals. In 2003, the international Hap(lotype) Map Consortium was installed to develop a 
map of common patterns of DNA variation across the human genome. The consortium has since determined the 
genotypes of ~11 million single nucleotide polymorphisms (SNPs), their frequencies and the degree of association 
between them, in more than 1100 DNA samples from populations with ancestry from Africa, Asia and Europe. 
The HapMap database has been the starting point for an era of genome-wide association (GWA) studies, which 
aim to reveal links between individual SNPs and specific traits or diseases. Structural variation was initially not 
considered in the HapMap project, but recent studies have provided extensive insight in the structural variation 
that occurs in HapMap individuals.
8
single nucleotide
polymorphisms
(SNPs)
single base pair 
change that occurs 
in more than one 
percent o f the 
general population.
Copy number 
variants (CNVs)
chromosomal 
deletions and 
duplications ranging 
in size from  
ikb -  3Mb. They are 
known to be causal 
factors fo r  a variety 
o f diseases
th us to develop a 'detailed und erstand ing o f the heritable variation in the hum an 
genom e’ (Box 1.1) [13]. The focus has in itia lly  been on com m on varian ts w ith  m od­
erate effects, predom inantly single n u cleotide p o lym o rph ism s  (SNPs). These were 
hypothesised to explain the m ajority o f disease burden -  the so-called com m on  
d isease-com m on varian t  (CD-CV) hypothesis [14,15]. The resulting g en om e-w ide  
association  (GWA) studies have revealed hundreds of candidate genes for various 
com m on com plex traits, thereby increasing our und erstand ing o f the m olecular 
pathw ays underlying com m on hum an diseases. Yet it has also become evident 
that the variants th u s far revealed by GWA studies explain only a m inority o f ge­
nom ic variab ility  und erlying  disease. This notion has raised new  questions about 
the role o f different types of genetic varian ts to disease susceptibility. An increas­
ing num ber o f scientific publications has attributed a role for rare genetic variants 
to the developm ent o f com plex disorders, especially psychiatric disorders (the 
com m on  disease-rare varian t  (CD-RV) hypothesis) [16,17]. The research in th is thesis 
aim s to id en tify rare genom ic variants and to assess their role in both schizophre­
nia patients and healthy individuals.
1 2  categories of genetic variation
SNP-based GWA studies have successfully  revealed associations between 
com m on single nucleotide varian ts and various com m on disorders like type 1 and 
type 2 diabetes, celiac disease, and breast cancer [18-22]. Still, the disease-related 
SNPs identified th u s far collectively explain only a sm all fraction o f total disease 
burden. It w as suggested that this is largely due to a lack of pow er in previous 
studies, w hich creates challenges in achieving genom e-w ide significance or in 
correcting for population differences [23]. Some propose an increase in sam ple size 
from  10 0 0 s to 10,000s to resolve these pow er issues, and th us to reveal variants 
that explain a larger fraction o f disease burden [22,24]. W e and others hypothesise 
that m ajor advances can be achieved by considering the contribution of genetic 
varian ts other than SNPs [16,25,26]. Based on nucleotide com position tw o  catego­
ries of genetic variation can generally  be defined: single nucleotide variants -  of 
w hich SNPs are the com m on  representatives -  and structural varian ts (Figure 1.1). 
SNPs are generally expected to be neutral or near-neutral them selves, and to serve 
as m arkers for non-neutral alleles. It is expected that any com m on genetic variant 
w ith  a non-neutral effect (e.g. those of structural nature) can be revealed by its 
proxy-SNP [27]. SNP-based GWA studies thu s provide a com prehensive and robust 
strategy to reveal com m on genetic variation underlying disease. S tructural variants 
are conceptually different from  SNPs in that they affect the structure and architec­
ture of the genom e (Figure 1.2). Theoretically, structural varian ts affect anything 
betw een 2 and 3 ,0 0 0 ,0 0 0 ,0 0 0  nucleotides, but in practice they are categorised 
according to their size: in sertion s a n d  deletions  (indels) are sm all (< 1kb), copy  
n u m b e r variants  (CNVs) are interm ediate (1kb -  3Mb), and ch rom osom al aberrations  
are large (> 3Mb). CNV has been the most prom inent type of structural variation 
in recent clinical genetic studies; it can occur in sim ple and com plex configura­
tions (Figure 1.2) [23,28,29]. Just like single nucleotide variants, they can occur both 
fre q u en tly  or rarely in the general population (Figure 1.1).
W hile GWA studies are the preferred strategy to detect com m on variants, they 
are not very effective in revealing genetic variants that occur only rarely in the gen­
eral population. It w as previously hypothesised that such rare variants m ay play a 
m ore prom inent role in disease developm ent than in itia lly  thou ght [16,17,23,30].
9
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Box 1.2. Microarray platforms used throughout this 
thesis.
32K BAC array
32,447 targets
Detects CNVs with minimal size o f $ookb 
Genome-wide coverage
Tiling-resolution BAC arrays allow for genome-wide detection of 
large deletions and duplications (Chapters 2 and 4). Log2-transfor- 
med test-over-reference fluorescence intensity ratios are analysed 
using a standard hidden Markov model (HMM) and plotted in a grap­
hical representation. Deletions and duplications can be identified as 
multiple consecutive clones in the ‘loss' or ‘gain' state.
Deletions
Affymetrix 250k SNP (Sty) array
250,000 targets
Detects CNVs with minimal size o f i00kb  
Genome-wide coverage
This type of arrays allows for genome-wide detection of smaller de­
letions and duplications (Chapter 2). It can also be used for validation 
of 32k BAC array results (Chapter 4). The 250k array is one of two 
separate arrays in the 500k assays that Affymetrix produces. Copy- 
number analyses are performed using the CNAG software package, 
which produces graphical representations of in-silico generated log2 
test-over-reference ratios.
Affymetrix GeneChip 6.0 array
1.8 million targets
Detects CNVs with minimal size o f i0kb 
Genome-wide coverage
This array type is similar in procedure and analysis to the 250K 
SNP array, only with higher resolution. It is used for genome-wide 
detection of very small deletions and duplications, for example in the 
general population (Chapter 5 and 6). Furthermore this platform is 
especially suitable for simultaneous analysis of CNV and SNP geno­
types. Copy-number analyses are performed using the Genotyping 
Console software, which produces graphical representations of in- 
silico generated log2 test-over-reference ratios.
Deletion
Duplication
10
Illumina GoldenGate 384bp Bead Array
384 targets
Detects CNVs with minimal size o f  i00kb  
Targeted to region o f  interest
This platform allows for detection of genetic variation in specific 
genomic regions, e.g. around the CNTNAP2 (Chapter 2) and RORA 
(Chapter 4) genes. The array design can be customized to target one 
or multiple specific regions. Copy number changes are assessed by 
simultaneous measurement of signal intensity variations (test- 
over-reference ratio) and changes in allelic composition (b allele 
frequency).
Deletions
Illumina HumanHap550v3 Bead Array
550,000 targets
Detects CNVs with minimal size o f  i00kb  
Genome-wide coverage
The HumanHap55ov3 array is similar in resolution to the Affymetrix 
500K assay, but partly targets different regions. It can be used for si­
multaneous analysis of copy number changes and SNP genotypes, as 
well as for validation of other array results (Chapter 3). Copy number 
changes are generally based on simultaneous measurement of test- 
over-reference ratios and b-allele frequencies. Several software pac­
kages are suitable for data analyses, e.g. PennCNV and OuantiSNP.
Deletions
allele 1 - 
allele 2 -
allele 1 
allele 2
-A- Reference
SN P
Figure 1.2. Various forms 
and configurations of  
genetic variation.
allele 1 
allele 2
C N V  (deletion) 
copy number: 1
allele 1 
allele 2
C N V  (deletion) 
copy number: 0
allele 1 
allele 2
C N V  (duplication) 
copy number: 3
allele 1 
allele 2
C N V  (complex) 
copy number: 2
A
A
ii
• 1
. G
en
er
al
 i
nt
ro
du
ct
io
n 
•
• 
Ra
re 
co
py
 
nu
m
be
r 
va
ri
an
ts
 
an
d 
th
ei
r 
ef
fe
ct
 o
n 
sc
hi
zo
ph
re
ni
a 
- t
ak
in
g 
th
e 
ge
no
m
e 
ou
t 
of 
th
e 
br
ai
n 
•
Box 1.3 Schizophrenia in DSM-IV
The Diagnostic and Statistical manual of Mental disorders (DSM) is the main guideline for clinicians and psychia­
trists worldwide, first published by the American Psychiatric Association (APA)in 1953. The current version -  DSM- 
IV TR -  was originally published in 1995, and revised in 2000, and defines schizophrenia as:
Schizophrenia is characterized by profound disruption in cognition and emotion, affecting the most fundamental 
human attributes: language, thought, perception, affect, and sense o f  self. The array o f  symptoms, while wide ran­
ging,frequently includes psychotic manifestations, such as hearing internal voices or experiencing other sensations 
not connected to an obvious source (hallucinations) and assigning unusual significance or meaning to normal 
events or holding fixed false personal beliefs (delusions). No single symptom is definitive fo r  diagnosis; rather, the 
diagnosis encompasses a pattern o f signs and symptoms, in conjunction with impaired occupational or social 
functioning.
W ithin this thesis, w e focus on rare copy num ber variants, w hich have been shown 
to play a m ajor role in patients w ith  rare and com m on disorders, as w ell as in 
subtle phenotypic differences w ith in  the general population.
1 3  Detecting copy number variation
The basis for the detection of CNV lies in classical cytogenetic tech ­
nologies. T raditionally karyotyping  has been the m ain technology for detecting 
structural and num erical chrom osom al anom alies on a genom e-w ide scale. A 
m ajor lim itation to karyotyping is the relatively low  resolution o f detection; only 
variants larger than 5 to io  m egabases (Mb) can be detected by this m ethod. Small 
deletions an d/o r d uplications -  not v isib le  by routine chrom osom e analysis -  can 
be detected by flu o rescen ce  in situ  hybrid isa tion  (FISH) [31]. Yet the FISH tech n o l­
ogy is not suitable for genom e-w ide application, as a single hybridisation experi­
m ent screens only for a lim ited num ber o f genom ic targets. Over the past decade, 
integration of karyotyping and FISH technologies has been achieved as a result of 
a num ber of developm ents: (1) the generation of genom e-w ide clone and oligo­
nucleotide resources integrated into the finished hum an genom e sequence; (2) the 
developm ent of h igh-throughput m icroarray platform s; and (3) the optim isation 
of com parative genom e hybridisation (CGH) protocols and data analysis system s. 
The resulting 'm olecular karyotyping’ techn olo gy allow s for sensitive and specific 
detection o f copy num ber changes thro ugh out the entire hum an genom e, and has 
been denoted array-based com parative g en om e h ybridisation  (array CGH) [25,32]. In 
array CGH, test and reference DNAs are differentially  labelled by fluorescent dyes 
and hybridised together to a glass-based m icroarray containing targets such as 
genom ic clones or oligonucleotides. The resulting fluorescent test-over-reference 
ratio is then m easured per target and plotted relative to the position o f each 
target in the genom e. Targets w ith  low  test-over-reference ratios indicate the 
presence o f a deletion. Likewise, high test-over-reference ratios in targets point to 
a duplication. The array CGH technology has enhanced the genom e-w ide resolv­
ing pow er from  the m egabase to the kilobase level, w hich has changed genom ics 
research dram atically.
For the research in this thesis w e applied array CGH using five different m icroar­
ray platform s, containing between 32 thou sand  and alm ost 2 m illion genom ic 
targets per array (Box 1.2). The discovery experim ents described in Chapters 2 and
Array CGH
a microarray-based 
technology to 
detect copy number 
variation on a 
genome-wide scale
12
4  w ere perform ed on m icroarrays that w ere based on polym erase chain reaction  
(PCR)-am plified large-insert clones, such as ba cteria l a rtific ia l ch rom osom es  (BACs). 
These arrays have been developed and fu rth e r im proved w ith in  our departm ent, 
leading to a an increase in genom e coverage from  one clone per subtelom ere to 
per m egabase (~3,ooo clones), and to a com plete t ilin g  coverage o f all unique 
genom ic sequences (-3 2 ,0 0 0  clones) [25,32,33]. Still, the relatively large insert sizes 
o f the clone-based array elem ents m ade these m icroarrays lim ited in their resolu­
tion; aberrations sm aller than 1 M b could not be reliably detected. As the research 
for th is thesis progressed, newer, higher-resolution array platform s w ere used, 
w hich have been produced by com m ercial com panies. The new est generations of 
genom ic m icroarrays -  as used in Chapters 3, 5 and 6 -  are based on sm aller oligo­
nucleotides targeting random  genom ic sequences or SNPs, and typ ically  provide 
ultra-high genom ic coverage (up to 1 probe per 10 0 0  base pairs). An additional 
advantage of the new  m icroarray platform s is th eir capab ility  to sim ultaneo usly 
detect CNVs and assess SNP genotypes. C onsequently they allow  for the genom e- 
w ide analysis of both types of genom ic variation w ith in  a single hybridisation 
experim ent, w hich provides increased fle xib ility  for studying the cause of disease. 
Box 1.2 show s the m icroarray platform s that w e used in the research for th is thesis, 
together w ith  som e m ain characteristics and exam ples o f graphical representa­
tions.
1 4  Copy number vari ation 
1 • T* in monogenic disorders
Early applications o f the array CGH technology w ere o f m ajor im portance in u n ­
ravelling the aetiology of m onogenic disorders and syndrom es. The first causative 
gene detected by array CGH w as that for CHARGE syndrom e (OM IM  #214800), 
a pleiotropic disorder com prising of colobom a, heart defects, choanal atresia, 
retarded grow th and developm ent, genital hypoplasia, ear anom alies and deaf­
ness. Vissers and colleagues [34] w ere the first to show  that m icrodeletions and 
m utations in the CH D 7  gene result in CHARGE syndrom e. The high specificity and 
sen sitivity has since m ade array CGH the preferred m ethod for the detection of 
disease-causing rearrangem ents in rare genom ic disorders [35,36]. It has also been 
successfully  introduced as a diagnostic application for m onogenic or m oderately 
heterogenic disorders [37,38]. Interpretation of array CGH results in these early 
disease-related studies w as quite straightforw ard; de novo  occurrence w as usually 
sufficient to prove causality  of a particular CNV. If parents w ere not available, test­
ing other unaffected fam ily  m em bers or a large sam ple from  the general popu la­
tion w ould  im ply association w ith  disease.
1 5 Copy number variation in 
1 • J  the general population
W hen CNV w as in itia lly  observed on a genom e-w ide scale, it w as thought to occur 
exclusively in patients. The first arrays could only detect deletions and d u p lica­
tions larger than 3Mb, w hich are likely to have an apparent phenotypic effect. 
However, as the resolution o f m icroarrays increased, CNV w as also detected in 
apparently healthy ind ivid uals. Studies on control cohorts have show n that CNV 
occurs thro ugh ou t the hum an population, and m ay affect 0.5 to 1% o f anyone’s
13
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genom e [39 -4 3]. These studies have resulted in a paradigm  shift in genetics, and 
provided new  insight in the effect o f CNV on the results of conventional genetic 
studies. For instance, SNPs out o f H ardy-W einberg e quilibriu m  had been previously 
discarded in GWA studies because they did not m eet qu ality  criteria, w h ile  they 
m ay actually  reflect the presence of a deletion [44]. Furtherm ore, uncertainty ex­
ists about the direct effect o f CNV; how  m uch does it contribute to norm al genetic 
variation, and how  m uch to disease [45]? Insight in the location and frequen cy of 
norm al structural varian ts helps in correctly interpreting putative CNV effects. The 
Database o f  G en om ic Variants (DGV) aim s to provide this insight, by collecting all 
structural variation w ith o u t any phenotypic effect [28]. At the start of th is thesis 
the DGV contained ~ 2 0 0 0  putative CNV regions; it has increased four-fold over 
the past five years. W hile  the DGV collects all structural variation from  apparently 
healthy individuals, it does not contain detailed phenotypic inform ation of these 
individuals, and th u s provides no insight in the phenotypic effect o f CNV. Assessing 
this phenotypic effect is one of the m ajor challenges in th is field, and is addressed 
more extensively in Chapter 5 and 6 o f th is thesis,
1 6  Copy number variation
1 • v  in complex diseases
The increasing num ber of deletions and duplications identified in the general 
population has raised hypotheses about their role in com m on, com plex disorders. 
Several studies have revealed com m on CNV as su sceptibility  factor related to im ­
munology, oncology, and psychiatric disease [46-51]. As is the case for com m on 
SNPs, however, each o f these com m on copy num ber variants (CNVs) only has a very 
sm all effect on disease developm ent. Follow ing the strategy used for m onogenic 
disorders, other CNV studies have m ainly focused on rare autosom al dom inant 
form s of disorders such as m ental retardation, and A lzheim er’s and Parkinson’s 
disease [35,37,52,53], a im in g  to reveal rare genetic varian ts w ith  large effect on 
disease. Indeed, several CNVs w ith  large effect have been identified, but these oc­
cur in very specific fam ilies only, and thu s still explain only a sm all fraction of total 
disease burden [54]. The challenge is th u s to assess the relative contribution of 
com m on and rare varian ts to the developm ent o f com m on diseases. This m ay re­
quire collecting very large cohorts (10,000s of patients and controls), jo in t analysis 
of SNPs and CNVs, and application o f h igh-throughput m icroarray and sequencing 
technologies.
1 7  CNV in complex diseases:• /  the schizophrenia example
As an exam ple o f com plex disorders in w hich CNV m ay play a role, w e have dedi­
cated a large part o f the research for th is thesis to schizophrenia. Schizophrenia is 
a severe psychiatric disorder that affects about 1% of the general population, and 
has a high heritab ility  (-8 0 % ), of w hich only a sm all portion can be explained by 
currently known susceptibility  variants. It w as in itia lly  thou ght to be caused by 
a single p artially  d om inant gene w ith  25% penetrance [55,56], but it has become 
evident that m any genetic (and environm ental) factors m ay play a role in schizo­
phrenia developm ent. Linkage and association studies have revealed candidate loci 
for schizophrenia on nearly all hum an chrom osom es, w hich collectively reflect only
Database of 
Genomic Variants
publicly available 
database containing 
all structural 
genomic variation 
that occurs in the 
general population. 
It is often used as a 
reference database 
fo r  CNV studies
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a sm all portion of total variance und erlying schizophrenia [7,57-72]. In an effort 
to pull out the m ost relevant genes, the SZGene Initiative collects and catalogues 
varian ts identified in all genetic association studies on schizophrenia, and provides 
a m eta-analysis-based ranking [73]. A m ong the highly ranked genes in the SZGene 
database are som e that have o rig inally  been identified through inherited chro­
m osom al aberrations, such as disrupted-in-schizophrenia 1 (DISC1) and catechol- 
O -m ethyltransferase (COMT). DISCi w as o rig inally  identified by a (rare) balanced 
translocation in a large Scottish fam ily  [74]. Likewise, COMT  has been originally  
identified as a candidate gene based on a 3M b hem izygous deletion o f chrom o­
som al region 22q11.2, resultin g in a rare syndrom e com prising schizophrenia: Ve- 
loCardioFacial Syndrom e [75-78 ]. The DISCi and COM T  exam ples indicate that rare 
structural variants m ay play a significant role in the developm ent of schizophrenia. 
It also show s that rare varian ts in even single fam ilies m ay point to im portant can­
didate genes for schizophrenia, w hich has been the starting  hypothesis for much 
o f the w ork described in this thesis, especially in Chapters 2 to 4.
A com plicating factor in unequivocally  id en tify in g (rare) genetic varian ts related 
to schizophrenia is the diagnosis of the disorder. Like m any psychiatric disorders 
the diagnosis of schizophrenia is based on qualitative clinical interview s. Although 
the D iagn ostic an d Statistical m a n u a l o f  M e n ta l disorders  (DSM; Box 1.3) provides 
diagnostic criteria, th eir qualitative nature leads to significant heterogeneity 
am ong patients diagnosed w ith  schizophrenia. It is likely that schizophrenia is 
caused by a com plex interplay o f genetic and environm ental factors, w hich com pli­
cates the identification o f individual su sceptibility  genes.
1 O  Aim and outline of this thesisAt the start o f th is thesis in 2005, it w as generally hypothesised that 
com m on com plex disorders w ould  be largely determ ined by com m on genetic 
variants, each w ith  sm all to m odest effects. The results of the first GWA studies on 
com m on diseases w ere prom ising and, therefore, it w as expected that su sce p tib ili­
ty factors for m any hum an diseases could be identified. At approxim ately the same 
tim e array CGH studies w ere initiated, providing a first glim pse on the existence 
and extent of hum an genom ic copy num ber variation. In th is thesis w e prim arily 
focused on the role o f rare CNV in health and disease. M ore specifically, w e aimed 
to id en tify the im pact o f rare CNVs on the developm ent of schizophrenia, and on 
phenotypic characteristics in the general population.
W e in itia lly  focused on the effect of rare CNVs on specific psychiatric pheno­
types. Chapter 2 describes the identification of (partial) deletions o f the contactin- 
associated protein-like 2 (CNTNAP2) gene in three unrelated patients diagnosed 
w ith  schizophrenia and several other features, such as epilepsy, m ental retardation, 
and delayed psychom otor developm ent. We detected the first CNTNAP2 deletion 
in a sm all discovery cohort of patients w ith specific psychiatric features com prising 
schizophrenia. We subsequently confirm ed this initial fin d in g  in a larger validation 
cohort of patients w ith  general schizophrenia, resulting in tw o additional cases. 
CNTNAP2 has recently been im plicated in various psychiatric disorders, such focal 
epilepsy, autism , and language disorders [7 6 -8 3 ]. The successful application of this 
tw o-stage approach prom pted us to also apply it to the identification o f rare v a ri­
ants w ith  a potential effect on m ore com m on subtypes of schizophrenia. Chapter 
3 describes the identification of CNVs in four genes (NRXNi, MYTiL, CTNND2, and
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ASTN2) in a discovery cohort o f patients w ith deficit schizophrenia. Subsequent 
screening in a validation cohort of patients w ith  general schizophrenia revealed 
seven additional cases harb ouring deletions and duplications in these loci, ind icat­
ing that these anom alies m ay be relevant to both rare and com m on subtypes of 
schizophrenia. In Chapter 4  w e applied a fam ily-based approach, using a fam ily  of 
w hich several m em bers w ere diagnosed w ith  distinct psychiatric phenotypes, such 
as depression and schizophrenia. Detailed structural and function al brain im aging 
analyses revealed a marked decrease in cortical and cerebellar glucose m etabolism  
in affected fam ily  m em bers harb ouring a partial genom ic duplication in isoform  
1 o f the retinoid-related orphan receptor alpha (RORa) gene. These observations 
indicate that a CNV in a single gene that segregates w ith in  a fam ily  m ay result in 
distinct phenotypic outcom es.
Interpretation of CNVs identified in schizophrenia patients requires insig ht into 
the occurrence o f structural variation in the general population and, in particular, 
its relation to brain developm ent. To th is end, w e participated in the Brain Im a g ­
ing Genetics (BIG) project: an initiative to study the genetics of brain phenotypes 
in the general population. This project is introduced in Chapter 5. By relating 
structural m agnetic resonance im aging (sMRI) brain analyses to m icroarray-based 
CNV analyses from  more than 6 0 0  Caucasian volunteers, insight into the relation 
between CNVs and brain structure w as indeed obtained. In Chapter 6 w e report a 
corollary of the BIG project, providing a com prehensive overview  of hom ozygously 
deleted regions in the hum an genom e. The high-resolution m icroarray platform  
used in the BIG study allow s for a clear d iscrim ination betw een heterozygous and 
hom ozygous deletions. We used the q uantitative pow er o f th is platform  to detect 
and validate regions of hom ozygous deletion (HDR), i.e., com plete genom ic losses 
w ith o u t any apparent phenotypic effect.
A lthough the field of schizophrenia genetics develops quickly, the introduction 
of d irect-to-consum er (DTC) genetic tests for psychiatric disorders has raised q ues­
tions about the clinical value of the genetic data currently available. Key questions 
are i f  and w hen  genetic research data for com plex psychiatric disorders w ould  be 
relevant for clinical use. In Chapter 7 w e explore the different argum ents used by 
health experts to answ er these questions, using schizophrenia as an exam ple. We 
concluded that view s on the relationship betw een com plex disorders and genet­
ics vary su b sta n tially  and, specifically, on w h o  determ ines i f  and w hen  genom ic 
results can be translated into clinical applications. Nevertheless, it is evident that 
advancem ents in genom ics research w ill im pact the current diagnostic fram ew ork. 
In the general discussion, w e propose to prepare for th is im pact on the health care 
system  and, more specifically, on the possibilities for application o f genom ic profil­
ing to schizophrenia in a diagnostic setting.
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2.CNTNAP2 gene dosage 
variation is associated with 
schizophrenia and epilepsy
Friedman,JI, Vrijenhoek T, Markx S, Janssen IM, van der Vliet WA, Faas 
BHW, Knoers NV, Cahn W, Kahn RS, Edelmann L, Davis KL, Silverman JM,
Brunner HG, Geurts van Kessel A, Wijmenga C, Ophoff RA, Veltman JA 
(2007) CNTNAP2 gene dosage variation is associated with schizophrenia 
and epilepsy. Molecular Psychiatry 13, 261-266
Abstract
A hom ozygous m utation o f the CNTNAP2 gene has been associated w ith a syndro­
me of focal epilepsy, m ental retardation, language regression and other neuro­
psychiatric problem s in children of the Old Order Am ish com m unity. Here w e report 
genom ic rearrangem ents resulting in haploinsufficiency of the CNTNAP2 gene in 
association w ith epilepsy and schizophrenia. G enom ic deletions o f varying sizes af­
fecting the CNTNAP2 gene w ere identified in three non-related Caucasian patients. 
In contrast, w e did not observe any dosage variation for th is gene in 512 healthy 
controls. Moreover, th is genom ic region has not been identified as show ing large- 
scale copy num ber variation. Our data th us confirm  an association of CNTNAP2 to 
epilepsy outside the Old Order Am ish population and suggest that dosage altera­
tion of th is gene may lead to a com plex phenotype of schizophrenia, epilepsy and 
cognitive im pairm ent.
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• 2 I Introduction
Investigations o f com plex brain disorders such as schizophrenia (M IM  
#181500) and epilepsy have dem onstrated considerable heterogeneity o f the ge­
netic and pathophysiological com ponents of these illnesses. Moreover, the pheno­
typic m anifestations of schizophrenia are num erous and variable, and m ay include 
delusions, disordered thought, hallucinations, negative sym ptom s, and cognitive 
and function al im pairm ent [84]. In addition, m any distinct epilepsy syndrom es do 
exist, w hich are defined by seizure characteristics, location, and age o f onset. These 
factors have com plicated the identification of genes and their products that serve 
as vu ln e ra b ility  factors for these disorders. Linkage and association studies have 
yielded several candidate genes for schizophrenia [71,73,85] and epilepsy [86], but 
despite these successes the genetic m echanism s und erlying the com prehensive 
pathophysiology of these brain disorders rem ain poorly understood.
Technical developm ents in m icroarray-based genom ic profiling have facilitated the 
routine genom e-w ide detection of genom ic copy num ber variation (CNV) w ith  a 
resolution o f up to ~100 kb [41,87]. As a result subtle CNVs have been linked to the 
pathogenesis o f a num ber o f diseases, ranging from  rare m onogenic to com plex 
disorders [25,34,37,46,48,52,88]. Moreover, lim ited evidence suggests a role for 
CNVs in the su sceptibility  to psychiatric disease such as schizophrenia [89].
In the current study w e used both genom e-w ide and targeted genom ic approach­
es to investigate CNVs in patients w ith  epilepsy and schizophrenia. These ap­
proaches revealed the presence o f unique CNVs on chrom osom e 7q34-36.1 in three 
unrelated patients w ith epilepsy and schizophrenia, all affecting the contactin- 
associated protein -  like 2 (CNTNAP2) gene.
CNTNAP2 has previously been associated to epilepsy [90], but not to schizophrenia. 
CNTNAP2 is one of the largest genes in the genom e and encodes Caspr2 (contactin- 
associated protein 2). Caspr2 is a m em ber of the neurexin superfam ily, a group of 
transm em brane proteins that m ediate cell-cell interactions in the nervous system. 
Caspr2 is predom inantly expressed in the nervous system  in the juxtaparan od al 
region of axons of m yelinated neurons and in oligodendrocytes [91]. Caspr2 is es­
sential to the localisation of voltage activated K+ channels in the juxtaparan od al 
region of axons, w hich m ay fu nction to stabilise conduction and help to m aintain 
the internodal resting potential. Targeted disruption o f Caspr2 results in marked 
reduction in the accum ulation o f K+ channels at the juxtap aran o d es in both 
central and peripheral nervous system s [91]. This is the first study that d em on­
strates an association between the CNTNAP2 gene and schizophrenia, and the first 
to dem onstrate the presence of dosage variations at th is gene, resulting both in 
epilepsy and schizophrenia.
2 2 Results
We identified a hem izygous deletion involving chrom osom e region 7q34 
to 7q36.1 in patient 1 by routine chrom osom e analysis (data not show n). Patient 1 
is a severely m entally retarded 21-year-old Caucasian m ale born to healthy non- 
consanguineous parents. No other fam ily  m em bers w ere reported to have mental 
retardation or epilepsy. At the age o f 2, the patient suffered from  seizures, first 
noticed by the parents and later confirm ed by EEG. A nticonvulsant m edication 
(carbam azepine) w as initiated and has rem ained necessary until today (Table 2.1). 
We used tiling-reso lu tion genom e-w ide array CGH to characterise the deletionin
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Figure 2.1. Genomic deletions 
of the CNTNAP2 locus in 
chromosome 7 in three 
patients. (A) Microarray- 
based chromosome 7 profiles 
fo r patients 1-3. The profiles 
fo r patients 1 and 2 were 
obtained from tiling-path 
resolution genome-wide 
arrays containing 32 447 
human BAC clones, indicated 
by small circles. The profiles 
show the 10.7Mb deletion 
of chromosomal region 
7q34-7q36.i in patient 1, 
and the 1.5Mb deletion 
of chromosomal region 
7q35-7q36.i in patient 2.
The profile fo r patient 3 was 
obtained from an array that 
contained 194 haplotype- 
tagging SNPs in the CNTNAP2 
locus, indicated by small 
circles. The 220 kb deletion 
in CNTNAP2 is represented 
by a simultaneous decrease 
in log2 R and shift from  
heterozygous to homozygous 
state o f the SNPs.
(B) MLPA confirmation of 
the deletions in CNTNAP2 in 
all three patients. Different 
probe sets were used to 
confirm the deletions, which 
varied in size. (C) Schematic 
overview of the deletions 
in all three patients. MLPA, 
multiplex ligation-dependent 
probe amplification; SNP, 
single nucleotide 
polymorphism.
de novo variants occurring 
in the patient, but not in 
either o f the -  healthy -  
parents]
detail (Figure 2.1a). By d oing so, w e found this deletion to be 10.7 M b in size and 
to encom pass 58 known genes, of w hich only EPHB6, EZH2 and CNTNAP2 are 
expressed in the brain. W e confirm ed the deletion by using both FISH and MLPA 
(Figure 2.1b). FISH analysis of both parents failed to reveal any chrom osom e 7 aber­
rations, ind icatin g  that the deletion occurred de novo in the patient.
We identified a second hem izygous deletion invo lving CNTNAP2 in patient 2 by 
tiling-reso lu tion array CGH. This 1.5 Mb deletion w as identified at the 7q35-7q36.i 
locus and found to encom pass four genes: CUL1, EZH2, PDIA4 and CNTNAP2 (Figure 
2.1a). The m icrodeletion w as confirm ed by MLPA analysis (Figure 2.1b). The patient 
is a 50-year-old Caucasian fem ale diagnosed w ith schizophrenia (age o f onset = 
18), epilepsy and severe cognitive im pairm ent as indicated by a WAIS III fu ll scale 
10=63 (Table 2.1). She com pleted 10 years o f m ainstream  education and w as as­
sessed to have a pre-m orbid I0 = 9 4  (derived from  WRAT-R Reading score) indicating 
a significant decrement in cognitive ability subsequent to the onset of schizophre­
nia. She also experienced a significant deterioration in com m unicative and self­
care abilities requiring prolonged institutionalisation. Her m other and both of the 
m other’s siblings suffered from  unspecified chronic psychiatric illnesses requiring 
prolonged institutionalisation. All three of th is patient’s m ale siblings w ere free of 
psychiatric illness. At age 34 the patient experienced her first and only docum ented 
seizure, characterised as generalised tonic-clonic. Her EEG (16 channel) dem onstrat­
ed slow  dysrythm ia in theta and occasional delta, predom inantly in the frontal area 
(Table 2.1).
The above results prom pted us to fu rth e r assess genetic variation in the m in i­
mal deleted region using a targeted single nucleotide polym orphism  (SNP) assay.
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Table 2.1. Overview of clinical characteristics of the three patients with a deletion in chromosome 7q34-7q36.i.
Patient 1 Patient 2 Patient 3
Deletion
Size
Number of genes 
Inheritance
11 Mb
58
De novo
1.5 Mb 
4
unknown
220 kb 
1
unknown healthy sister does not 
show deletion
Patient details
Gender 
Year of birth 
Ethnicity
Male
1979
Caucasian
Female
1955
Caucasian
Female
1973
Caucasian
Status at birth
Premature birth 
Severe respiratory pro­
blems, neonatal sepsis
normal
Premature birth dizygotic twin. 
Severe respiratory problems
Family history
Schizophrenia
Epilepsy
- - Aunt with bipolar disorder 
Father's cousin with epilepsy
Physical illness - Mother and 2 maternal 
aunts with chronic severe 
mental illness
Epilepsy
Age 1st seizure
Type
2
focal right frontotempo- 
ral epilepsy with secon­
dary generalisation
34
General Tonic-Clonic 
Seizure
16
brainstem regulation disorder
EEG
Therapy
Slow theta/delta 
carbamazepine
Dysrythmic theta/delta 
dilantin
Not determined 
none
Schizophrenia
Age of onset
Type
Could not be determined
18
Paranoid
21
Paranoid
Other featres
Speech
Cognitive abilities 
Additional features
Almost absent 
Severe mental retarda­
tion
Severely delayed psycho­
motor development
Autistic features
Deteriorated 
Progressive cognitive 
deterioration, 10=63 at 
ascertainment 
Difficulties in communi­
cation
Mild cerebral atrophy
Normal 
Normal IQ
We genotyped the cohort o f 312 patients w ith  schizophrenia and a cohort of 312 
Dutch control subjects for 194 haplotype tag g ing  SNPs in the CNTNAP2 locus. The 
X2-test for association revealed no SNP to be significantly (p < .05) associated with 
schizophrenia. However, detailed copy num ber analysis of all data revealed a hemizy- 
gous deletion involving CNTNAP2 in one patient from  the cohort of 312 schizophrenic 
patients (Patient 3), represented by 15 consecutive hom ozygous SNPs w ith  an average 
log2T/R-value o f -0.42 (Figure 2.1a). Subsequent MLPA analysis confirm ed the dele­
tion, w hich encom passes 220 kb and only affects intron 3 of the CNTNAP2 gene (Fig-
20
ure 2.1b). The patient is a 32-year-old Caucasian fem ale diagnosed w ith  schizophre­
nia w h o  has suffered from  epileptic seizures starting  from  age 16. Her IQ is reported 
as norm al. Fam ily history revealed one aunt w ith bipolar disorder and a paternal 
cousin w ith  epilepsy (Table 2.1). Analysis of the healthy dizygotic tw in  sister of the 
patient did not reveal any deletion at th is locus (Figure 2.1b).
The Database of Genom ic Variants (DGV) [28] contains no CNVs larger than 10 
kb in the 7q34-7q36.1 chrom osom al region in w hich all deletions observed in the 
present study occurred. In addition, w e did not observe any deletions in our cohort 
o f 312 healthy controls tested on the targeted SNP array, nor in an additional cohort 
o f 100 healthy ind ivid uals analyzed by MLPA. Moreover, no CNV has been observed 
at th is genom ic locus in more than 500 m entally retarded patients and 100 u naf­
fected parental sam ples tested on tiling-reso lu tion BAC arrays in the diagnostics 
laboratory at Radboud U niversity M edical Centre Nijm egen. Sequence analysis of 
all 24 exons o f the CNTNAP2 gene revealed no additional m utations in these three 
patients.
2  3  Discussion
Recently, a syndrom e characterised by focal epilepsy, m acrocephaly, 
dim inished deep tendon reflexes, m ental retardation and other neuropsychiat­
ric disturbances (designated as Cortical Dysplasia-Focal Epilepsy Syndrom e) w as 
described in association w ith  a hom ozygous m utation of the CNTNAP2 gene in Old 
Order Am ish children [90]. The results o f the current study dem onstrate a rela­
tion betw een dosage variation of the CNTNAP2 gene and a com plex phenotype 
com prising epilepsy outside the Old Order Am ish com m unity. Sequence analysis 
o f all 24 exons o f the CNTNAP2 gene in all three patients revealed no m utation in 
the rem aining allele, indicating that haploinsufficiency o f th is gene leads to the 
disease. Given that these deletions are not com m on events nor located in id en ti­
fied regions of high copy num ber variance [37,41,87] these fin d in gs are unlikely to 
be coincidental. Moreover, unlike the neuropsychiatric presentation suggestive of a 
pervasive developm ent disorder in the Am ish children w ith  a hom ozygous m uta­
tion of CNTNAP2 [90], tw o out of three subjects in the current study presented 
w ith  a diagnosis of schizophrenia. To our knowledge, th is is the first report o f an 
association between the CNTNAP2 gene and schizophrenia. However, it is note­
w o rth y  that a chrom osom al translocation d isru ptin g the CNTNAP2 locus seem s to 
result in Gilles de la Tourette syndrom e (M IM  #137580) and obsessive com pulsive 
disorder [79], although the causality  o f th is translocation w as recently questioned 
[92]. In the context o f these data an association between CNTNAP2 d isruptio ns and 
susceptibility  to schizophrenia seem s feasible w hen considering the substantial 
evidence for m yelin related dysfunction and aberrant neuronal m igration [93,94] in 
the brains o f schizophrenic patients.
Even though the three patients in the present study show ed m oderate clinical 
overlap, they exhibited differences that m ay be related to the varying size of the 
deletion. The deletion in patient 1 affected 57 other genes in addition to CNTNAP2. 
The more severe phenotype observed in th is patient as com pared to the other tw o 
(e.g. severe m ental retardation, m ultiple epileptic seizures, severely delayed psycho­
m otor developm ent) m ay be the result o f an additive effect o f one or more of these 
other genes. Because o f the severe m ental retardation and in a b ility  to com m un i­
cate, a diagnosis of schizophrenia could not be determ ined in th is patient. Similarly,
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the deletion in patient 2 encom passes four additional genes, am ong w hich are the 
cullin-1 (CUL1) and enhancer of zeste hom olog 2 (EZH2) genes, w hich are involved 
in protein ub iquitinatio n and histone m ethylation, respectively [95,96]. Although 
these genes have been reported to be only indirectly involved in brain function 
[95 ,9 6 ], th ey m ay have also contributed to the phenotype of th is patient. Patient
3 had the sm allest deletion encom passing only intron 3 of the CNTNAP2 gene, and 
presented w ith  the least severe phenotype (norm al IQ, norm al speech and higher 
levels of fu n ctio n in g ) w hich still included epilepsy and schizophrenia. A lthough no 
exons w ere affected in the CNTNAP2 deletion found in patient 3, regulatory m otifs 
w ith in  th is region m ay have affected the expression of the CNTNAP2 gene. A lter­
natively, exam ples exist o f enhancers that act over long distances, affecting other 
genes than those in w hich they reside [97]. Functional analysis o f th is intronic CNT- 
NAP2 deletion, however, is not possible in th is patient as expression of th is gene is 
lim ited to specific regions in the brain [91].
Table 2.3. Name and location of FISH probes.
Probe name Location status'
RP11-137O4 ^7:137,552,005-137,723,618 normal
RP11-188A12 ^7:143,039,543-143,039,935 deleted
RP11-79M8 ^7:144,254,565-144,381,963 deleted
RP11-79K23 £^7:147,191,959-147,343,032 deleted
RP11-106C6 ^7:147,678,481-147,853,627 deleted
RP11-90K11 ^7:148,672,492-148,672,786 normal
Probes indicated with 'normal'showed normal copy number, while those indicated with 'deleted' were deleted.
Our study and that of others [90] indicate that rare point m utations and/or 
dosage variation at the CNTNAP2 gene can cause both neurological and psychiatric 
disorders. Exam ples of other rare causative m utations in these disorders include 
SCN1A gene m utations in patients w ith  generalised epilepsy w ith  febrile  seizures 
[98], m utations in the KCNN3 gene [99] as w ell as the SYNGR1 gene [100] in schizo­
phrenia, and the association o f rare varian ts of the KCC3 gene w ith  bipolar disorder 
[101]. On the other hand, the 22q11 region involved in DiGeorge syndrom e is known 
to show  genom ic dosage variation in a w ide range o f cognitive and neurological 
deficits [102], and copy num ber variation at m any other genom ic loci has been 
associated w ith a variety of neurological system  disorders (see review  by Lee and 
Lupski [103]).
In conclusion, th is study confirm s the recently reported association between 
the CNTNAP2 gene and epilepsy in patients outside the Old Order Am ish com m u­
nity and dem onstrates an association betw een CNTNAP2 and schizophrenia. Our 
results highlight CNTNAP2 as a strong candidate gene for epilepsy and schizophre­
nia. The results fu rth e r support the notion that copy num ber variation is a poten­
tia lly  im portant source of genetic susceptibility  to both com plex brain diseases.
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2 * 4  Material and methods
Patient material
Genomic DNA from EDTA venous blood was obtained from three independent sources. 
Patient 1 was brought to the diagnostics department at the Radboud University Medical 
Centre for routine karyotyping with a clinical presentation of severe mental retardation, 
epilepsy, and language development problems among other findings (Table 2.1). Patient 2, 
who presented with schizophrenia and epilepsy was identified from a cohort of 23 patients 
with syndromal schizophrenia (e.g. schizophrenic accompanied by numerous minor physical 
anomalies, mental retardation, seizure disorder and other medical problems) recruited from 
Pilgrim Psychiatric Centre, W. Brentwood, N.Y., USA, and referred to the Department of Human 
Genetics, Radboud University Medical Centre for array-based Comparative Genomic Hybridi­
sation (array CGH) analysis. Patient 3 was identified from a cohort of 312 schizophrenic pa­
tients recruited at the Department of Psychiatry, Utrecht University, and the Netherlands for 
targeted Single Nucleotide Polymorphism (SNP) array analysis. These were analysed together 
with 312 healthy individuals of Dutch origin as a control set. The cohorts were collected fol­
lowing institutional review board approval and obtaining signed informed consent.
Array-based Comparative Genomic Hybridisation
Array CGH was performed as described previously [37,104] using a tiling-resolution bacterial 
artificial chromosome (BAC) array. All data were mapped on the NCBI build 35 of the UCSC 
Genome Browser hg 17 [105].
Singe Nucleotide Polymorphism assay
To assess genetic variation in the genomic region around CNTNAP2, we developed a targeted 
single nucleotide polymorphism (SNP) assay for the Illumina® GoldenGate Bead Array (Il­
lumina Inc., San Diego, CA, USA). The assay consisted of 194 haplotype tagging SNPs in the 
CNTNAP2 locus (chr 7: 145,444,787 -  148,582,400; NCBI build 35 of the UCSC Genome Browser 
hg17 [105]; average spacing between two SNPs was 16 kb). We performed a straightforward 
X2-test for association of individual SNPs with schizophrenia. We also checked for copy num­
ber changes by simultaneous measurement of both signal intensity variations (log2R) and 
changes in allelic composition [106].
Multiplex ligation-dependent probe amplification
To confirm the microarray analysis, samples were screened with multiplex ligation-depen­
dent probe amplification (MLPA) essentially as described previously [107]. MLPA probes were 
designed for exons 2, 3, 4, 5, 14, 24 (one probe each exon) and intron 3 of CNTNAP2 (3 different 
probes), and for exon 3 of PDIA4 and exon 14 of NOS3 (both one probe each exon). Sequences 
of test and control probes are in Table 2.2. Probes were developed in accordance with a pro­
tocol provided by MRC-Holland (Amsterdam, The Netherlands). Ten probes were combined in 
one MLPA assay, in combination with three standard control probes. Equal amounts of probe 
mix and hybridisation buffer were added to 100-200 ng. of DNA from each sample, followed 
by heat denaturation and overnight incubation at 60°C. Ligation products were amplified by 
regular PCR with the use of a 6-FAM-labeled primer set. Amplification products were identi-
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Table 2.2. Names and sequences of MLPA probes.
Probe name Sequence
Control 1 F GGGTT CCCTAAGGGTT GGACGCGCCCAGTCCTT CCTGCAAACGGAG
Control 1 R ACCTCGGTCATCTAGCCCCACCCCTGCTCTAGATTGGATCTTGCTGGCAC
Control 2 F GGGTT CCCTAAGGGTT GGAGCCTGCGGT GAACACT GT GAACGT GCAGAT CGCCTTC
Control 2 R TCCGGTTTGACAGAGGCATGCTGGGCCATCATGCTTCTCTAGATTGGATCTTGCTGGCAC
Control 3 F GGGTTCCCTAAGGGTTGGACAAACAGGAAAATGGGACTTTGGTTGTGCTGAAGACGGGCCTGCG
Control 3 R GTGAACACTGTGAACGTGCAGATCGCCTTCTCCGGTTTGACAGAGTCTAGATTGGATCTTGCTGGCAC
Exon 3 F GGGTTCCCTAAGGGTTGGACATCAGGAATCCATTATGGTGTCATT
Exon 3 R ATTACATGTGAAGGCTGCAAGgtTCTAGATTGGATCTTGCTGGCAC
Intron 3.1 F GGGTTCCCTAAGGGTTGGACAAACCATTTCAGGTGGCCTGAG
Intron3.i R TCT CCTAAGGAAAGCAAGGGTGGTCTAGATTGGATCTTGCTGGCAC
Intron 3.2 F GGGTTCCCTAAGGGTTGGACTTAATCACTTCCCATAAGACCCCACCTG
Intron 3.2 R CTAATACCCCCACCTGCTAATACCCATCTAGATTGGATCTTGCTGGCAC
Intron 3.3 F GGGTTCCCTAAGGGTTGGAGATGAGAAGATGGGATTAAACAGCCCGAGTA
Intron 3.3 R GGATTTGTCCCCTGTTAGACTGTAGAAGAAGTCTAGATTGGATCTTGCTGGCAC
Exon 4 F GGGTTCCCTAAGGGTTGGAGCACGAATTACAGCATCCGATTATTGCCCGCTATGTGCGCA
Exon 4 R TAGTGCCTCTGGATTGGAATGGAGAAGGTCGCATTGGACTCTCTAGATTGGATCTTGCTGGCAC
Exon 5 F GGGTT CCCTAAGGGTT GGACT GCACGGAGAAGGACAGCAAGGAGATTACATT
Exon 5 R ACCTTGGAACTGAAAAAAGCCAAGCTGGTCCTCTCTAGATTGGATCTTGCTGGCAC
Exon 14 F GGGTTCCCTAAGGGTTGGAGCATCGAACGCAACTGCACAGATCCCAAGTACTAC
Exon 14 R TGTAACTGCGACGCGGACTACAAGCAATGgtgagtTCTAGATTGGATCTTGCTGGCAC
Exon 24 F GGGTTCCCTAAGGGTTGGAGGTGATTTTCACCATCCTGTGCACCCTGG
Exon 24 R TCTTCCTGATCCGGTACATGTTCCGCCACTCTAGATTGGATCTTGCTGGCAC
PDIA4_F GGGTTCCCTAAGGGTTGGAGTGAGTGGCTACCCCACCATCAAGATCCT
PDIA4 R t a a g a a g g g g c a g g c t g t a g a c t a c g a g g t c t a g a t t g g a t c t t g c t g g c a c
NOS3_F GGGTTCCCTAAGGGTTGGACAGCACCCAGGACATCTGTCTTCCCACCCACAGGTCCTGTGTATGGATG
NOS3 R AGTATGACGTGGTGTCCCTCGAACACGAGACGCTGGTGCTGGTGGTAACTCTAGATTGGATCTTGCTGGCAC
fied and quantified by capillary electrophoresis on an ABI 3730 genetic analyzer (Applied Bio­
systems, Foster City, CA, USA). Data were normalised by dividing each probe's signal strength 
by the average signal strength of the sample. This normalised peak pattern was divided by 
the average peak pattern of all samples in the same experiment. Values for control wild-type 
peaks were centred at 1.0. A copy number loss was called below a fixed threshold value of 0.7.
Fluorescent in situ hybridisation (FISH) analysis
Fluorescent in situ hybrisation (FISH) experiments were performed for de novo checking 
on metaphase spreads prepared from patient-derived lymphoblast cell lines using routine 
procedures. Probe labelling, slide preparation, and hybridisation were carried out as described 
elsewhere [34], using probes listed in Table 2.3.
Sequence analysis
In order to sequence all 24 exons of the CNTNAP2 gene, we designed primers in the intronic 
region surrounding each exon using Primer3 [108], and performed standard PCR reactions. 
Primer sequences and conditions are in Table 2.4.
24
Table 2.4 . Names and sequences of primers, and PCR conditions for sequence analysis.
Primer Sequence (5’-  3 ’) Primer Sequence (5’-  3 ’)
Exon 1F CATCTCCCTTCAAGAACCCT Exon 1R TGCACTTCGGAGTTGATACC
Exon 2F AACCAACACATACCAATCGTT Exon 2R GATTTCTGGTGTCTGCCAAC
Exon 3F TGTAGAATATTCCATTGTCAGTTG Exon 3R TGCTTAGTAAATCCTGTACCATTTT
Exon 4F AATCACAAGCCCTACCATTG Exon 4R GGTAGTTTATTGTCAGAGAAAGCA
Exon 5F CAGACACCTGTTGGAAGTGG Exon 5R tttgaatgaCTAGGTGTTTCATT
Exon 6F AGCTTTGATGGAATGTCAGC Exon 6R AAATTGTCAGTGTCTTGTTTAGAGA
Exon 7F TTTTGGAGGCAGAATGCTAT Exon 7R CATTTTGCCCAAACACAAAT
Exon 8F GGCTGTGCTTCAAAACTTGT Exon 8R ACCAGCAAAACCAAACAAAG
Exon 9F CAGTTTGAATTGTAAGCAGCA Exon 9R TTTTGTTTTGCTCAGTGGAA
Exon10F TGGCCAGGTAGAATACCCAC Exon 10R TTGGGATGTTTCACTGGTCT
Exon 11F AGACAGCTTGGAATTTGGC Exon 11R AGCTTCAAAGCACAGCTCAA
Exon 12F GCCACTGGGACATTTATCTG Exon 12R AGAAACAAACCATTGGTGGA
Exon 13F GACCATTTAAGTGTGGCTCA Exon 13R CCTGTTGGATTCTTTAGGCA
Exon 14F GAAGTGGGTGTAAGTGTGGC Exon 14R TTCTTCTATCACATGAGTTTGACAC
Exon 15F AAGCAACTAGCAGAAAATTCAT Exon 15R AGAGCAAGTCTGATTGCAGG
Exon 16F AACTCAAGCAATGGGTATCTG Exon 16R ATCAAAAGGCCTTCCACAAT
Exon 17F TTTGTCGTCTAGAATTTACTGCT Exon 17R AACCTTGCATAGGCTGATTTT
Exon 18F TGCAGTGTCATCTCCTACCA Exon 18R TGGAAAATTCCTACCTAAGTTGA
Exon 19F TTACTCAGATGCCCTTCCTG Exon 19R tggggaataaataacaaacca
Exon 20F AGGAATTGAGGGGATGTGA Exon 20R CCCTCAAAACAAAACCAATG
Exon 21F AAAGAGTGATGTCATCCCCA Exon 21R GATAGTTTTAAAATCCAAACTCACA
Exon 22F AGCTTTGGACACAAGCATTC Exon 22R tccattccatagtcccaaga
Exon 23F GGGAAAACAGGAAGTGTTGA Exon 23R ATGTCATAATCTTTAAACAGCAAA
Exon 24F GAGCTGTAGTGAAGTGGGGA Exon 24R TATGAAGCAGGGTGCTTTTG
PCR Mix 2.5 ul. PCR io x Buffer II PCR program- Co49
1.5 ul. MgCl2 25 mM me "30 94oC
0.075 ul. dNTP 100mM x03Co065
1.875 ul. MO "45 72oC
2 ul. AmpliTaq Gold 5U/ul. 7' 72oC 
00 4oC
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3«Recurrent CNVs disrupt 
three candidate genes in 
schizophrenia patients
Vrijenhoek T, Buizer-Voskamp JE, van der Stelt I, Strengman E, GROUP,
Sabatti C, Geurts van Kessel A, Brunner HG, Ophoff RA, Veltman 
JA (2008) Recurrent CNVs disrupt three candidate genes in 
schizophrenia patients. American Journal of Human Genetics. 83,
504-510
Abstract
Schizophrenia is a severe psychiatric disease w ith  com plex aetiology, affecting 
approxim ately one percent of the general population. M ost genetic studies so 
far focused on disease association w ith  com m on genetic variation such as single 
nucleotide polym orphism s, but recently it has become apparent that large-scale 
genom ic copy num ber variants (CNVs) are involved in disease developm ent as 
w ell. To assess the role of rare CNVs in schizophrenia, w e screened 54 patients w ith 
deficit schizophrenia using A ffym etrix' GeneChip 250K SNP arrays. We identified in 
total 9 0  CNVs, 77 o f w hich have been reported previously in unaffected control co­
horts. A m ong the genes disrupted by the rem aining rare CNVs are MYTiL, CTNND2, 
N RXN i and ASTN2, genes that play an im portant role in neuronal fu n ctio n in g  b-ut 
-  except for NRXN1 -  have not been associated w ith schizophrenia before. We stu ­
died the occurrence of CNV at these 4  loci in an additional cohort of 752 patients 
and 70 6  norm al controls from  The Netherlands. We identified 8 additional CNVs of 
w hich the 4  that affect coding sequences w ere only found in the patient cohort. 
Our study supports a role for rare copy num ber variants in schizophrenia suscep ti­
bility and identifies at least three candidate genes for th is com plex disorder.
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Introduction
Schizophrenia [MIM #181500] is a severe psychiatric disease w ith 
complex aetiology. It is characterised by a variety of psychotic sym ptom s includ­
ing delusions and hallucinations, reduced interest and drive, altered emotional 
reactivity, and disorganised behavior [84]. Despite the fact that schizophrenia oc­
curs at a high frequency (~ 1%) in the general population and heritability is around 
0.80, genetic studies so far have largely failed to identify susceptibility factors that 
confer risk alleles for the disease [73,109,110]. This indicates that schizophrenia is a 
clin ically and genetically heterogeneous disease. Am ong the strongest candidate 
genes are D IS C  and genes in the 22q11 region, such as CO M T  and PRODH, w hich 
have been identified in itia lly  as rare, high-penetrant cytogenetic variants that 
either disrupt or com pletely delete the genes involved [74,77]. Genom ic m icroar­
rays allow  for the system atic genom e-w ide analysis of a more subtle form of 
cytogenetic variation, i.e. copy num ber variation (CNV): genom ic deletions and/ 
or duplications of 1kb to 3Mb in size [41]. Recent m icroarray studies have identified 
m any of such CNVs in a variety of complex disorders, including mental retardation 
[37,88], autism  spectrum disorder [51,111-113], and schizophrenia [50,69,83,114-116]. 
It has now become evident that rare CNVs can have im portant im plications in the 
aetiology of schizophrenia. W hile rare CNVs m ay be related to psychiatric diseases, 
little is known about the identity of the genes affected by these variants and even 
less about the frequency by w hich these individual CNVs occur in the different 
disorders [117]. Here we combined a genom e-w ide CN V  screen in patients w ith 
deficit schizophrenia w ith a targeted, but considerably larger, follow -up study in a 
general schizophrenia patient-control cohort. The deficit subtype of schizophrenia 
is characterised by prim ary enduring negative symptoms, and is chronic in course 
[118]. Patients w ith such a severe subtype of schizophrenia therefore provide a 
good reference set to detect CNVs, of w hich recurrence assessm ent and further 
characterisation can be done in the larger cohort.
2  Results
We in it ia lly  performed a genom e-w ide screen for CNVs in a small 
discovery cohort of 54 Dutch patients w ith deficit schizophrenia according to the 
Diagnostic and Statistical M anual of Mental Disorders (DSM-IV-TR) [119]. Extensive 
phenotypic inform ation from medical records and interview s was available for 
all patients, including the Com prehensive Assessm ent of History and Symptoms 
(CASH) and the Schedule for Deficit Syndrome (SDS; M aterial and Methods). We 
hybridised genom ic DNA of these patients to A ffym etrix’ GeneChip 250K SNP (Nsp) 
arrays, and identified genom e-w ide C N V  using the Copy Num ber Analyzer for 
Affym etrix GeneChip (CNAG) software [120], w hich uses a Hidden M arkov Model 
(HMM) algorithm  to calculate copy num bers (GEO accession number: GSE12714). 
We identified a total of 90 CNVs (Table 3.1), w ith an average genom ic size of 353 
kb (varying from 9kb to 1.7 Mb, Table 3.1). Most of these CNVs (85%, n=77) were 
previously reported by Redon et al. [41] -  w ho used the sam e Affym etrix platform 
to study CNVs in 270 unaffected HapM ap ind ividuals -  or observed by us and listed 
in our internal C N V database. The latter contains data from genom ic m icroar­
ray analyses on more than 400 unaffected Caucasian ind ividuals (Material and 
Methods). The occurrence of these CNVs in these relatively sm all control cohorts
3.1
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Table 3.1. Recurrent CNVs in 54 patients with deficit schizophrenia.
Chr Start Pos End Pos Size Type Freq Internal
database
Redon et al.
[41]
1 120,784,882 120,863,833 78,951 dup 1 yes no
2 242,636,531 242,717,659 81,128 del 2 yes yes
3 163,346,161 163,418,680 72,519 dup 1 yes no
196,922,636 197,016,536 9 3 ,900 dup 1 yes no
4 132,320,223 132,707,929 387,706 dup 1 yes yes
5 32,149,934 32,185,000 35,066 dup 1 yes yes
57,428,887 57,429,407 520,000 dup 1 yes no
6 168,234,261 168,445,626 211,365 dup 1 yes yes
79,059,234 79,223,531 164,297 dup 1 no yes
7 64,212,891 64,362,128 149,237 del 2 yes yes
8 137,757,137 137,931,617 174,480 del 2 yes yes
137,907,179 137,931,617 24,438 del 1 yes yes
17,599,309 17,660,647 61,338 del 1 no yes
17,583,258 17,622,543 39,285 dup 1 yes no
9 4 6 ,363,383 4 6 ,537,355 173,972 dup 1 yes yes
10 4 6 ,363,383 47,154,881 791,498 dup 2 yes yes
18,907,033 18,918,255 11,222 dup 2 yes yes
11 25,045,288 25,077,409 32,121 dup 1 no yes
31,202,250 31,305,740 103,490 dup 1 yes yes
12 31,904,362 31,954,269 4 9 ,907 dup 1 yes yes
33,432,314 34,006,004 573,690 del 1 yes yes
50,962,670 51,063,303 100,633 dup 1 yes yes
106,223,861 106,246,130 22,269 dup 1 yes yes
14 19,336,854 19,384,798 47,944 dup 1 yes yes
19,336,854 19,489,991 153,137 del 9 yes yes
18,427,103 19,257,253 830,150 del 1 yes yes
15 18,427,103 20,089,383 1,662,280 del 11 yes yes
18,427,103 20,089,383 1,662,280 dup 4 yes yes
19,257,253 19,407,629 150,376 dup 1 yes yes
19,349,313 20,089,383 740,070 dup 1 yes yes
19,821,421 20,005,562 184,141 dup 2 yes yes
19,821,421 20,089,383 267,962 del 1 yes yes
19,876,834 20,089,383 212,549 dup 1 yes yes
34,344,361 34,560,001 215,640 dup 2 yes yes
16 6,576,121 6 ,675,138 99,017 del 1 no yes
21,856,623 22,284,504 427,881 dup 1 no yes
17 31,459,625 31,501,499 41,874 dup yes yes
31,473,221 31,923,810 450,589 dup 1 no yes
41,513,416 41,719,833 206,417 del 2 yes yes
41,587,072 41,719,833 132,761 dup 1 yes yes
41,635,580 41,719,833 84,253 dup 1 yes yes
21 9 ,887,804 13,891,798 4 ,0 0 3 ,9 9 4 del 1 yes no
22 20,809,825 20,892,741 82,916 dup 1 yes no
24,043,842 24 ,235,625 191,783 del 1 yes yes
24,043,842 24 ,235,625 191,783 dup 2 yes yes
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Pat ent  1 chr  2p25 3 ?c
strongly indicates that they occur frequently in the general population and do not 
represent rare genom ic variants underlying disease [41]. Previously, we and others 
[37,50,83,114,115,121] have shown that rare CNVs m ay be responsible for a significant 
proportion of common neurological disorders. For th is reason, we focused on the 
rare CNVs as an underlying cause of schizophrenia.
We identified 13 rare CNVs in our discovery cohort not described by Redon et 
al. [41], not present in our internal unaffected control database, nor previously 
observed in our diagnostic genom e-w ide m icroarray studies encom passing more 
than 1300 patients w ith unexplained mental retardation (Table 3.2). The HMM 
algorithm  detected twelve variants, but visual inspection and subsequent valid a­
tion revealed one additional CN V that contained too few SNPs for the algorithm  
to detect it (12 SNPs in a 98kb region on chromosome 9). Some of the rare vari­
ants do overlap w ith regions listed in the Database of Genom ic Variants (DGV), 
however, most variants detected in our patients extended beyond those reported 
in the DGV. Each of the CNVs w as detected in one patient only, illustrating the 
rare nature of these variants. Seven rare variants did not affect any gene, nor were 
they located in h ighly conserved regions. No inform ation is available w hether the 
CNVs are inherited or have arisen de novo in these patients. Based on the gene 
content we selected and validated 4 CNVs for further study; tw o duplication CNVs 
in chromosomal regions 2p25.3 and 5p15.2, and two deletions in chromosomal re­
gions 2p16.3 and 9q33.1 (Figure 3.1a). We validated all four CNVs by either m ultiple 
ligation-dependent probe am plification (MLPA) or genom ic quantitative PCR (Fig­
ure 3.1b). The deletions (237 and 98 kb in size) each affect a single gene: neurexin-1 
(NRXN1) on chromosome 2p16.3 and astrotactin-2 (ASTN2) on chromosome 9q33.1. 
The duplications were considerably larger (967 and 930 kb) and affect 4 genes on 
chromosome 2p25.3 and 7 genes on chromosome 5p15.2, respectively. Interestingly, 
the breakpoints of both duplications disrupt the term inal parts of two genes:
Figure 3.1. Four rare 
CNVs in patients 
with schizophrenia.
(a) CNAG plots 
of deletions and 
duplications in 
four patients.
Upper x-axis:
Log2 test-over- 
reference ratios of 
hybridization signals 
of individualed 
SNPs and the 
corresponding HMM 
algorithm (dark 
line). Lower x-axis: 
moving average (10 
SNPs) result of the 
individual Log2- 
ratios. (b) MLPA 
(patients 1,2 and 4) 
and qPCR (patient 3) 
validation of all four 
CNVs. (c) Location 
of duplications and 
deletions in the 11 
patients and the 
control subject in the 
respective genomic 
regions. Displayed 
are duplications 
(light horizontal 
lines) and deletions 
(dark horizontal 
lines), affected genes, 
and adjacent genes
Deficit schizophrenia
schizophrenia
subtype
characterised by 
enduring negative 
symptoms, and 
severe hallucinations 
and delusions
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Table 3.2. Rare CNV in 54 patients with deficit schizophrenia
Chr Start Pos End Pos Size Type genes
disrupted
#  genes
2 859,616 1,826,716 967,100 dup MYT1L 4
118,093,425 118,112,588 19,163 dup - -
51,063,670 51,300,517 236,847 del NRXN1 1
3 104,949,024 105,130,355 181,331 del - -
3,778,229 3,787,310 9,081 del - -
5 10,270,604 11,200,814 930,210 dup CTNND2 7
9 12,144,939 12,356,992 212,053 del - -
118,409,012 118,507,481 98 ,469 del ASTN2 1
10 72,413,270 72,572,954 159,684 dup - -
16 86,246,025 86,581,418 335,393 dup JPH3, BANP 5
17 30,104,540 30,185,180 80,640 dup - -
18 6 ,303,320 6 ,616,549 313,229 dup L3MBTL4 1
20 43,794,873 43,811,618 16,745 del - -
Figure 3.2
Shown are Log T/R plots 
based on Illumina 550K 
BeadChip array results. 
(a) Patient 5 with a 
3.8 Mb duplication in 
2p26.3, affecting the 
whole of MYTiL plus 
ten other genes. (b) 
Patient 6 with a 56 kb 
intergenic duplication. 
(c) Patient 7 with an 
exonic deletion in 
NRXNi. (d) Patient
8 with an intronic 
duplication in NRXNi. 
(e) Patient 9 with 
an exonic deletion 
in NRXNi f )  Patient 
io with an intronic 
deletion in NRXNi.
(g) Patient 11 with a 
duplication affecting 
PAPPA and ASTN2. (h) 
Unaffected control with 
an intronic deletion in 
NRXNi.
31
• 3
. R
ec
ur
re
nt
 
CN
Vs
 
di
sr
up
t 
3 
ca
nd
id
at
e 
ge
ne
s 
in 
sc
hi
zo
ph
re
ni
a 
pa
tie
nt
s 
•
• R
are
 
co
py
 
nu
m
be
r 
va
ria
nt
s 
an
d 
th
ei
r 
ef
fe
ct
 o
n 
sc
hi
zo
ph
re
ni
a 
- t
ak
in
g 
the
 
ge
no
m
e 
ou
t 
of 
the
 
br
ain
 
•
Table 3.3. Expression levels of genes affected by rare CNVs in 65 human body tissues. The first column lists average 
expression over tissues, the third the average expression in the brain, and the fifth the ratio of the two. SD = 
standard deviation.
Gene average
expression
SD/av average expression 
brain
SD brain/ 
av
brain/all tissues
MYT1L 99.32 1.70 238.22 0.86 2.40
TPO 55 96 5.58 15.96 0.12 0.29
SNTG2 13.73 0.16 14.00 0.11 1.02
NRXNi i55.23 1.24 353.88 0.60 2.28
ASTN2 86.81 0.70 134.88 0.35 1.55
TRIM32 78.77 0.27 76.83 0.24 0.98
CTNND2 187.10 1.27 438.18 0.47 2.34
DAP 191.92 0.55 120.28 0.44 0.63
ROPN1L 27.06 3.91 12.38 0.09 0.46
CCT5 252.85 0.24 228.11 0.15 0.90
MARCH-VI 219.70 0.34 266.03 0.29 1.21
myelin transcription factor 1-like (MYTiL) at chromosome 2P25.3 and catenin delta 2 
(CTNN D2) at chromosome 5P15.2. These observations suggest that, next to dosage 
variation, these CNVs m ay also have disruptive effects, as has been reported before 
[115,122]. The two genes affected by the deletions, N R X N i and ASTN2, as well as the 
genes at the breakpoints of the tw o duplications, M YTiL  and CT N N D 2, are highly 
expressed in the brain as compared to several other tissues [123] (Table 3.3), and 
they have all been im plicated in neuronal functioning, adhesion and migration
[124-127].
Table 3.4 displays detailed dem ographic and diagnostic inform ation of the four 
index patients. All patients were diagnosed w ith schizophrenia of the paranoid 
type and all fulfilled the deficit syndrome criteria, according to the SDS (Material 
and Methods). All four patients were hospitalised and have been on antipsychotic 
drugs for several years. At the tim e of inclusion all four patients were severely 
ill, w ith considerable delusions and hallucinations. Additionally they displayed 
aggressive behaviour during psychosis, and fulfilled criteria for formal thought 
disorder and physical anergia.
In a second phase analysis we studied copy num ber variation w ithin  these four 
regions in a larger cohort, consisting of 752 additional patients w ith schizophrenia 
and 706 unaffected controls. The patients were recruited from a variety of psychi­
atric hospitals and institutions in the Netherlands, partly coordinated via academic 
hospitals in Am sterdam , Groningen, M aastricht, and Utrecht (The Genetic Risk 
and Outcome of Psychosis (GROUP) project). All patients have been diagnosed 
for subtypes of schizophrenia according to the DSM -IV-TR [119]. The controls were 
volunteers and were all screened for any psychiatric history, of w hich the m ajority 
by the use of the CASH (Material and Methods). Both cases and controls were of 
Dutch decent. Genom ic DNA of all patients and controls was hybridised to Illum ina 
Hum anHap550v3 Bead Array (M aterial and Methods). CNVs were only included if 
they were detected by 2 different software packages, PennCNV [128] and O uan- 
tiSNP [108]. We analyzed these data for CNVs in the four candidate regions, with
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Table 3.4. Detailed clinical features of four index patients with CNVs.
Patient i Patient 2 Patient 3 Patient 4
Demographics Sex Male Male Female Male
MPA Facial and toe
MR
syndactyly 
Mild MR Yes - Yes •W1
5=
Ita
ft
Other - - Stereotypical move­
ments
Epilepsy
Diagnostics Diagnosis DSM- 
IV (according to 
CASH)
Age of onset
Paranoid type 
(295.30)
18
Paranoid type
(295.30)
20
Paranoid type
(295.30)
20
Paranoid type (295.30) 
26
5=<U
a0
.N
u
P
W1
<V
e<v
<n
OJ
It
ereu
m
a
g
1^
W1
>
z
u
5=<U
5
Core symptoms Severe delusi­
ons/ hallucinati­
ons of sexual/ag­
gressive content
Isolation, chaotic 
and aggressive 
behavior
Severe delusions/ 
hallucinations; very 
aggressive behavior
Bizarre delusions, anhe- 
donia, paranoid/soma­
tic delusions; aggressive 
behavior
Fulfilling SDS cri­
teria (total score 
if present)*
Yes Yes Yes Yes (12)
Additional infor­
mation
Physical anergia; 
formal thought 
disorder
Physical anergia; 
formal thought 
disorder
Physical anergia; sui­
cidal; formal thought 
disorder
Physical anergia; formal 
thought disorder
CNV Chromosome 2p25.3 2p16.3 5p15.2 9 q33.1
<vO'
Size (kb) 1014 3 00 VO 1019 98
Type Duplication Deletion Duplication Deletion
No. genes 4 1 7 2
Candidate gene MYT1L NRXNi CTNND2 ASTN2
Gene function Neural cell 
differentiation, 
nervous system 
development
Synaptic 
formation and 
maintenance, 
axon guidance
Cell motility, dendri­
tic branching, neuron 
adhesion
Glial-guided neuron 
migration, axonal 
guidance
* Six items can be scored on a range from 0-4
extended boundaries to include the entire coding and non-coding sequence of 
genes that were disrupted in the index patients.W ithin the candidate regions, 
we detected CNVs in 7 additional patients and in 1 control (Figure 3.1; Table 3.5; 
Figure 3.2). Four of the CNVs identified in the patient cohort were located w ithin 
the N R X N i gene at 2p16.3, of w hich one affected exonic sequences. In addition,
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Table 3.5. Detailed clinical features of the additional 7 patients and one control with CNVs in the candidate regions.“-” = not present; NA = not assessed.
Demographics Gender
Patient 5 
Male
Diagnostics Diagnosis DSM-IV Undifferen- 
(according to CASH) tiated type 
(295.90)
Age of onset 
Core symptoms
Fulfilling SDS crite­
ria (total score)*
Additional infor­
mation
20
Bizarre d e lu si­
o n s/ h a llu cin a ­
tions; aggres­
sive behaviour; 
anhedonia
NA
Physical a n ­
ergia; form al 
thought 
disorder
Patient 6
Male
Paranoid
type
(295 -Bo)
NA
NA
NA
Twin
Patient 7 
M ale
Patient 8 
M ale
Paranoid type U ndifferentiated
(295-30)
22
Delusions
Yes (10)
Physical
anergia
type (295.90)
19
D elu sio n s/ hal­
lucinations
NA
Patient g 
Female
Undifferentiated 
type (295.90)
NA
Episodic with 
partial rem is­
sion and negative 
sym ptom s
NA
Twin; form al No
thought disorder
Patient io 
Female
Patient 77 
Female
Paranoid type Unknown type 
(295.30) (295.XX)
29
D e lu sio n s/ h a l­
lucinations
NA
NA
NA
NA
Probably NA
psychosis in 1st 
or 2nd degree 
relative
Control 7 
Female
CN V Chrom osom e 
Size (kb)
Type
No. genes 
C N V  effect
2P25-3
3,134
Duplication
W hole of 
MYTiL
2P25-3
56
2pi6.3
25
Duplication Deletion
Intergenic Exonic 
sequence of 
NRXNi
2pi6.3
114
Duplication
2pi6.3
230
Deletion
Intronic sequence Coding sequence
o f NRXNi of NRXNi
2pi6.3
65
Deletion
Intronic 
sequence of 
NRXNi
9q33-i
359
Duplication
2pi6.3
110
Duplication
Term inal part of Term inal part 
ASTN2 of ASTN2
tw o novel CNVs were identified at 2p25.3: a 3.8 Mb duplication affecting 11 genes 
including M YTiL, and a 56 kb duplication not affecting any known gene. Finally, a 
360 kb duplication w as observed in the 9q33.1 region that affected part of both the 
ASTN2 and PAPPA [MIM #176385] genes. The single C N V identified in the control co­
hort is an intronic duplication w ithin  the N R X N i gene (Figure 3.1). Table 3.5 displays 
phenotypic characteristics of these patients; the control subject w ith the duplica­
tion w ithin  the N R X N i gene was free of any clinical psychological features.
3 3  DiscussionClearly most CNVs in our study were observed in N R X N i; three dele­
tion CNVs affecting coding sequences, and three w hich were entirely intronic (2 
duplications and 1 deletion). Even though Redon et al. [41] observed one unaffected 
HapM ap individual w ith a deletion in N RX N i, deletions in th is gene have gener­
a lly been linked to neurological disorders, such as mental retardation [88], autism 
[51,111,129,130] and schizophrenia [50,115]. All of the apparently pathogenic dele­
tions reported so far affect the first few exons of the N R X N i gene, including the 
promoter region. In addition, rare missense m utations in exon 1 have been associ­
ated w ith autism  [131]. In our study we encountered two patients w ith deletions 
affecting the promoter region and exon 1, as w ell as a deletion affecting exons 8 
to 10. The CNVs in the other tw o patients and one unaffected control were located 
in intronic sequences for w hich as yet it cannot be discerned w hat their relation 
to disease m ay be (Figure 3.1; Table 3.5). Sim ilarly, the larger duplications in the 
2p25.3 region affecting m any genes are more likely to be causative than the 56 kb 
intergenic duplication observed in this region. The M YTiL  located in this region is 
a member of the myelin transcription factor 1 fam ily, w hich regulate proliferation 
and differentiation of oligodenderocytes [132] by regulating transcription activity 
in the central nervous system [127]. Although M YTiL  itself has not previously been 
linked to disease, a deletion in its homologue, M YTi, was recently observed in a 
patient w ith mental retardation [133]. In addition, Law et al. [134] hypothesised that 
M Y T i regulates N R G i expression in schizophrenia patients. We hypothesise that 
the (partial) duplications of M YTiL  in patients 1 and 5 in our study cohort m ay af­
fect th is regulatory function in the CNS by either disruption or dosage effects. For 
ASTN2 at 9q33.1 an exonic deletion was observed in patient 4, and a partial duplica­
tion in patient 11, suggesting that disruption of this gene m ay have functional con­
sequences. The other gene affected by the duplication in patient 11 -  pregnancy- 
associated plasma protein A (PAPPA) -  is predom inantly expressed in the placenta 
[135] and thus not likely to be involved in the development of schizophrenia. As yet, 
little is known about ASTN2 -  except that it is h ighly expressed in the brain (Table 
3.3) -  but its homologue ASTN  is known to play an im portant role in neuronal 
m igration [126,136]. Apart from the C N V in 5p15.2 that disrupted the C T N N D 2  gene 
in patient 3, we did not identify any additional aberration w ithin th is locus, which 
suggests that CNVs in this locus are extrem ely rare and, thus, likely to be patho­
genic. Interestingly, C T N N D 2  is located in the critical region for autism  spectrum 
disorder [MIM #209850] and mental retardation in Cri du Chat syndrome [MIM 
#123450] [137-139].
In conclusion, we identified rare CNVs affecting 4 neuronal genes in a selected 
cohort of 54 schizophrenia patients. A subsequent targeted but considerably larger
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follow -up study did not reveal any coding sequence-affecting CNVs in these loci in 
the control cohort, whereas 4 were found in the patient cohort. In total we identi­
fied four sm all exonic deletions disrupting a part of a gene im plicated in neuronal 
functioning, as well as 3 large duplications w ith possibly sim ilar disruptive effects. 
The frequency of these rare CNVs combined is considerable in the selected cohort 
of Dutch patients w ith deficit schizophrenia (4 in 54 patients, 7 %  of cases). Even in 
the larger unselected Dutch cohort of schizophrenia patients we identified these 
rare CNVs in 7 out of 752 cases (0.9%), even though we screened only 5.7 Mb of 
genom ic sequence. The freque ncy of rare CNVs affecting genes reported by Walsh 
et al. [115] in patients w ith schizophrenia or schizoaffective disorder is much higher 
(24 %  of cases), but they also identified such variants at considerable frequency in 
controls (5%). W hile the results from us and others [114,115,121] dem onstrate the 
relevance of rare CNVs in schizophrenia, they also challenge the clinical interpreta­
tion of non-recurrent rare CNVs, even if  they affect genes. Our findings indicate 
that it is im portant to carefully interpret the individual CNVs in order to assess 
their involvem ent in disease. Large-scale CNV-based association studies are es­
sential to unravel the role of CNVs in disease aetiology, but they should take into 
consideration that the consequences of intronic or intragenic CNVs are likely to 
be different from CNVs that affect coding sequences. Small single gene CNVs are 
different from larger CNVs affecting m any genes, and deletions m ay clearly exert 
different effects than duplications. Finally, assessing inheritance patterns of CNVs 
and their segregation w ith disease w ill be of added value for establishing the true 
clinical relevance of this im portant class of genom ic variation.
3  4  Material and Methods 
Patient material
In the first part of the study 54 patients with deficit schizophrenia -  according to DSM-IV-TR 
criteria [119] -  were investigated. Inpatients and outpatients were recruited from different 
psychiatric hospitals and institutions throughout The Netherlands. All patients were of Dutch 
descent, with at least three out of four grandparents of Dutch ancestry. Detailed medical and
Table 3.6. Names and sequences of MLPA probes for array validation.
Name forward sequence reverse sequence length 
half probe
MYTiL_SNTG2_N GAAAATGCCTAT GACATCCGGCT g a a g c t g a c g a a a g a g g t g c t g a <N
ASTN2_I GTGCAGATGAAGAAACCGACGCCCA t g g g c g a a a g g g a c c t g c t c a a g t t 25
NRXNiJ I CTAACAGCTTCTGGCTATTTCGCAACTGCTG g g t t t g a g t c c t a c t g t t g c c g t g g c t g a a a 31
MYTi L_XIX GGCTCTGAAGCT GTGTTTTGCCCACAGCCAGAA g a c t t g g a c c c a t t c c a g g a g g c t c t a g a a g a a 33
ASTN2_XVI CTCTTCCTGTCTTGTGCCTCTCCAGAGACCACAGA g c t g g g c a g c a a g a a g g a g c t c a a g t c c a t g c c c t 53
NRXNiJ V GTCACCGTGACAACCCTGCCTTCCCATGCTCCCTT GTTTAT t g c t g a c tg t g c t c t t g t t t c c c t t c a a g g t c t g g c g c a c c 41
MYTi L_XXIV CCTAGGTCCTCCTGGTGTTACATGTCACGCACACTT GTGCGTT tc a g a t t a c c a c g a t g g a g a g c a a c c t g a a g a c c a t c g a a g a g 43
ASTN2_XVIII GCTGTCCCCAACAGTGGAGCCCTCCAGTACTGTGGTCTCCTTGGA g t g g g t g g a t g t t c a g c c a g c t a t t g g g a c c a a g g t c t c c g a c t a 45
NRXNi j CAGCAGCAGTCGCCTTATCCATAGACCTCAGGAAATTCGCTTTGACCGA t g c a t g c t t c a g g c t c t g g c t c g a g c t g a g g g g a a t a a c c g g g c a g g t a 49
36
psychiatric histories were collected, including the Comprehensive Assessment of Symptoms 
and History (CASH), and the Schedule for Deficit Syndrome (SDS). The CASH is a structured 
interview for major psychoses and affective disorders, to make diagnoses using DSM-IV-TR 
criteria. It is used for research purposes only. The SDS was used to measure deficit syndrome 
[118]. This instrument measures 6 negative symptoms on a 5-point scale. The negative symp­
toms are restricted affect, diminished emotional range, poverty of speech, curbing of interest, 
diminished sense of purpose and diminished social drive. When at least 2 out of 6 symptoms 
are predominantly present in the last 12 months and are not due to paranoia, anxiety, depres­
sion, mental retardation or drugs/medication -  and the diagnosis of schizophrenia is made 
-  then a person is considered to have the deficit subtype of schizophrenia. The concept of the 
deficit syndrome is defined as a subtype of schizophrenia in which primary enduring negative 
symptoms predominate, and in which the course is chronic. Estimations of the prevalence 
of the deficit syndrome among patients with schizophrenia are about 15% in first episode 
patients and about 25-30% in the population of the more chronically ill patients [140]. In the 
second phase a larger sample of 752 additional patients with general schizophrenia and 706 
controls -  all of Dutch ancestry -  was investigated. The additional patients were recruited 
in different psychiatric hospitals and institutions in the Netherlands, partly coordinated via 
academic hospitals in Amsterdam, Groningen, Maastricht, and Utrecht (Genetic Risk and Out­
come of Psychosis (GROUP) project). Of all patients detailed medical and psychiatric histories 
were collected, including the CASH. Only patients with a DSM-IV diagnosis of schizophrenia 
were finally included as cases. The controls were volunteers and were free of any psychiat­
ric history. Fingerprinting (Illumina DNA panel, 400 SNPs) of all samples excluded related 
patients and controls. Ethical approval was obtained from the local Ethics Committees. All 
participants gave written informed consent.
Internal controls
Within our diagnostic cytogenetic laboratory we have collected over 1300 mentally retarded 
patients. We hybridised genomic DNA from 500 of these and from 100 unaffected parents to a 
custom tiling-resolution array consisting of 32,447 BACs. Genomic DNA from the remaining 800 
patients and 300 parents were hybridised to the Affymetrix GeneChip 250K SNP (Nsp) array. The 
total set of patients and parents were used as an internal control database in this study.
Microarray hybridisation
The 54 selected patients were initially analysed for copy number variation using Affymetrix' 
GeneChip 250K SNP (Nsp) arrays. Genomic DNA from EDTA venous blood was obtained from 
all patients and hybridisation to the microarrays was performed according to standard proto­
cols (Gene Chip Mapping 500K Assay Manual)
The second-phase samples were genotyped at UCLA, USA on HumanHap550v3 BeadArray™ 
(Illumina, San Diego, USA), according to standard protocols.
Copy number analysis
We analysed copy number variation in the first-phase cohort with the CNAG version 2.0 
software as described previously (Affymetrix, Santa Clara, CA, USA) [120]. We set the HMM 
algorithm thresholds for N=1 and N=3 to -30 and 40 respectively, which means that the algo­
rithm detects deletions for 4 consecutive SNPs with a LogR of -.3 or lower, and duplications for 
4 consecutive SNPs with LogR of .4 or higher. We previously reported on this algorithm for the 
same array type, with an estimated false discovery rate of 5 %  [141]
37
• 3
. R
ec
ur
re
nt
 
CN
Vs
 
di
sr
up
t 
3 
ca
nd
id
at
e 
ge
ne
s 
in 
sc
hi
zo
ph
re
ni
a 
pa
tie
nt
s 
•
• R
are
 
co
py
 
nu
m
be
r 
va
ria
nt
s 
an
d 
th
ei
r 
ef
fe
ct
 o
n 
sc
hi
zo
ph
re
ni
a 
- t
ak
in
g 
the
 
ge
no
m
e 
ou
t 
of 
the
 
br
ain
 
•
In order to screen for the presence of potential CNVs in the second-phase samples we used 
PennCNV [128] and OuantiSNP [142] software. Both programs rely on an Objective Bayes Hid- 
den-Markov Model to estimate copy number variations, in which the hidden states denote 
the unknown copy number at the inspected SNPs. We used genotype data to assess copy 
number variation, based on simultaneous measurement of both signal intensity variations 
(log2R) and changes in allelic composition. All potential CNVs detected were subsequently 
visually inspected and confirmed using the BeadStudio software (Illumina, San Diego, USA).
Multiplex ligation-dependent probe amplification
To confirm the microarray analysis, patients 1, 2 and 4 were screened with multiplex ligation- 
dependent probe amplification (MLPA) essentially as described previously [107]. MLPA probes 
were designed for exons 19 and 24 of MYTiL, exon 2 of SNTGD2 (Patient 1), exons 1, 2 and 4 of 
NRXNi (Patient 2) and exons 1, 16 and 18 of ASTN2 (Patient 4). Sequences of test and control 
probes are in Table 3.6. Probes were developed in accordance with a protocol provided by 
MRC-Holland (Amsterdam, The Netherlands). Ten probes were combined in one MLPA as­
say, in combination with three standard control probes. Equal amounts of probe mix and 
hybridisation buffer were added to 100-200 ng. of DNA from each sample, followed by heat 
denaturation and overnight incubation at 60°C. Ligation products were amplified by regular 
PCR with the use of a 6-FAM-labeled primer set. Amplification products were identified and 
quantified by capillary electrophoresis on an ABI 3730 genetic analyzer (Applied Bio systems, 
Foster City, CA, USA). Data were normalised by dividing each probe's signal strength by the 
average signal strength of the sample. This normalised peak pattern was divided by the aver­
age peak pattern of all samples in the same experiment. Values for control wild-type peaks 
were centred at 1.0. A copy number loss was called below a fixed threshold value of 0.7.
Genomic quantitative PCR
Genomic quantitative PCR (gOPCR) was performed for validation of the duplication in patient 
3 by SYBR Green-based quantification according to the manufacturer's protocol (Bio-Rad, 
Veenendaal, the Netherlands). PCRs were performed on an iCycler (MyiO single colour Real­
Time detection System, Bio-Rad, Veenendaal, the Netherlands). Primers were developed by
Table 3.7. Names and sequences of qPCR primers for array validation.
Name left primer* right primer %CG Length
(kb)
DAP I AGGCAAAACCAAGTGCTCTG CCTCAAATGACATCCAACCAG 43 109
CTNND2_XXII ccagtgtggctcttctttcc GAAATGGCTGGTAGGTCTCG
3
3 91
LOC134145 ATTGGACTCCAGACCACGTC GTACAGGGCCTCTTTTCACG 54 94
bpi0268446 AGCCACATTCCAGAAAGACG CTCTCGTGTCCCCAGTCTTC 46 116
CTNND2_XI ttgcagGAGTCCTTTGGAAC GAATTTTCCCAGCCTGAGTG 52 118
TAS2R1 GAATTGGAACTTTGGCTTGC CAGATGAAGAGTGGGTGACG 53 83
CTNND2JI CAGCCTTCATCAGCCTCAG GATGGCAGAGGTGGTTTCTG 56 96
"Upper case letters denotate exonic sequences; intronic sequences are denoted by lowercase letters
the Primer3 program [108]. Sequences of the primers used to quantify genomic DNA are 
shown in Table 3.7. PCR products were between 80 and i2obp. All primer pairs were validated 
in triplicate using serial genomic DNA dilutions that result in an end concentration of the
38
equivalent of 400, 200, 100, 50 and 25 pg/pl DNA. All primers were 100 ± 5%  efficient, which 
means that the PCR product is doubled in each cycle. OPCR quantifications were performed 
in duplicate on 1 ng./pl DNA and included a water control. All comparative threshold cycle 
(Ct) values were within the range of DNA dilutions used to validate the primers. The melting 
curves and agarose gel analysis of all PCR products showed a single PCR product. All controls 
were negative. DNA copy number differences between two samples were calculated by the 
Ct or 2AACt method. In short, the Cts of three reference genes, CFTR,SLQ6A2, and TRAF2 and 
the gene of interest were measured in the two samples. Then, for each sample the Ct of each 
of the reference gene was subtracted from the Ct of the gene of interest, which results in 
the ACt. The AACt is subsequently calculated by subtraction of the ACts of both samples. A 
detailed derivation of the formula to calculate the fold difference, 2AACt, has been described 
by Livak and Schmittgen [143]. The final DNA copy number difference between two samples 
is calculated from the average difference of the three reference genes from the gene of inter­
est.
Expression data analysis
To assess expression of identified genes we downloaded a set of 353 expression samples of 
65 normal human tissues that had been hybridised to Affymetrix GeneChip Human Genome 
U133 Plus 2.0 arrays (GSE3526; 20) from the Gene Expression Omnibus [144]. For the identified 
genes we calculated the ratio of expression in brain tissue over the median expression of the 
gene in all tissues.
Acknowledgements
We are grateful to the patients for their cooperation. We thank Joseph DeYoung for technical 
assistance, Harry van Someren for database management and Christian Gilissen for bioinfor- 
matic support. This work was supported by a grant from the Netherlands Organisation for 
Health Research and Development (ZON-MW, to JAV). The GROUP project was also supported 
by a grant from ZON-MW, within the Mental Health program (project number: 10.000.1001). 
In addition, genome-wide SNP genotyping of the Dutch schizophrenia sample was funded by 
the NIMH RO1 MG078075 to RAO.
39
• 3
. R
ec
ur
re
nt
 
CN
Vs
 
di
sr
up
t 
3 
ca
nd
id
at
e 
ge
ne
s 
in 
sc
hi
zo
ph
re
ni
a 
pa
tie
nt
s 
•
• Rare copy  n u m b e r  v a r ia n ts  a n d  th e ir  e ffec t o n  sch iz o p h re n ia  - ta k in g  th e  g e n o m e  o u t  o f  th e  b ra in  •
-p*o
4. A duplication of 
RORa is associated with 
brain function changes: 
interpretation of CNV using 
intermediate phenotypes
Vrijenhoek T, Friedman JM, Markx S, Mikhno A, Leung DK, Moeller JR, 
Khandji AG, Janssen IM, van der Vliet WA, Fallon BA, van Heertum R, 
Saxena C, Parrella M, Edelmann L, Brunner HG, Geurts van Kessel A, 
Davis KL, Veltman JA (2010) A duplication of RORais associated with 
brain function changes: interpretation of CNV using intermediate 
phenotypes. Submitted manuscript
Abstract
A num ber of rare copy num ber variations (CNVs) have recently been im plicated in 
the development of neuropsychiatric disorders such as autism  and schizophrenia. 
Interpretation of the role of disease-associated CNVs is difficult, and would benefit 
from detailed analysis of the clinical characteristics. Current psychiatric classifica­
tion systems provide robust diagnostic criteria, but more detailed (quantitative) 
neuropsychological and neuroim aging measures could improve the analysis. Here 
we report on a rare partial duplication of the R O R a i (retinoid-related orphan recep­
tor alpha i) gene that co-segregates with highly refined neuropsychological, struc­
tural and functional im aging phenotypes in a fam ily of which m embers varied in 
clinical diagnosis. Although three fam ily m embers w ith the duplication were diag­
nosed differently according to standard psychiatric classification, their underlying 
brain phenotypes are clearly associated w ith the RORazduplication. This report 
demonstrates that the functional interpretation of rare CNVs can be improved by 
detailed clinical and im age analysis, w hich provides useful insight into the impact 
of complex genetic variation on brain functioning in sm all, select samples.
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• 4 1 IntroductionRecent associations of copy num ber variants w ith neuropsychiatric dis­
eases such as autism  and schizophrenia hold promise for the discovery of entirely 
novel m echanism s of disease pathogenesis [49,115]. The detection of such CNVs 
gives great insight into genom ic variation, but the am ount of variation observed 
in apparently healthy ind ividuals is troubling clinical interpretation [38,145]. W hile 
large-scale association studies are essential to reveal the contribution of common 
genom ic variants to disease, the effect of rare genom ic variants is best studied 
in detail in fam ilies. Indeed, one of the strongest candidate genes for schizophre­
nia -  disrupted in schizophrenia (D IS C ) -  was orig inally identified as a genomic 
im balance in one large pedigree [74]. This balanced translocation disrupting 
D IS C  w as associated w ith m ultiple psychiatric diagnoses in this fam ily, including 
schizophrenia, schizoaffective disorder, recurrent m ajor depression, and adolescent 
conduct and em otional disorders [74]. Despite th is psychiatric heterogeneity trou­
bling the genotype-phenotype association, the translocation associated w ith the 
psychophysiologic abnorm alities of prolonged latency and decreased am plitude 
of the P300 event-related potential (ERP) in fa m ily  m embers w ith either psychotic 
or affective psychiatric diagnoses. This exam ple illustrates how the use of a more 
refined interm ediate phenotype can improve the investigation of the im pact of 
complex genetic variation on brain functioning, even in a single fam ily. Moreover, 
neuropsychological and functional im ag ing interm ediate phenotypes have been 
successfully used to improve associations w ith genetic variation and phenotype 
in patients w ith psychiatric disease [146]. In th is study we combine the power of 
high-resolution genom ic m icroarrays w ith that of detailed neuropsychological as­
sessment, m agnetic resonance im aging (MRI) and positron em ission tom ography 
(PET), and identify a genom ic duplication in the transcription factor retinoid-relat­
ed orphan receptor alpha (RORa) in a m ultiple affected fa m ily  with heterogeneous 
psychiatric phenotypes.
Table 4.2. Sequences of the test and control synthetic probes for the complete MLPA analysis
Probe name
RORa.a_intron2
RORa.a_exon3
RORa.d_exoni
Control2
RORa.a_exon9
RORa.b_exon2
RORa.c_exon2
Control
RORa.a_exon4
RORa.a_exon11
RORa.a_exon1
Control4
Controls
forward sequence reverse sequence length 
half probe
CATCTCCACCTGTTTGTACTG
CATCAGGAATCCATTATGGTGTC
CGCACCGCGGCTTAAATGATGTATT
cgcgcccagtccttcctgcaaacggag
CTATGCACCTGACTGAAGATGAAATTGCATT
CAGGTGATGCTTTTGTTCTTACTGGCGTCTGTG
CTGTTTTCCCTGACAGCTCTTCAACCTGTAGCTCC
GCCTGCGGTGAACACTGTGAACGTGCAGATCGCCTTC
GCTGCCAACACTGTCGATTACAGAAATGCCTTGCCGTAG
GAGACACTTTATATGGCCCTGCACAGACCTGGAGCGCCACA
CTCTGAAAACAGAAGATAGAGGGAGTCTCGGAGCTCGCCATCT
GACCCTGACAACCTGGAAAAGTACGGCTTCGAGCCCACACAGGAG
CAGCAATTATGCCAGCCTGACCTACCTTCAGATGGCTTGAAATGGTT
AGTGTGTGTTGAAGAGAGAGG
ATTACATGTGAAGGCTGCAAGGT
TTGTGATCGCAGCGATGAAAGGTGA
acctcggtcatctagccccacccctgc
ATTTTCTGCATTTGTACTGATGTCAGCAGgt
TAAGTGAATCCAAAGGCCTCCTGACCTGTCCTC
CTGAGCAGGCTGTTCTGGTCTCAACTTGAGCACAT
TCCGGTTTGACAGAGGCATGCTGGGCCATCATGCTCC
GGAT GTCTCGAGATGgtgagctctcacagcttgagttgt
CACTGCACATCTTTTGGTGATCGGGGTCAGGCAAAGGAGGG
CCAGCGATCTCTACATTGGGAAAAAACATGGAGTCAGCTCCGG
GGAAAGCTCTTCCAGCTCTACCCCAGGAACTTCCTGCGCTAGCTG
TACTACAGTCTGCATCACTATGTCTGAGACCCTTGTGTTCTCCATCC
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Figure 4.1. 
Duplication in 
RORa. (a) 250K SNP 
array results of 
chromosome 15 of 
Subject 1. The upper 
panel shows the 
Log2 ratio of test 
versus reference 
intensities fo r each 
SNP on chromosome 
15. A value of 
0.5 represents a 
duplication in 
the patient's DNA 
compared to a pool 
of DNA from healthy 
individuals. The 
lower panel shows 
the average Log2 
ratio of test over 
reference intensities 
over 4 consecutive 
SNPs, using a sliding 
window. (b) MLPA 
plots showing the 
presence of the 
RORa-duplication 
in Subjects 1,2 and 
3, but not in the 
brother of Subject 
3 and the half­
brothers of subjects 
1 and 2, nor in any of 
the healthy controls. 
(c) Snapshot of 
the UCSC Genome 
Browser showing 
the breakpoints of 
the duplication as 
detected by the 250K 
SNP array.
4 2  ResultsWe performed genom e-w ide C N V  screening using a custom 32K tiling - 
path BAC array [37] on genom ic DNA from the proband (Subject 1) w ith schizo­
affective disorder, seizure disorder, mental retardation, and dysm orphic facial 
features and identified a rare genom ic duplication on chromosome 15q22 (Figure 
4.1a; Table 4.1). The breakpoints were fine-m apped w ith the Affym etrix 250K SNP 
array (Affymetrix, Santa Clara, CA, USA) to the first tw o exons of the isoform 1 of 
RO Ra  (Figure 4.1c). The affected exons are unique for isoform 1, w hich is specifically 
expressed in the brain [147]. These exons encode the characteristic N-term inal part 
that distinguishes this isoform from the other three, and w hich determ ines its 
binding activity [148]. We further confirmed the duplication w ith a targeted m u lti­
plex ligation-dependent probe am plification (MLPA) assay consisting of nine syn­
thetic probes targeting all four RO Ra  isoforms (Figure 4.1b; Table 4.2). MLPA testing
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Table 4.1. Detailed clinical features of members of a single family with various psychiatric disorders
Clinical
Characteristic
Subject 7 
(Pro band)
Subject 2 
(Sister)
Subject 3 
(Mother)
Subject 4 
(Half Brother)
Subject 5 
(Half Brother)
Subject 6
(Maternal
Uncle)
RORa Duplication 
Present
Yes Yes Yes No No No
Age 40 38 63 29 31 58
Gender Female Female Female Male M ale M ale
Developmental
History
Speech and motor 
delays
Speech and motor 
delays
Norm al Norm al Norm al Norm al
Seizure Disorder Present Absent Absent Absent Absent Absent
Facial Dysmorphisms Present Present Absent Absent Absent Absent
Psychiatric Diagnosis Schizoaffective D is­
order
Schizophrenia M ajor Depression None None Schizoaffec­
tive Disorder
Intellectual Abilities FSIO = 54
Global im pairm ents
FSIO = 59
Global im pairm ents
FSIO = 97
Im pairm ent restricted 
to tests of non-verbal 
skills:
1. Block design
2. M atrix reasoning
3. D igit-sym bol 
substitution
FSIO = 102 
No im pairm ents
FSIO = 108 
No im pairm ents
FSIO = 116 
No im p air­
ments
MRI Findings 1. Peri-sylvian fissure 
atrophy
2. Pre-pontine atrophy
3. Ventricular enlarge­
m ent
1. Peri-sylvian fissure 
atrophy
2. Borderline pre-ponti- 
ne atrophy
3. Ventricular en larg e­
m ent
1. Peri-sylvian fissure 
atrophy
2. Pre-pontine 
atrophy
None None None
FDG PET W hite m atter hyper­
m etabolism : CC, 1C, 
mPFC.TC, SC, lingual 
gyrus
W hite m atter hyper­
m etabolism : CC, 1C, 
m PFC.TC, SC, lingual 
gyrus
W hite m atter hyper­
m etabolism : CC, 1C, 
m PFC.TC, SC, lingual 
gyrus
W hite m atter hyper-m eta- 
bolism : lingual gyrus.
W hite m atter hyper-m eta- 
bolism : lingual gyrus
W hite matter 
hyper-m eta- 
bolism : lingual 
gyrus
W hite m atter hypo- 
m etabolism : SC, OC, 
IPC
W hite m atter hypo- 
m etabolism : SC, OC, 
IPC
W hite m atter hypo- 
m etabolism : SC, OC, 
IPC
W hite m atter hypo-m eta- 
bolism : OC, IPC.
W hite m atter hypo-m etabo- 
lism :O C , IPC
W hite matter 
hypo-m etabo- 
lism : OC, IPC
Figure 4.2. Axial 
and sagittal 
Ti-weighted 
MRI images 
demonstrating 
brain structural 
abnormalities 
in the three 
family members 
affected with 
the RORa 
duplication. 
Arrows in panels 
A, C and E indicate 
peri-sylvian 
fissure atrophy in 
subjects 1,2 and 
3 respectively. 
Arrows in 
panels B, D, and 
F indicate pre­
pontine atrophy 
in subjects 1,2 and 
3 respectively.
of 200 healthy controls revealed no duplication in the RORa  region, nor has it been 
observed in genom e-w ide m icroarray databases encom passing more than 900 
unaffected sam ples and more than 1300 unexplained mental retardation samples 
available at the Radboud University N ijm egen Medical Centre (unpublished data). 
Furthermore, the latest version of the Database of Genom ic Variants [28] contains 
no CNVs at this locus.
We obtained phenotypic data and DNA from three relatives of the proband 
affected w ith psychiatric disorders: a sister w ith schizophrenia, mental retardation 
and dysm orphic features (Subject 2), the mother w ith recurrent m ajor depression
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Figure 4.3. White 
matter brain map of 
abnormal glucose 
metabolism in 
family members 
with and without 
RORa duplication 
(FAMdup+ and 
FAMdup-) compared 
to healthy controls 
(NC), in which the 
FDG/PET thresholded 
z-map is superimposed 
on a single subject, 
structural MRI image 
(SPM5 Ti-weighted 
map). Axial, sagittal 
and coronal slices 
depict statistically 
significant alterations 
of white matter glucose 
metabolism located in 
the neighborhood of 
the corpus callosum 
(CC), lentiform nucleus 
(LN), and internal 
capsule (IC); the medial 
prefrontal (MPFC), 
superior temporal 
(STC), occipital (OC) 
and inferior parietal 
(IPC) cortices, plus 
somatosensory cortex 
(SC). The upper rows 
show brain regions 
with significant hyper­
glucose metabolism 
in the three FAMdup+ 
fam ily members 
only (a), and in all six 
fam ily members (b).
The lower rows show 
brain regions with 
significant hypo­
glucose metabolism 
in the three FAMdup+ 
fam ily members only 
(c), and in all six fam ily  
members (d).
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Figure 4.4.
The canonical 
variates analysis 
classification 
function that best 
differentiated 
the group of 
three RORdup+ 
family members 
from the group 
of 17 RORdup- 
individuals. The 
solid disks and 
surrounding ellipses 
are the mean 
score and its 95%  
confidence interval 
classification; of 
RORdup+ (left) and 
of RORdup- (right) 
N C are indicated, 
by crosses. All 20 
individuals were 
classified correctly.
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Classification By WM Glucose Metabolism
Intermediate (or 
endo-) phenotypes
-  quantitatively 
measurable and 
heritable features 
that may have a 
more direct relation 
to gene structure 
and activity than the 
diagnosed disease
(Subject 3), a maternal uncle w ith schizoaffective disorder (Subject 6), and from 
tw o half brothers unaffected w ith psychiatric disorders (Subjects 4 and 5) (Table
4.1). We applied our targeted MLPA assay to these five fa m ily  m embers and identi­
fied the same RO Ra  duplication in Subject 2 and Subject 3, but not in Subjects 4, 5, 
and 6 (Figure 4.1b).
Since the duplication did not co-segregate w ith a single psychiatric diagnosis in 
th is fa m ily  we hypothesised that refinem ent of the phenotype utiliz ing neurop­
sychological, structural and functional im ag ing data obtained on these subjects, 
w ould reveal specific biological traits associated w ith the duplication. 
Neuropsychological profiles based on the W echsler Adult Intelligence Scale -Third 
Edition (WAIS-III) [149] demonstrate cognitive im pairm ent in those individuals 
harbouring the duplication. Subjects 1 and 2 met criteria for moderate mental 
retardation as indicated by Full Scale IQ (FSIO; M aterial and Methods) scores in the 
extrem ely low range (57 and 59 respectively, w ith a global pattern of im pairm ent 
for both). Subject 3, although achieving an average FSIQ score of 97, demonstrated 
a focal pattern of im pairm ent involving non-verbal cognitive skills, including visuo- 
constructive ability, v isuo -analytic ability, and cognitive processing speed. Interest­
ingly, Paunio and colleagues [150] have reported an association between the I5q22 
region containing RORa  and visual attention performance in Finnish schizophrenia 
fam ilies. None of the fa m ily  m embers w ithout the RORa  duplication demonstrated 
any global or focal neuropsychological im pairm ents.
Ti-w eighted MRI im ages demonstrated all three ind ividuals harbouring the 
duplication to have peri-sylvian fissure and pre-pontine atrophy (Subjects 1 and 3 > 
Subject 2), w hile Subjects 1 and 2 also showed ventricular enlargem ent (Figure 4.2). 
None of the three fa m ily m embers w ithout the duplication showed any anatom i­
cal abnorm alities on MRI.
Fluoro-2-deoxy-D-glucose (FDG) positron em ission tom ography (PET) scanning 
(Figure 4.3) on all fa m ily  m embers as well as 14 unrelated normal controls in ­
dicated an abnorm al m etabolism  pattern unique to the three fa m ily members 
affected w ith the RORa  duplication. At a threshold of |z| > 2.0, the voxelated map
47
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(Figure 4.3) showed significant w hite matter hyper-m etabolism  in fam ily  members 
affected w ith the RORa duplication in the corpus callosum  (CC), internal capsule 
(IC), in the vicin ity of the medial prefrontal cortex (mPFC), tem poral cortex (TC), and 
sensorim otor cortices (SC). In addition, the map shows significant w hite matter 
hypo-m etabolism  in fa m ily  m embers affected w ith the RORa duplication in the 
v ic in ity of the sensorim otor cortex (SC), occipital cortex (OC), and inferior parietal 
cortex (IPC). Figure 4 .4  depicts results of the canonical variates analysis applied to 
the FDG-PET data from the fam ily m embers and 14 normal controls (M aterial and 
Methods). M etabolic activity from those w hite matter regions highlighted in Fig­
ure 4.3 produced a classification function (i.e., linear com bination of subject prin­
cipal com ponent scores) that m axim ally differentiated the three fam ily members 
affected w ith the RORa duplication from the three unaffected fam ily members 
and the 14 normal controls w ithout the duplication (Figure 4.4).
4  3  DiscussionThe combined results of the genomic, neuropsychological, and neu­
roim aging studies conducted in this fam ily show that partial duplication of the 
gene encoding R O R ai co-segregates w ith specific interm ediate phenotypes not 
apparent from the standard clinical diagnosis. As is often the case for psychiat­
ric disorders, each fa m ily  m ember in the current study presents w ith m ultiple 
clinical features, thereby troubling assessm ent of a clear genotype-phenotype 
relationship. Intermediate phenotypes based on im aging and neuropsychological 
functions have been used successfully in psychiatric genetics [146,151]. The results 
presented here dem onstrate how the analysis of interm ediate phenotypes can 
improve the interpretation of the im pact of complex genetic variation on brain 
functioning, even w ith a sm all sam ple size.
W hile the duplication identified in th is study is the first to be reported in the RORa 
gene, Klar and colleagues [152] described a balanced reciprocal t(4;15)(q22.2;q21.3) 
translocation affecting intron 1 of R O Rai in three fam ily  m embers w ith profound 
obesity. The reported phenotype did not include subnorm al intelligence, however, 
neither form al neuropsychological testing nor im aging studies were performed. 
RORa is a member of the superfam ily of nuclear receptors [147], w hich in the 
mouse is strongly expressed in the Purkinje cell layer of the cerebellum and thala-
Figure 4.5.
Schematic 
representation of 
the hypothetical 
effect of the 
RORa-1 duplication. 
Depicted are exons 
1-4 (number 1 to 
4) for the normal 
RORa-i isoform.
The upper panel 
shows that the last 
nucleotide of exon 
2 is translated into 
serotonin together 
with the first two 
nucleotides of 
exon 3. In the case 
of insertion of the 
duplicate (exon 1' 
and 2'; lower panel), 
the last nucleotide of 
exon 2 is translated 
into tryptin together 
with the first two 
nucleotides of exon 
1’. This results in a 
stop-codon further 
downstream. A 
similar scenario 
takes place in case 
the duplicate is 
inverted.
staggerer mice
mice with severe 
ataxia as a result of 
-  what turned out to 
be - a deletion in the 
RORa gene
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mus [153,154]. RORa is expressed to a lesser extent in other brain regions such as 
brainstem  nuclei, olfactory bulb, hippocampus, and cerebral cortex (m ainly in layer 
IV) [154-156]. Although an extensive survey has never been performed, the results 
of Sashihara and colleagues [153] indicate that specific isoform regulation exists 
w ithin  the brain. For example, isoform 1 and 4 are co-expressed in the m urine and 
hum an cerebellum [37].
Both the staggerer [156,157] and R O R a-/- mouse [153] lack functional RORa protein 
and demonstrate a severe cerebellar ataxia due to m assive cerebellar neurodegen­
eration [158], w hereas the individuals affected w ith the partial RORa duplication 
reported here show no gross cerebellar abnorm alities, rather, peri-sylvian and pre­
pontine atrophy. Moreover, the staggerer mouse shows decreased m etabolic activ­
ity in several thalam ic nuclei and in tem poral association cortex, and increased 
m etabolic activity in deep cerebellar nuclei [159], whereas the ind ividuals affected 
w ith the RORa  duplication demonstrate prim arily alterations in subcortical m eta­
bolic activity. Negative consequences for higher cognitive functions are observed, 
however, both for affected ind ividuals reported here w ith the RORa  duplication as 
they have been for RORa  m utant mice [160]. These findings suggest that the RORa1 
isoform regulates distinct sets of downstream  target genes, w ith possible profound 
effects on subcortical functioning.
RO Ra  plays a role in neuroprotection from apoptic stim uli via a decrease in reactive 
oxygen species (ROS) production [161]. The decrease in ROS production and the 
subsequent neuron-protection is specific to the expression of the RORa1 isoform 
[161], affected in th is study. S im ilar to Klar and colleagues [152], we could not detect 
expression of the RORa1 isoform in w hite blood cells w hich could be expected as 
th is isoform is known to be specifically expressed in the brain [147]. However, it 
seems unlikely that the duplication resulted in an over-expression of functional 
RORa1 given that the duplication affects only part of the gene, and the neuronal 
pathology suggested by the neuropsychological and brain im aging findings. A 
likely scenario is one w here the duplication results in a fram eshift that leads to an 
early stop-codon and thus a non-functional protein, as depicted in Figure 4.5.
In conclusion, th is report shows that detailed clinical analysis provides insight into 
relationships between genotype and interm ediate phenotypes when studying rare 
CNVs. By perform ing in-depth neuropsychological assessm ents and im ag ing stud­
ies we provide a significant contribution to the clinical interpretation of genomic 
variation, in show ing that a rare duplication in RORa1 co-segregates w ith neurop­
sychological im pairm ent and distinctive patterns of brain atrophy and decreased 
brain glucose m etabolism .
4 . 4  Material and methods 
Subjects.
The subjects reported on here represent a single pedigree recruited from ongoing genetics 
investigations at the Mount Sinai Hospital, New York, NY and Pilgrim Psychiatric Center, W. 
Brentwood, NY. Subjects were enrolled after obtaining informed consent in accordance with 
protocols approved by the Institutional Review Boards of these facilities. Subjects received 
a psychiatric diagnostic interview with the Diagnostic Interview for Genetic Studies (DIGS)
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[162]. The DIGS is a clinical interview constructed for the assessment of major mood and 
psychotic disorders and their spectrum conditions. It provides a detailed assessment of the 
course of the illness, chronology of psychotic and mood syndromes, and comorbidity.
Intellectual abilities were assessed with the Wechsler Adult Intelligence Scale-Third Edi­
tion (WAIS-III) [149], a widely used measure of adult intelligence. The WAIS-III consists of 12 
subtests yielding a Verbal intelligence quotient (VIQ), Performance IQ (PIQ) and Full Scale IQ 
(FSIQ) scores based upon age-referenced norms. VIQ consists of subtests examining various 
verbal or verbally-mediated skills, such as vocabulary, abstract thinking, range of acquired 
information, understanding of societal behaviours, simple arithmetic calculations, and short­
term auditory memory for digits). PIQ consists of subtests examining non-verbal skills, such 
as visual attention, visual-spatial construction ability, visual pattern and analogy analysis, 
and rapid graphomotor copying skills).
Magnetic resonance imaging (MRI)
A Philips Achieva 3.0T MRI using an eight channel SENSE coil was used to acquire the high 
resolution T1 weighted images. After a localizing and SENSE calibration a 3D MPRAGE 
sequence was used with a TR 6.6ms, TE 3.0ms, flip angle 8°, preparatory TI 791ms, matrix 
256x256, FOV 256mm and a slice thickness of 1mm, no interslice space for an effective voxel 
size of 1mm cubed.
FDG-PET Imaging Protocol
Routine clinical consent was obtained from each subject prior to initiating the PET scan. Writ­
ten IRB approved informed consent was obtained for each control. The PET scan imaging pro­
tocol was the same for both the patients and control groups. The subjects were injected with 
178 ± 6 MBq of 18F-FDG. Thirty minute scans were performed starting after 40 minute post 
18F-FDG injection on a Siemens ECAT EXACT HR+ (Siemens Medical Solutions, Malvern, PA). 
Eight minute 18Gd transmission scan was obtained just prior to PET scanning for the purpose 
of the attenuation correction of PET scans. 18F-FDG was prepared in our Radiopharmacy using 
18F produced by our on-site cyclotron. For comparison purposes, healthy volunteer 18F-FDG 
scans were obtained for 14 subjects (12 female, 2 male) previously used in another study [163]. 
All scans were reconstructed to match the healthy volunteer scans, using standard filtered 
back-projection routines with attenuation correction.
Data processing was implemented as previously described [164], they are discussed here 
briefly noting modifications where necessary. MRI data were segmented into gray matter 
(GMp), white matter (WMp), and CSF (CSFp) probability maps. PET data 40 to 70 minutes post 
18F-FDG injection were motion corrected to their 40-minute frame and co-registered to their 
corresponding MRI. The MRI was then processed through the Freesurfer image analysis suite 
v4.05, which is freely available for download online. Freesurfer results were used in conjunc­
tion with GM , WM , and CSF in an in-house procedure to remove non-brain areas from MRI p’ p p r 
images. PET data were partial volume corrected for CSF spillover using a 2-compartment 
method [165], using GMp+WMp (tissue) and CSFp from above. A spherically symmetric point 
spread function with a FWHM of 5.1 mm was assumed. Brain extracted MRI images were 
non-linearly registered to the colin27 2 mm MNI template using the Advanced Normalization 
Tools symmetric normalization (SyN) package [166], freely available online. SyN was tied for 
first place overall in a recent evaluation of 14 non-linear deformation algorithms [167]. The 
resulting non-linear transforms were applied to MRI co-registered partial volume corrected 
FDG maps and WMp to bring them into MNI space (FDGMNI, WMpMNI) for white matter princi­
pal component analysis (PCA). An average of all subjects' WMpMNI was made and then binary
50
thresholded at 0.5 for use as binary white matter mask in PCA.
A group discriminant analysis of FDG-PET images was used to quantify the accuracy with 
which the RORa duplication phenotype might be identified based on regional abnormali­
ties in white matter glucose metabolism. The discriminant analysis was a canonical variates 
analysis (CVA) applied to the combined FDG-PET data of the six family members and the 14 
NC. The covariates used in the CVA were the subject scores obtained from a principal com­
ponent analysis (PCA) of the subject-by-voxel interactions effects in the combined data of 
the six family members and 14 NC (SSM/PCA). The principal component brain maps and their 
associated subject scores quantified subject differences in regional glucose metabolism that 
were independent of subject differences in global metabolism. The classification function is 
associated with a specific z-score map of brain regions with elevated and/or diminished WM 
glucose metabolism; it is constructed from a specific linear combination of the SSM principal 
component maps. The coefficients of the linear combination are the same as the coefficients 
used in calculation of the classification function.
Genetic analyses.
Array CGH was performed as described previously [37], using a tiling-resolution BAC array.
In brief, we constructed a tiling-resolution genome-wide array consisting of 32,447 Bacterial 
Artificial Chromosome (BAC-) clones to screen the subjects for copy number variations. Next, 
genomic DNA from each subject was labelled with Cy3-dUTP and hybridised once against a 
sex-mismatched reference pool that had been labelled with Cy5-dUTP (both labels from Am- 
ersham Biosciences, GE Healthcare UK, LTD). We used GenePix® 6 software to identify spots 
and to measure fluorescence intensities, and entered all data into a database for further 
analysis. We normalised the log2-transformed test:reference ratio and analyzed them for loss 
and gain regions using a standard Hidden Markov Model. All data were mapped on the NCBI 
build 36 of the UCSC Genome Browser hg 18 [105].
Validation was performed using the Affymetrix 250K SNP Array (Affymetrix, Santa Clara, 
CA, USA), according to the manufacturer's protocol. Affymetrix provides two microarrays, 
each containing approximately 250,000 SNPs, and together these form the 500k assay. For 
this study, we selected the Nsp 250k SNP array, which contains 262,264 25-mer oligonucle­
otides. The 250k SNP array experiments were performed according to protocols provided by 
the manufacturer (Affymetrix, Inc., Santa Clara, CA). Copy-number estimates were deter­
mined using the CNAG software package (version 2.0).
To confirm the results of the array CGH, all samples were screened with Multiplex Ligation 
Probe Amplification (MLPA) [107]. We designed 9 synthetic probes for the complete MLPA 
analysis, which were used in three separate probe mixes. As a reference, three control probes 
were added in each probe mix. The synthetic probes were developed using MELTingeny© ver­
sion 1.0.1 to design the 5' and 3' half-probes. MLPA probes were designed for exons 1 and 3 and 
intron 2 of isoform a, exon 2 of isoform b, exon 2 of isoform c, exon 1 of isoform d and exons 4,
9 and 11 of the overlapping part of RORa. Sequences of test and control probes are in shown 
Table 4.2. MLPA reactions were performed with a starting volume of 8 |jl containing 120 ng. 
DNA. The products were analyzed by capillary electrophoresis using 0.2ul. xnM GeneScan®- 
LIZ 350 on an ABI Prism® 3100 Genetic Analyzer model capillary sequencer (Applied Biosys­
tems) in the GeneScan mode.
51
• 4
. A 
du
pl
ic
at
io
n 
of 
RO
R 
is 
as
so
cia
te
d 
wi
th
 
br
ain
 
fu
nc
tio
n 
ch
an
ge
s:
 i
nt
er
pr
et
at
io
n 
of 
CN
V 
us
in
g 
in
te
rm
ed
ia
te
 
ph
en
ot
yp
es
 
•
• R
are
 
co
py
 
nu
m
be
r 
va
ria
nt
s 
an
d 
th
ei
r 
ef
fe
ct
 o
n 
sc
hi
zo
ph
re
ni
a 
- t
ak
in
g 
the
 
ge
no
m
e 
ou
t 
of 
the
 
br
ain
 
•
Acknowledgments
Array CGH analyses was funded by a grant from the NIH (1R01 MH067806-01A2) awarded 
to J.I.F. The SNP microarray and MLPA analyses was funded by The Netherlands Organisation 
for Health Research and Development (ZonMW grant 917-66-363 to J.A.V.). Funding for the 
acquisition and analysis of PET and MRI data was funded by the Department of Radiology, 
Columbia University, College of Physicians and Surgeons, New York.
52
5. Towards endophenotypes: 
exploring the effect of copy 
number variation on normal 
brain morphology
Vrijenhoek T, Rijpkema M, Steehouwer M, Makkinje R, Hehir-Kwa JY, 
AriasVasques A, Geurts van Kessel A, Brunner HG, Fernandez G, Franke 
B, Veltman JA (2010) Towards endophenotypes: exploring the effect 
of copy number variation on normal brain morphology. Manuscript in 
preparation
Abstract
Recent technological advances have revealed a num ber of genom ic regions that
-  when deleted or duplicated -  may play a role in the aetiology of psychiatric dis­
orders. However, too few copy num ber variation (CNV) studies have thus far been 
performed to be certain about the involvement of each of these regions. Moreover, 
the exact effect of these CN V regions on the development of psychiatric disease 
is largely unknown. Even less is known about the im pact of copy num ber variants 
(CNVs) on normal brain development, w hich further complicates interpretation of 
psychiatric effects. To provide prelim inary insight in the effect of CNVs on the brain, 
we here aim  to identify relationships between rare CNVs and brain m orphology in 
healthy individuals. We obtained high-resolution CN V profiles as well as magnetic 
resonance im aging scans from 601 healthy, right-handed Caucasians between 18 
and 35 years of age. We performed individual t-tests for association between each 
of 9 regional brain volum es and copy num ber variation in 614 genom ic regions. We 
identified five CN V regions w ith putative effects on w hole brain, w hite and grey 
matter, globus pallidus, caudate nucleus, am ygdala and hippocam pus volumes. 
Most interesting were findings of overlapping CNVs on chromosome I9qi3.42 seen in 
23 individuals, which may affect white and grey matter volumes; deletions occur in in­
dividuals with lower white matter (and higher grey matter) volumes, while the reverse 
is true for duplications. The results in this study provide a first indication that rare CNVs 
may affect brain morphology in healthy individuals and indicate that this approach 
may be useful to unravel the complex relation between CNVs and psychiatric disease.
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• 1  Introduction
Rare and de novo  copy num ber variation (CNV) is being increasingly 
considered as a possible cause for various psychiatric diseases, such as autism, 
mental retardation, schizophrenia, and Alzheim er’s and Parkinson’s disease 
[34,35,49,50,52,53,66,85,115,129,138,168-174]. Causality of certain copy num ber vari­
ants (CNVs) has generally been confirmed by assessing segregation w ith disease 
or de novo occurrence in specific fam ilies, and/or by ruling out recurrence in the 
general population. W ith the low frequency and large size of CNVs identified in 
early array CGH studies -  a result of lim ited array resolution -  causality could be 
easily proven. Yet the current high-resolution microarray and sequencing platforms 
allow  for the detection of m any more and sm aller CNVs, w hich complicates inter­
pretation of their effect on the development of psychiatric disease. Comprehensive 
overviews of CN V  in the general population are currently available, ind icating that 
between 5 and 18 %  of the hum an genome may be subject to copy num ber varia ­
tion [28,29,39-43,175-181]. W hile these overviews have shown global occurrence 
of C N V in the general population, they have not provided insight in the effect of 
specific CNVs on normal brain development. This makes one w onder about the oc­
currence and phenotypic effects of CNVs in the general population. In other words, 
w hat should be considered as normal CNV?
In the context of this thesis we have been particularly interested in the effect 
of C N V  on normal brain m orphology and functioning. Most genetic studies in 
psychiatry make use of clearly distinguished cohorts of cases and controls, assum ­
ing an underlying threshold that separates healthy ind ividuals from patients. Yet 
in practice a psychiatric diagnosis is typ ically made through clinical exam ination, 
w hich generally consists of direct interview ing based on criteria described in the 
Diagnostic and Statistical M anual of Mental disorders (DSM; Box 1.3) [119]. Not only 
does this system of diagnosis blur the boundaries between the various psychiatric 
disorders, it also imposes a threshold between health and disease that m ay be arti­
ficial [59]. If psychiatric disorders are extreme positions on a continuum  of normal 
traits, it w ould be useful to study quantitative markers that have a more direct re­
lation to the underlying genotype than diagnostic phenotypes do. This idea is un­
derlying the endophenotype  concept in psychiatry (Box 5.1) [182]. Endophenotypes 
have been successfully used in genetic studies on various psychiatric traits and 
diseases, e.g. electroencephalogram s for the identification of GABRA2 variants as 
risk factors for alcoholism , and auditory gating deficiencies for the identification of
Box 5.1. Definition of endophenotypes.
Endophenotypes are quantitative and disease-associated traits which can be measured independently of 
disease-status.The concept of endophenotypes was originally introduced by John and Lewis in 1966, who used it 
in evolution and insect biology. Gottesman and Gould (2003) applied the term to psychiatry. According to their 
definition, an endophenotype:
• is associated with illness in the population;
• is heritable;
• is primarily state-independent;
• co-segregates with illness within the family;
• is found in non-affected family members of psychiatric patients at a higher rate than in 
the general population.
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CHRNA7 variants as risk factors for schizophrenia [151,183]. H igh-resolution im aging 
technologies now allow  for detailed analyses of the structure and organisation of 
the brain, and to relate changes in brain m orphology and function to genetic varia­
tion. For example, it w as shown that the catechol-O-m ethyltransferase (COMT) 
gene -  w hich regulates dopam ine uptake in the cerebellar blood flow  -  resulted in 
reduced prefrontal cortex activity [146,184]. Likewise fMRI studies have shown that 
serotonin receptor variants affect am ygdala activation [185,186].
The Brain Im aging Genetics (BIG) project aim s to assess the relative contribution 
of variation in the hum an genome to brain structure and functioning in healthy 
individuals, thereby developing novel endophenotypes and assessing the relevance 
of existing ones. The m ain strategy is to uncover possible relationships between 
genom ic variation and brain structure by com bining high-resolution genomic 
technologies w ith structural m agnetic resonance im ag ing (sMRI), as w ell as self-re­
ported health status and internet-based m em ory performance testing. The project 
has collected data from -15 0 0  apparently healthy ind ividuals. In the current study 
we use part of this population to perform an explorative study on the relationship 
between CNVs and morphologic variation in specific brain structures. We screened 
th is cohort first for rare CNVs w ith a m ajor phenotypic effect; analysis of subtle 
effects of more common CNVs w ill require a larger cohort. The current study thus 
serves as a pilot to provide a proof-of-concept; larger follow -up studies w ill be 
required to firm ly establish putative relationships.
Table 5.1. Frequency and size of the CNVs and CNVRs 
identified in this study.
Frequency Average size (kb)
CNVs
0 2,067 41
1 9,378 69
3 5,093 115
4 2,418 54
Total 18,956 78
CNVRs
Private 1257 69
Rare 614 157
Common 110 212
Total 1981 104
Rare CNVRs 
(2 -  30 individuals)
Losses only 278* 71
Gains only 199* 147
"These numbers are high, and are mainly due to a high number of extremely rare CNVs, i.e. 
CNVRs with 2 gains (86 CNVRs) or 2 losses (108 CNVRs).
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• 5 2  CNV identification and brain morphology measurement
From the -15 0 0  BIG participants we selected a homogeneous subset for our 
analyses. W hile extreme cases m ay be of particular interest for C N V studies, 
assessing generally applicable relations between CNVs and brain m orphology 
requires m axim um  phenotypic homogeneity. We thus selected 601 volunteers of 
Caucasian origin, between 18 and 35 years of age, w ith no (self-reported) neuro­
logical or psychiatric history, and right-handed. The handedness is im portant, as it 
is known to affect brain morphology, and m ay thus bias the analyses. We obtained 
saliva-derived DNA sam ples from all ind ividuals and hybridised these to Affym e- 
trix  GeneChip SNP 6.0 arrays, com prising 1.8 m illion genom ic loci for copy number 
analysis [39]. After stringent quality control (Box 5.2) we identified a total of 18,957 
putative CNVs larger than 10kb in size in 601 ind ividuals (Table 5.1); on average 31 
CNVs per ind ividual. The m axim um  size of the CNVs w as 2.9Mb, and the median 
size w as 39kb. We subsequently merged the individual CNVs across sam ples into 
1981 non-overlapping putative CN V regions (Table 5.1). As the focus of our study 
was on rare CNVs we included all CNVs that occurred in more than tw o but less 
than 30 (5%) individuals.
We obtained sMRI im ages for all 601 ind ividuals from the C N V analyses; 27 
individuals had low quality im ages and were thus discarded from the rest of the 
analysis. Im aging w as performed on 1.5 (n = 218) and 3.0 (n = 356) Tesla scanners. 
Automated volum etry in FSL-First [187] was used to segm ent hippocam pus and
Table 5.2. Characteristics of non-corrected brain structure volumes
Structure Mean Std. Deviation Minimum Maximum
Brainstem 21.6 2.5 15 29.5
Accumbens 0.7 0.1 0.5 1.1
Amygdala 2.4 0.4 1.6 3.6
Caudate nucleus 57 0.6 4.0 7.9
Hippocampus 5.6 0.6 3.8 7.7
Lateral ventricle 12.6 6 .0 3.3 45.8
Globus pallidus 1.9 0.2 1.4 3.1
Putamen 6.4 0.7 4.4 8.3
Thalamus 11.3 1.1 7.8 14.7
Grey matter 835.9 78.2 631.8 1144.3
White matter 476.9 54.4 344.8 686.2
Box 5.2. CNV quality control
Data from the Affymetrix 6.0 SNP array were analysed for copy number variations using the Affymetrix Geno- 
typing Console Version 2.1 software. We removed 7 samples based on stringent quality control criteria (Contrast 
OC < 0.4, MAPD < .4, >100 CNVs per individual). Furthermore we excluded copy number variants smaller than 10 
kb in size, covered by less than 10 probes, or with an average distance between consecutive probes of more than 
20kb. Finally we excluded all CNVs in centromeric regions on chromosomes 2, 9, 14, 15 and 16, as these are known 
technical artifacts.
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six subcortical structures (hippocampus, am ygdala, nucleus accumbens, caudate 
nucleus, thalam us, globus pallidus and brainstem), as well as total w hite and grey 
matter (Table 5.2). Volum es of bilateral structures were corrected for total brain (= 
grey m atter +  w hite matter) volum e for further analysis.
Relationships between CNVs and brain 
morphology
Based on the CN V and sMRI results we created a database, in w hich each of the 574 
ind ividuals w as assigned a copy num ber value (0, 1, 2, 3, or 4) for each CN V region, 
and a total-brain-volum e-corrected volum e m easurem ent for each brain structure. 
We used this database to assess the relationships between rare C N V regions and 
brain morphology. Bi-allelic-based association models that exist for SNP-based as­
sociation studies cannot be directly applied to C N V  loci, as the latter are generally 
m ulti-a lle lic  [188,189]. Instead we performed 3735 individual t-tests for differences 
in mean brain structure volum es between the ind ividuals that carry a deletion 
at a particular CNVR, and those that do not (9 brain structures x 415 rare CNVRs 
w ith at least one deletion). Likewise, we performed 3024 individual t-tests (9 brain 
structures x 336 rare CNVRs w ith at least one duplication) for gains. We ranked the 
outcomes of these t-tests by test statistics for losses and gains separately. Eight 
tests provided strong evidence for a possible relation (p < .001) between deletions 
or duplications and the volum e of a particular brain structure (Table 5.3). All of 
these showed a one-sided effect, i.e. the mean brain structure volum e differed 
significantly for either deletions or duplications, but never for both.
The most convincing association between rare CNVs and brain structure vol­
umes w as observed for a 32kb sized C N V  region on chromosome ^ 1 3 . 4 2 .  Changes 
in w hite and grey m atter volum es were strongly related to duplications in this re­
gion, both w ith a p-value <.001 (Table 5.3). Mean w hite m atter volum e was higher 
for individuals w ith a duplication in th is region compared to ind ividuals with 
normal copy num ber (Figure 5.1). This result w as confirmed by the observation that 
the sam e individuals w ith a duplication had significantly lower grey m atter vol­
umes than those w ith normal copy number. A dosage effect of this genom ic region
Table 5.3. Top results from individual t-tests for the relation between deletions/duplications and brain structures.
UCSC Genome browser t-test deletions t-test duplications
position (hgi8)
Brain structure Start End #  samples F-value p-value F-value p-value
Globus Pallidus 1 151021254 151040529 27 26.348 <.0001 .606 .437
Globus Pallidus 3 97734848 97810154 3 15.413 <.0001 NA NA
Caudate Nucleus 3 97734848 97810154 3 14.878 <.0001 NA NA
Amygdala 3 97734848 97810154 3 13277 <.0001 NA NA
Whole brain 6 7299469 7378072 2 NA NA 14.699 <.0001
Hippocampus 16 68617455 68792025 18 1.303 .254 12.958 <.0001
Grey matter 19 59414087 59446197 23 3.629 .057 14.138 <.0001
White matter 19 59414087 59446197 23 3.629 .057 14.138 <.0001
NA = not assessed; t-test were only performed for regions with at least two losses or two gains
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on the w hite (and grey) m atter volum es was also observed in individuals w ith a 
copy num ber loss at this region, although the evidence for th is group was not as 
strong. The individual CNVs w ithin th is region showed large overlap in a ~ io kb  re­
gion, and their breakpoints were generally consistent, w ith three exceptions. W hite 
matter volum e of one individual w ith four copies of this locus (indicated by an “x” 
in Figure 5.1) was higher than that observed for most of the other ind ividuals with 
four copies. Interestingly, the duplication in this single individual comprised the 
entire LILRBA6 gene, w hile the m ajority of other CNVs in this region only affected 
the 5’UTR region of this gene. Another exception at this locus w as a larger dele­
tion (23kb, indicated by a “+ ” in Figure 5.1). Just like the aberrant duplication, the 
deletion affected the entire LILRBA6 gene, but this did not seem to affect the w hite 
matter volum e of this ind ividual. This is in contrast w ith the largest (32kb) deletion 
observed in th is region, deleting both the LILRB3 and the LILRBA6 genes com­
pletely. The w hite (and grey) matter volum e for th is individual (indicated by a “*” in 
Figure 5.1) w as the most aberrant of all individuals w ith a deletion in this region.
Figure 5.1. Deletions 
and duplications 
on chromosome 
I9qi3 and their 
relation to white 
and grey matter 
volumes. Top panel: 
graphs showing the 
change in white 
and grey matter 
volumes (as %  of 
total brain volume) 
with copy number 
state (1,2,3,4). x, + 
and * correspond 
to individuals 
with deletions and 
duplications as 
shown in the lower 
panel. The lower 
panel also shows 
the affected genes in 
this region -  LILRB3 
and LILRA6 (based
Breakpoints of individual CNVs varied substantially in a 19 kb region on chrom o- on UCSCgenome 
some iq 2i.3  (Figure 5.2; left). The m ajority of CNVs in this region (93%) were gains, browser build 36, 
but the t-test indicated a strong association w ith deletions (Table 5.3). O nly tw o hgi8). 
individuals harboured a partly overlapping deletion in this region affecting the 
LCE1E gene. Figure 5.2 shows that the large mean globus pallidus volum e for this 
deletion group w as due to a single individual w ith an extrem ely large globus palli­
dus volum e. The other individual showed a below-average globus pallidus volume, 
w hich puts question marks to the relevance of this observation. Duplications of a 
79 kb region on chromosome 6p24.3 were also found in tw o ind ividuals only (Fig­
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ure 5.2; centre), whose mean total brain volum es were significantly higher than of 
those w ith normal copy num ber in this regions. In this case, total brain volum es of 
both ind ividuals were higher than average, indicating that th is effect m ay be gen­
uine, even though no genes are affected. Another interesting result w as obtained 
for a large i75kb CN V region on chromosome i6 q 22.i, show ing association w ith 
hippocam pus volum es only for copy num ber gains (Figure 5.2; right). Most CNVs at 
th is locus (either deletions or duplications) m ay result in a disruption of the PDPR 
gene. Interestingly, two duplications that either did not affect the PDPR gene or 
com pletely contained the gene (and therefore m ay be hypothesised not to disrupt 
its function), showed less of an effect on the hippocam pal volum e (indicated by “+ ” 
and “*” in Figure 5.2).
Figure 5.2. Deletions 
and duplications 
on chromosomes 
1421.3 (left), 6p24.3 
(center), and i6q22.i 
(right) and their 
relation to globus 
pallidus, whole brain 
and hippocampus 
volumes respectively. 
Top panel: graphs 
showing the 
change in white 
and grey matter 
volumes (as %  of 
total brain volume) 
with copy number 
state (1,2,3,4). + 
and * correspond 
to individuals with 
duplications as 
shown in the lower 
panel. The lower 
panel also shows 
the affected genes 
(based on UCSC 
genome browser 
build 36, hgi8).
The last region in Table 5.3 is a 75kb region on chromosome 3qii.2, for w hich the 
t-tests showed strong evidence for effects on three different brain structure vol­
umes: those of globus pallidus, caudate nucleus, and am ygdala. This effect was due 
to the tw o ind ividuals w ith deletions in this region, w hich both had low amygdala 
and caudate nucleus volumes, but differed substantially in globus pallidus volume 
(Figure 5.3). As we noted earlier for the CNVs on chromosome iq2i.3, the effect of 
globus pallidus volum e is largely determ ined by one individual w ith extremely 
high globus pallidus volum e. It is noteworthy that this individual both had a rare 
CN V  at iq 2i.3  as w ell as at 3qii.2. The 3q ii.2  region does not affect any genes; the 
nearest gene -  EPHA6, a member of a fa m ily of receptor tyrosine kinases -  is 
200kb dow nstream  of this CN V region.
5 4 DiscussionOur results are the first to provide insight in the relation between rare 
CNVs and normal brain morphology. Despite the explorative nature of this study, 
w hich lacks power to identify statistically significant associations, we were able 
to identify at least five regions of copy num ber variation w hich m ay affect brain 
m orphology in apparently healthy ind ividuals. Our focus w as on rare CNVs, which 
have recently emerged as causal factors for M endelian disorders, as well as for rare 
autosom al dom inant subtypes of otherwise common psychiatric disorders, such as
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autism , mental retardation, schizophrenia, and Alzheim er’s and Parkinson’s disease 
[49,50,52,53,66,85,115,129,138,168-174]. W ith this study we aim ed to contribute to 
the knowledge about the role of such rare CNVs in normal brain development, 
w hich has thus far remained elusive [17,22,23,190].
We identified on average 31 individual CNVs larger than 10kb per individual, 
w hich is comparable to w hat others reported when using the same m icroarray 
platform [39]. The num ber of CNVs per individual increases w ith microarray resolu­
tion; ultra-high resolution m icroarray -  containing 42 m illion probes -  revealed on 
average 50 CNVs larger than 10kb per individual [43]. We applied stringent quality 
criteria (Box 5.2) to m inim ise the num ber of false positives, thereby accepting an 
increase in the num ber of false negatives.
Ninety-three percent (n = 17,700) of the CNVs entirely or partia lly overlapped 
the sam e genom ic region in two or more ind ividuals. W hile various statistical and 
algorithm ic approaches have been used for optim al m erging of individual CNVs 
into C N V  regions (CNVRs) [39,42,43], in this study we sim ply merged all overlap­
ping CNVs (down to an overlap of a single base pair) into a single region. This 
approach fitted best w ith the explorative nature of our study; it allowed us to 
perform comprehensive and detailed post-hoc analyses of all CNVs in a particular 
region of interest. As a result, the breakpoints of individual CNVs w ithin  a region 
varied substantially, w hich m ay have complicated interpretation.
We in it ia lly  performed t-test analyses to rank putative effects of CNVs on mean 
volum es of subcortical brain structures, hippocampus, total w hite and grey matter, 
and total brain volum e. Correction for total brain volum e reduced potential bias 
resulting from overall large or sm all brains, but on the other hand created interde­
pendency between the different structures. Detailed analyses of five h ighly ranked 
CNVRs provided further insight into the true nature of their relationship w ith brain 
morphology. These analyses showed that some of the t-test results m ay not repre­
sent true effects, e.g. mean values of globus pallidus volum es were largely biased 
by a single ind ividual. Although this m ay be scanning bias, we do note that this 
individual harbours two of the five most highly ranked rare CNVs. It w ould thus be 
relevant to study th is individual in more detail, especially since we currently only 
have self-reported health inform ation. A more reliable association w as identified 
between a 32kb sized CN V region on chromosome 19qi3 -  varying in copy number 
in 4 %  of our study cohort -  and w hite/grey m atter volum es. Duplications in this 
region are strongly related to deviations in both w hite and grey m atter volumes. 
Deletions in this region also seem to have a considerable effect on the w hite/grey 
matter volumes, although the t-test for deletions does not reach significance. The 
individual w ith the largest deletion in this region has the lowest w hite m atter vol­
ume (and the highest grey m atter volume) of all ind ividuals w ith a CN V in this re­
gion. This indicates that a larger deletion -  affecting more genom ic content -  may 
have a larger effect on w hite (and grey) matter volum es. A num ber of psychiatric 
disorders -  including schizophrenia, chronic depression, bipolar disorder, obsessive- 
compulsive disorder and posttraum atic stress disorder -  have been associated 
w ith changes in w hite matter volum es and structures. However it is yet unclear 
w hether changes in w hite matter structure are a direct cause of the psychiatric 
disorder or a secondary consequence of abnorm al brain function [191]. Because 
we used relative w hite and grey matter volum es in our study design we could not 
assess w hich of the two would be more likely affected by copy num ber variation. 
The deletions and duplications on chromosome 19q13 do not affect m yelin-related
60
Figure 5.3. Deletions 
and duplications on 
chromosome 3qn.2 
and their relation 
to globus pallidus 
(top left), caudate 
nucleus (top right), 
and amygdala 
(bottom) volumes 
respectively. Top 
panel: graphs 
showing the change 
in globus pallidus, 
caudate nucleus 
and amygdale 
volumes (as %  of 
total brain volume) 
with copy number 
state (1,2,3,4). x, + 
and * correspond 
to individuals with 
duplications as 
shown in the lower 
panel. The lower 
panel also shows 
the affected genes 
(based on UCSC 
genome browser 
build 36, hgi8).
CN VR  (chr3) and caudate nucleus C NVR (chr3) and am ygdala
Copy Number
C NVR with individual deletions (black) and duplication ( )
Chrom osom e 3
97740000 I 97750000 I 97760000 I 97770000 I 97780000 I 97790000 I 97800000 I 97810000 I
genes, w hich would im plicate an effect on w hite m atter specifically. Instead, the 
region overlaps two genes - LILRB3 and LILRA6 - w hich belong to the sam e cluster 
of leukocyte im m uno globulin -like receptors, and are thought to control in flam m a­
tory and im m une responses [192]. Genes involved in im m une response are gener­
a lly known to vary in copy number, reflecting normal im m unologic variation. It is 
of interest that the im m une system has even been im plicated in the development 
of various psychiatric diseases, e.g. Rett syndrome [193]. Although m any m icroar­
ray-based CN V studies have been performed for various psychiatric disorders, the 
I9 q i3  region was not covered sufficiently on the m icroarray platform previously 
used (prof. dr. Evan Eichler, personal com m unication). Assessing the role of the CN V 
on chromosome I9qi3 in the development of psychiatric disorders thus requires 
h ighly targeted analyses. CNVs on chromosome iq 2i.3  also affected genes involved 
in im m une response: the LCE1E and LCE1D genes (Table 5.3). However, as the high 
ranking of this region is m ain ly due to a bias in average globus pallidus volumes 
(Figure 5.2), it is unlikely that CNVs in th is region affect brain morphology.
CNVs on chromosome i6 q 22.i affected tw o genes of unknown function -  PDPR 
and CLEC18C. Interpretation of a putative role of this region in brain morphology 
is therefore challenging. Still, it is noteworthy that ind ividuals w ith a duplication 
spanning this entire region (“*” in Figure 5.2) or not affecting the PDPR gene at all 
(“+ ” in Figure 5.2) have higher hippocampus volum es than the other individuals 
w ith three copies. This m ay suggest a disruptive effect of duplications in this region, 
resulting in lower hippocampus volum es. Obviously, it is too early to draw definite 
conclusions on this issue, but it may be an interesting region for follow-up, espe­
cially regarding the role of the hippocampus in m em ory retrieval and emotion [194].
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CNVs on chromosome 3qii.2  showed high correlations w ith the volum es of 
three different brain structures; those of caudate nucleus, am ygdala and globus 
pallidus. The region comprises two deletions and one duplication (Figure 5.3), 
w hich do not directly affect genes. The individual w ith the lowest caudate nucleus 
and am ygdala, as well as the highest globus pallidus volum es (Figure 5.3) carried 
the larger of tw o deletions. The am ygdale is a m ajor factor in the regulation of 
m em ory and emotion [195-197]. The basal ganglia -  to w hich both the caudate nu­
cleus and the globus pallidus belong -  are im portant in various functions, includ­
ing motor control, learning, and movement [19 8 -20 0 ]. Dysfunction of the basal 
ganglia can lead to movement disorders like Parkinson’s and Huntington’s disease 
[201,202]. W hile the basal ganglia are known to directly affect motor control, there 
is increasing evidence that their role is also im portant at a more fundam ental level 
of movement behaviour; the m otivation to move [203]. In Parkinson’s disease for 
instance, the lack of motivation to move seems to be an im portant factor. Despite 
the absence of genes that w ould im plicate this region directly w ith brain develop­
ment, the putative m ovem ent-related effect of th is region m ay provide a basis for 
a more extensive study.
In conclusion, we have shown that correlations m ay exist between rare CNVs 
and brain structure volum es, although independent replication and more detailed 
follow -up studies are required to fu lly  discern their biological relevance. We have 
shown that our genotype-phenotype approach using quantitative brain endophe- 
notypes in large control cohorts m ay provide novel insight into the role of genomic 
copy num ber variation in psychiatric disease.
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6 . Homozygous deletions 
in the human genome: 
what don’t we need?
Vrijenhoek T, Webber C, Konst R, Steehouwer M, Marques AC, 
Makkinje R, Hehir-Kwa JY, Rodriguez Santiago B, Rijpkema M, 
Fernandez G, Geurts van Kessel A, Brunner HG, Franke B, Pon- 
ting CP, Veltman JA (2010) Homozygous deletions in the human 
genome: what don't we need? Submitted manuscript
Abstract
In contrast to indispensable regions of the hum an genome, whose identification 
rem ains a m ajor challenge, non-essential DNA can now be readily identified. H igh­
resolution microarrays allow  genom e-w ide detection of homozygous m icrodeleti­
ons, each corresponding to a complete DNA loss. We have detected 2050 hom ozy­
gous microdeletions larger than 10kb in 597 healthy Caucasian individuals using 
Affym etrix GeneChip SNP 6.0 microarrays. Together these lie w ithin 90 distinct re­
gions of homozygous deletions (HDRs), 58 of w hich were subsequently confirmed 
by PCR. The confirmed HDRs together represent 2.8 Mb of hum an sequence whose 
complete loss is unaccom panied by an overt phenotype. We show that most con­
firm ed HDRs contain low -densities of functional sequence, presum ably because 
their removal causes little change in fitness. HDRs show significant reductions in 
conserved sequence and non-coding RNA loci, as well as a significant increase in 
pseudogenes. The latter indicates that deletions provide a m echanism  for remo­
ving pseudogenes from the hum an genome. The num ber of protein-coding genes 
affected by HDRs on the other hand is not significantly lower compared to random 
genom ic regions of sim ilar size. Am ong the 36 protein-coding genes in HDRs are 
some w ith known and seem ingly im portant functions, such as the LCE3 cluster 
(implicated in psoriasis), ADAM3A (male m urine infertility), and M GAM  (digestion 
of malted dietary oligosaccharides). In sum m ary, we present a comprehensive map 
of relatively large and validated HDRs in Caucasian genomes, illustrating the evolu­
tionary strategies for retaining and discarding essential and non-essential regions 
of the hum an genome.
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Introduction
Com parative genom ics approaches indicate that only a sm all m inor­
ity (5 -10 % ) of hum an DNA bases are sufficiently well conserved to be considered 
as functional [204,205]. The rem aining poorly-conserved 9 0 -9 5 % , much of which 
represents the evolutionary debris of transposable elem ent sequence, appears 
to be functionally inert and thus, presumably, m ight be deleted w ithout pheno­
typic consequence. Indeed, studies in mice have shown that knocking out highly 
conserved sequence elem ents m ay not result in an overt phenotype, im plying 
that even such regions m ay be dispensable [20 6 -20 8 ]. Homozygous deletions 
of the hum an genome -  revealing apparently dispensable regions -  can now be 
identified experim entally by exploiting the quantitative power of high-resolution 
microarray technology, w hich has often been used for the identification of copy 
num ber variants (CNVs). The high resolution and increased dynam ic range of this 
technology now allow  for discrim ination between heterozygous and homozygous 
losses; the latter usually being sm all and thus difficult to detect. Despite the in ­
creased quantitative power of m icroarray technology, a reliable survey of dispens­
able regions in the hum an genome strongly depends on subsequent validation of 
homozygous deletions.
Recent studies on CNVs in healthy ind ividuals show that deletion alleles occur 
across the general population [39,42,175]. In regions free of functional sequence, 
homozygous deletion alleles are not selected to be retained or purged w ithin the 
hum an population, and do not result in altered fitness. Genom ic regions that are 
lost in individual hum an genomes m ight therefore be expected to exhibit low 
densities of genes and of other categories of functional sequence. Moreover, genes 
that are absent from apparently healthy ind ividuals m ay be expected to contribute 
little or nothing to overall fitness [205,209,210]. Such genes are therefore expected 
to show low constraint in their sequence evolution and to be “environm ental” in 
function, i.e. involved in processes such as chem osensation, toxin degradation, im ­
m unity and reproduction [205,211].
The degree of selective constraint in regions of homozygous deletions (HDRs) 
and elsewhere m ay be inferred from the extent of cross-species sequence conser­
vation relative to a neutral evolutionary model [212,213]. Functional sequences may 
be predicted using the phastCons score -  w hich estim ates the rate of individual 
nucleotide substitutions based on a phylogenetic hidden M arkov model [213] -  or a 
neutral model of insertions and deletions (indels) [214] w hich pinpoints 'indel-pu- 
rified sequence’ that is expected to be functional. In addition, non protein-coding 
RNA (ncRNA) loci -  whose transcribed nucleotides fall outside previous protein- 
coding gene annotations -  specifically provide insights into functionality beyond 
those provided by the sm all proportion of the hum an genome that encodes 
protein (~1%) [215]. The biological relevance of this large fraction of transcribed, yet 
noncoding, hum an sequence rem ains unclear and, thus far, the functions of only 
a sm all num ber of ncRNAs have been proposed. Nevertheless, we have previously 
argued that m any more ncRNAs are functional, as their sequences and promot­
ers are better conserved than putative neutrally evolving sequence [216] and they 
often show apparently regulated spatiotemporal expression profiles. Based on 
this we w ould hypothesise that functional ncRNA loci w ill be underrepresented in 
genom ic regions that show homozygous deletions in a subset of the population. 
Here we have detected and validated regions of homozygous deletions (HDRs) in a
6 .1
homozygous
deletions
complete loss of 
DNA at a certain 
chromosomal locus
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Figure 6.1.
Eigenstrat principal 
component analysis 
of populations 
based on genotype 
information. 
Calculation of 
Fst showed no 
subdivision between 
the Hapmap CEU 
population and 
our dataset. This 
was confirmed by 
an ANOVA analysis 
which showed no 
significant difference 
between these two 
populations (p =
0.6).
large cohort of healthy individuals, and have assessed their functional content. We 
provide evidence of reduced selective constraint w ithin HDRs, on protein-coding 
genes, non-coding loci and other non-coding functional elements, relative to 
random sam ples of genom ic sequence. This study provides a system atic overview 
of coding and non-coding gene loci that m ay be com pletely lost in the hum an 
population apparently w ithout affecting overall fitness.
6  2 Results
We performed genom e-w ide copy num ber analysis in 597 DNA 
sam ples from apparently healthy, h ighly educated Dutch volunteers, all between 
18 and 35 years of age. Eigenstrat principal component analysis shows all to be 
of Caucasian origin (Figure 6.1; M aterial and Methods). Using the Affym etrix 
GeneChip SNP 6.0 platform w ith conservative quality control, we in itia lly  identi­
fied 2050 autosom al candidate homozygous deletions larger than iokb, w hich 
together were contained w ithin  90 distinct, non-overlapping regions of hom ozy­
gous deletion (HDRs). We then sought to validate all regions by conventional PCR, 
alw ays using sam ples w ith and w ithout homozygous deletions, and primers inside 
and outside of the candidate HDR, in order to exclude technical artefacts (Figure
6.2). We confirmed 58 regions (6 2%) as containing homozygous deletions, together
covering 2.8Mb of euchrom atic genom ic sequence. Confirm ation rate was lower 
than expected, yet the confirmed HDRs represented 1815 of the original 2050 (88%) 
candidate homozygous deletions, dem onstrating that the m ajority of recurrent 
homozygous deletions were confirmed. The homozygous deletions that could 
not be confirmed were either single unique observations -  likely to be technical 
artefacts -  or they were located in regions that showed frequent heterozygous 
deletions in the population, in w hich the homozygous deletions turned out to be 
falsely called. This shows the difficulties inherent in correctly interpreting hom ozy­
gous deletions detected in a single individual, and therefore the im portance of
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independent validation for such events. W hile CNVs are generally enriched near te ­
lomeres or centromeres [217], HDRs appear random ly distributed over the genome 
(Figure 6.3). Nearly all ind ividuals (9 6 %) were found to be affected by at least one 
homozygous deletion, w ith a m axim um  of eight homozygous deletions in five in ­
dividuals, containing between 235 and 355kb of genomic sequence. On average, each 
individual carries three homozygous deletions covering 123kb of DNA (Figure 6.4).
Homozygous deletion alleles of genes and other functional elem ents are 
expected to be strongly and preferentially purged from the hum an population. 
Consequently, genom ic regions that are observed to be hom ozygously deleted are 
expected to contain a lower density of functional sequence compared to random 
sam ples of genom ic sequence. To test this hypothesis, we estim ated the am ount 
of functional sequence content (as measured by the fractions of either indel- 
purifying or phastCons sequence) w ithin the confirmed HDRs. We subsequently 
compared this content to that of a random ly drawn set of hum an genome se­
quence regions matched in size and num ber to the experim ental HDRs (Figure 6.5). 
Indeed, HDRs show significant reductions in functional elements, nam ely indel- 
purified sequence (-4 4 % ; p  < 0.002; Figure 6.5A), and phastCons sequence (-3 8 % ; p
< 0.002; Figure 6.5B), over the genom e-w ide averages. These results indicate that 
HDRs have been subject to lower degrees of evolutionary constraint over m any 
tens of m illions of years of vertebrate evolution, and thus are h ighly likely to have 
also been under reduced constraint w ithin the short tim e span of modern hum ans 
[213,214]. In addition, HDRs show a 1,0 8 1%  increase in sequence that has been 
segm entally duplicated during prim ate evolution (p < 0.002), w hich is known to in-
Figure 6.2. Detection 
and validation of 
homozygous deletions.
(A) Representative 
example of 10 
individuals with a 
homozygous deletion 
on chromosome 2, 
as detected onto 
Affymetrix 6.0 SNP 
arrays. Array plots 
showing the Log2 test- 
over-reference (T/R) 
intensity ratio of probes 
in the region of interest 
for 10 individuals.
The homozygous 
deletions are clearly 
distinguishable by 
a significant drop in 
intensity ratios for 10 
or more consecutive 
probes. (B) Agarose 
gel image showing 
the results of the PCR 
validation experiment 
for this homozygous 
deletion. Normal PCR 
products are visible 
for all individuals in 
the regions proximal 
and distal to the 
deleted region, while 
no product is present 
in the region for all 10 
individuals, confirming 
the presence of a 
homozygous deletion.
In contrast, the positive 
control shows a normal 
PCR band at this 
position, excluding 
PCR artefacts. 1-10: 
individual ID; C: positive 
control; B: negative 
control; M: 100bp 
marker
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Table 6.1. Genes located in homozygous deletion regions
Completely overlapping
Ensemble ID Gene name Gene function
ENSG00000087128 TMPRSS11E2 Transmembrane protease, serine 11E Precursor (EC 3.4.21.-)
(Serine protease DESC1)
ENSG00000174982 OR4S2 Olfactory receptor 4S2
ENSG00000181903 OR4C6 Olfactory receptor 4C6
ENSG00000181927 OR4P4 Olfactory receptor 4P4
ENSG00000184490 pseudogene
ENSG00000184674 GSTT1 Glutathione S-transferase theta-4 (EC 2.5.1.18)
ENSG00000185897 FFAR3 Free fatty acid receptor 3 (G-protein coupled receptor 41)
ENSG00000187225 LCE3C late cornified envelope 3C
ENSG00000188439 OR4P1P Seven transmembrane helix receptor
ENSG00000197475 ADAM3A ADAM metallopeptidase domain 3A (cyritestin 1)
ENSG00000197888 UGT2B17 UDP-glucuronosyltransferase 2B17 Precursor (UDPGT 2B17)
(EC 2.4.1.17)
ENSG00000198502 HLA-DRB5 HLA class II histocompatibility antigen, DRB5 beta chain
Precursor (DR beta-5)(DR2-beta-2)(Dw2)
ENSG00000203817 FAM72C Family with sequence similarity 72, member C Fragment
ENSG00000203818 HIST2H3PS2 Histone H3
ENSG00000203820 FCGR1C Putative high affinity immunoglobulin gamma Fc receptor
IC Precursor
ENSG00000204983 PRSS2 Trypsin-1 Precursor (EC 3.4.21.4)
ENSG00000205497 OR51A4 Olfactory receptor 51A4
ENSG00000206077 ZDHHC11B Probable palmitoyltransferase ZDHHC11B (EC 2.3.1.-)
ENSG00000212659 KRTAP9-6 Putative keratin-associated protein 9-2-like 2
ENSG00000212661 AC006432.15-1 Ovostatin homolog 1 Precursor
ENSG00000215247 AC026740.6-2 Putative uncharacterised protein
Partially overlapping (affecting at least one coding exon)
Ensemble ID Gene name Gene funtion
ENSG00000101307 SIRPB1 Signal-regulatory protein beta-1 isoform 3 Precursor
ENSG00000132256 TRIM5 Tripartite motif-containing protein 5 (EC 6.3.2.-)(RING finger
protein 88)
ENSG00000140386 SCAPER S phase cyclin A-associated protein in the endoplasmic
ENSG00000163202 LCE3D reticulum
ENSG00000163935 SFMBT1 Late cornified envelope protein 3D
ENSG00000165714 LOH12CR1 Scm-like with four MBT domains protein 1
ENSG00000167346 MMP26 Loss of heterozygosity 12 chromosomal region 1 protein
ENSG00000176895 OR51A7 Matrix metalloproteinase-26 Precursor (MMP-26) (EC
ENSG00000179087 MGAM 3.4 .24 .-)
Olfactory receptor 51A7
ENSG00000181001 OR52N1 Maltase-glucoamylase, intestinal [Includes Maltase(EC
ENSG00000181009 OR52N5 3.2.1.20)(Alpha-glucosidase);Glucoamylase(EC 3.2.1.3)
ENSG00000187238 LCE3B Olfactory receptor 52N1
ENSG00000188086 AC134504.2 Olfactory receptor 52N5
ENSG00000188818 ZDHHC11 Late cornified envelope protein 3B
ENSG00000196115 ADAM5P Putative testis serine protease 5 (EC 3.4.21.-)
ENSG00000203825 pseudogene Probable palmitoyltransferase ZDHHC11 (EC 2.3.1.-)
Disintegrin and metalloproteinase domain-containing
protein 5
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duce copy num ber changes by non-allelic homologous recombination [218]. HDRs 
also show a 5 6 %  reduction in recombination rate (p = 0.01). This is consistent with 
Hill-Robertson interference, which is known to increase the fixation of deleterious 
alleles in the population [219-221].
Table 6.2. NcRNAs located in homozygous deletion regions
Chromosome Start End
147499177
Number of sup­
porting ESTs
2chr1 147497339
chr1 147531500
chr1 147555710
chr1 147646502
chr1 147661602
chr3 163925220
chr3 166407441
chr5 12627968
chr13 56672570
chr14 85470774
chr14 105963554
chr19 48407782
147532129 2
147558367 8
147647099 3
147662864 4
164562045  23
166855860 27
12858295 17
56674318 2
85665875 16
105964152 2
48444638  3
Figure 6.3. Overview 
o f HDRs from the 
Nijmegen cohort.
Colored bars 
indicated HDRs 
that are frequent 
(present in >5% of 
all individuals; long 
bars), rare (<5%; 
medium bars) and 
private (present in 
a single individual; 
short bars).
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Table 6.3. GOslim terms enriched/depleted among genes overlapped by homozygous deletion regions.
Description GO Identifier Percentage change 
over expected
p-value*
protein binding 0005515 -82% 5.51X10-3
intracellular 0005622 -54% 1.84X10-2
organelle 0043226 -67% 1.83X10-2
regulation of biological process 0050789 -87% 2.91X10-2
*False Discovery Rate corrected
Table 6.4. NcRNA loci are significantly depleted within homozygous deletions. Comparison of the observed den­
sity (fraction of bases that are transcribed) of human ncRNAs within HDRs to the density expected from a random 
set of segments with a similar size and G+C content sampled from the human intergenic sequence (defined as 
sequence outside human ENSEMBL protein-coding gene annotations and 1.5 kb flanks). Simulations were perfor­
med 10,000 times.
all frequent rare unique
Observed Density 3.7X10-4 0 0 1.2X10-4
nt 3772 0 0 1192
Expected Density 9 .6 X10-4 3 1 0­ 4 2.9 X10-4 2.1X10-4
nt 9830 3366 3003 2148
Observed/Expected 0.384 0.000 0.000 0.555
p-value 0.0138 0.0001 0.0001 0.2937
These data support the general d ispensability of the confirmed HDRs. Never­
theless, these regions often partially or entirely overlap functional sequence, more 
specifically 36 protein-coding genes (Table 6.1) and 12 ncRNA loci (Table 6.2). W hilst 
the num ber of pseudogenes in HDRs is substantially higher (+285%, p < 0.002), the 
num ber of protein-coding genes is not significantly lower than expected (3%  re­
duction, p = 0.4). However, compared to genom e-w ide averages, HDR protein-cod­
ing genes tend to be shorter (8 7% reduction; p < 0.002), to contain fewer introns 
(6 8 %  reduction; p < 0.002) and to consist m ostly of single exons (350% increase in 
single-exon genes; p = 0.01). Analysis of Gene Ontology annotations shows that 
HDRs overlap significantly fewer proteins w hich are (/) intracellular (-55%, p = 3x10- 
4, after correction for False Discovery Rate [FDR] = 1.84x10^), (ii) protein-binding 
(-8 3%, p = 5x10-5, FDR = 5.51x10^) or (///) involved in regulation (-8 7% , p = 9x10-4, FDR 
= 2.91x10-2; Table 6.3). Instead, m any of the protein-coding genes affected by ho­
mozygous deletions are involved in receptor activity (+138%, p = 0.008, FDR = 0.14). 
These observations are consistent w ith previous reports of environm ent-sensing 
genes tending to be more dispensable [205,222-224].
The m ajority of the 36 HDR protein-coding genes are known to contribute to 
im m unological and olfactory processes, am ong w hich are some w ith possible im ­
m unologic effects. For example, a highly recurrent HDR on chromosome 1 overlaps 
tw o mem bers of the late cornified envelope 3 gene cluster (LCE3B and LCE3C). 
Deletion of this region was recently shown to increase risk of psoriasis vulgaris 
in ind ividuals from Spain, The Netherlands, Italy, and the United States, especially
69
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when in the homozygous state [47]. However, this cluster w as not associated w ith 
another type of psoriasis (psoriasis arthritis) in a Germ an cohort [225], indicat­
ing that susceptibility m ay be disease- and population-specific. Another highly 
recurrent HDR affects UGT2B17, w hich encodes a minor histocom patibility antigen. 
Homozygous deletion of U GT2B17  results in an im m unogenic reaction after stem 
cell transplantation as a result of differential expression between donor and recipi­
ent [226]. Other genes w ithin  HDRs possess non-im m unological roles. An HDR 
on chromosome 8 overlaps the ADAM m etallopeptidase dom ain 3A (ADAM3A  or 
cyritestin 1) gene. In mice, knock-out of the orthologous gene leads to loss of zona- 
binding ability  and oviduct migration of sperm, thereby resulting in male infertility 
[227]. However, deletion of ADAM 3A  in hum ans occurs in fertile and non-fertile 
men w ith equal frequency [228], w hich suggests that th is gene m ay perform an 
alternative function or is non-functional in hum ans. Nevertheless, fem ale volun­
teers were strikingly overrepresented in our group of HDR carriers; 29 out of 39 
HDR carriers (75%) were female, w hich is higher than w ould be expected from the 
gender distribution of the total cohort (p = 0.003; X2-test). The fertility status of 
the m ales in our population w ould need to be determ ined in order to verify the 
true significance of this finding. A recurrent HDR on chromosome 7 overlaps the 
m altase-glucoam ylase (M GAM ) gene, w hose product plays a crucial role in alpha- 
glucogenic starch digestion in both mice and hum ans [229,230]. Normal starch 
digestion results in synthesis of glucose, w hich is the m ain energy source for the 
brain, especially in development during childhood [230]. As all of the individuals in 
our study receive university-level education, it is not likely that they suffered from 
a severe glucose shortage. Still, 2 .8 %  of these ind ividuals carry a homozygous dele­
tion in M G A M , suggesting that (partial) deletion of this gene has little or no effect.
In contrast to protein-coding genes, ncRNA loci are greatly underrepresented in 
HDRs (6 2%  decrease, p < 0.05, perm utation test). This observation provides further 
support for both the dispensability of the HDRs and, more generally, the function­
a lity of m any ncRNA gene loci. Notably, ncRNA loci are only significantly under­
represented w ithin  HDRs occurring in more than 1 individual (p < 10 -4, permutation 
test; Table 6.4). This suggests that for rarer alleles it is likely that loss of the HDRs 
is, indeed, m ild ly deleterious but selection has had insufficient tim e (numbers of 
generations) to remove them  from the hum an population.
Finally, we sought to determ ine w hether the 2.8 Mb covered by the HDRs is rep-
Figure 6.4. Frequency 
histogram of the number 
of homozygous deletions 
per individual. More than 
9 6 %  of all participants 
contained at least one 
validated homozygous 
deletion larger than 
iokb in their genome.
The average number of 
homozygous deletions 
per individual was 3.1, 
with an average total 
genomic length of i23kb.
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resentative of all com m only hom ozygously deleted regions in the hum an genome. 
M any studies have previously identified homozygous deletions (as part of com­
plete C N V analyses) in healthy individuals, using various populations and microar­
ray platforms [39,42,43,175,180,231]. Three of these studies provided inform ation 
on the specific copy num ber genotypes; the others did not discrim inate between 
heterozygous and homozygous deletions. Two of these studies were performed on 
an Illum ina platform, w hich is known to differ in coverage and probe position. We 
specifically compared our results to homozygous deletions identified by the same 
array platform in HapM ap ind ividuals [39]. Raw array data from these experiments 
were obtained directly from Affymetrix, and individual homozygous deletions and 
HDRs were inferred using the sam e quality control criteria as before (M aterial and 
Methods). We identified 61 putative HDRs in 90 HapM ap individuals of Caucasian 
origin. The percentage of overlapping basepairs between the HDRs in Caucasian 
HapM ap sam ples and the validated HDRs in our study w as 5 5 %  (Figure 6.6). This 
indicates that we have detected the m ajority of recurrent HDRs larger than 10kb 
present in the Caucasian population, but that more population-specific and rare 
HDRs are to be expected.
6 3  DiscussionOur survey of homozygous deletions has shown that 0 .12 %  of hu­
man genom ic sequence is com pletely absent from one or more of 597 healthy 
individuals, and that th is is reasonably representative for Caucasian populations.
It is notable that this represents only a tin y fraction of the - 9 0 %  of the human 
genome that appears free of selective constraint and thus is likely to be devoid of 
function [205]. If only 0 .12 %  of the Caucasian genome is com m only and homozy­
gously deleted then, contrary to our previous expectations, m ight instead a much 
larger portion of the hum an genome be functional? Two characteristics of our 
study indicate w hy this m ight not be the case. The first is that we focused only on 
homozygous deletions as the m echanistic criterion to discrim inate functional from 
non-functional sequence. Homozygous deletions w ill be found preferentially in
Table 6.5. Percentage of 1000 randomly sampled windows of size x in the human 
genome assembly that contain no predicted functional sequence, specifically either 
indel-purified sequence (IPS) or phastCons sequence (see text), or neither IPS nor phast- 
Cons sequence. For example, 6.4% and 3.7% of x = 25 kb windows do not contain IPS or 
phastCons sequence, respectively, while 3.4% of 25 Kb windows contain neither IPS nor 
phastCons sequence.
Window Size, x No IPS No phastCons No IPS nor phastCons
100b 85.6% 90.8% 82.0%
500b 70 .4 % 76 .7% 63.2%
1kb 57.2% 64.6% 4 8 .4 %
5kb 25.8% 23.3% 17.0%
10kb 14.4 % 13.6% 8.6%
25kb 6 .4 % 3.7% 3.4 %
50kb 3.1% 2.6% 2.5%
100kb 1.6% 1.3% 1.3%
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regions whose deletion alleles have a high population frequency. The possibility of 
detecting deletion alleles -  both heterozygous and homozygous -  in such studies is 
lim ited to the content present on the array platform. The reference genome used to 
select targets for these array platforms is currently incomplete, thus resulting in a 
biased analysis of CNVs. In this study we found that 6 .4 %  of the genome was subject 
to CNV, which is sim ilar to w hat has been reported previously [41,43,179]. Yet it is clear 
that a more unbiased and complete view  of the population distribution of deletion 
alleles requires analyses of entire genomes, which are currently underway [232,233]. 
Furthermore it is expected that other types of genetic variation could lead to loss 
of functional elements w ithout phenotypic effect. This was clearly demonstrated in 
previous analyses on homozygous nonsense SNPs and pseudogenes [234]. Interest­
ingly, GO -analysis in both studies showed enrichment of genes involved in olfactory 
reception [234] and im m une response, which is consistent w ith our results.
A second characteristic of our study is the lower lim it (iokb) on the sizes of
Figure 6.5. 
Homozygously 
deleted regions in 
the human genome 
are depleted in 
indel-purified 
sequence and 
evolutionarily 
conserved sequence. 
(A) A set of sequence 
regions, matched 
in size and number 
to the set of 
homozygously- 
deleted regions 
observed in this 
study, was randomly 
drawn from the 
human genome.
The fraction of 
this sequence that 
was defined as 
indel-purified (IPS) 
was recorded. This 
process was repeated 
500 times and 
the 500 recorded 
IPS fractions 
used to construct 
the histogram 
shown. The value 
observed from the 
experimental set 
of homozygously- 
deleted regions is 
0.043 (indicated 
using the black 
arrow). (B) As 
fo r (A) but using 
phastCons elements. 
The value observed 
from the set of 
homozygously- 
deleted regions is 
0.032 (black arrow).
72
Figure 6.6. Overlap 
between homozygous 
deletion regions 
detected in different 
populations. (A)
A Venn-diagram 
showing the overlap 
in HDRs between our 
Caucasian participants 
(indicated by the 
left circle) and the 
Caucasian individuals 
of HapMap (right 
circle), identified by 
the same microarray 
platform. The diagram 
shows that 5 4 %  of 
the total number of 
HDRs were observed 
in both cohorts. The 
cohort-specific HDRs 
occurred only rarely in 
either of the cohorts. 
(B) A Venn-diagram 
showing the overlap 
in HDRs between our 
Caucasian cohort 
(upper-left) and the 
African (lower) and 
Asian (upper-right) 
cohorts of HapMap. 
Proportions represent 
fractions of all HDRs 
observed in the 
three studies. This 
diagram shows less 
overlap than between 
the two Caucasian 
cohorts. Furthermore, 
it appears that the 
African cohort harbors 
more population- 
specific HDRs than 
the other cohorts, 
although most were 
observed in very 
few  individuals and 
not independently 
validated.
the homozygous deletions we targeted in this study. We set th is lim it in order 
to be well above the m inim al detection lim it of the array platform, and to make 
independent validation of each region practically feasible. We predict however 
that there w ill be a much larger fraction ( -4 0 % )  of the genome that could harbour 
homozygous deletions between 1 and io kb  w ithout resulting in substantial reduc­
tions in fitness (Table 6.5) [43,179]. Furthermore, there are few  large (>10 kb) re­
gions of the hum an euchrom atic genome that are essentially devoid of functional 
sequence (Table 6.5). Given the spacing of predicted functional elem ents on the 
hum an genome, the chance of a random ly-sam pled io kb  segm ent of the human 
genome containing at least one functional elem ent is approxim ately 9 0 % , and for 
larger segm ents th is becomes even higher (Table 6.5). Thus, there appear to be two 
orders of m agnitude ( ~ io %  vs. 0 .12%) more hum an genom ic sequence that would 
be predicted to accept a HDR, w ithout substantially reducing fitness, than we find 
to be hom ozygously deleted in 597 healthy ind ividuals. Com bined approaches to 
detect genetic variation in large populations w ill be critical to obtain an accurate 
overview of all non-functional sequence in the hum an genome.
In conclusion, our data provide a system atic screen of homozygous deletions 
in the hum an population. Functionally inert sequences, such as pseudogene and 
transposable elem ent sequences, are 3.9- and 1.2-fold enriched in such segm ents (p
< 2 x 10 -3 and p = 1.5X10-2, respectively), indicating that rather than a steady d im in u ­
tion in their sizes over tim e [235], neutrally-evolving sequences tend to be removed 
from a genome by the fixation of large deletion alleles. W hile our species’ low 
effective population size makes it more likely that functional elements, including
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genes, w ill occasionally be lost through genetic drift, the large homozygous dele­
tion alleles we observed here are expected to be fixed at a more rapid rate. At that 
point such sequence w ill have become lost forever from our evolutionary lineage.
4 Material and Methods 
Sample collection
Saliva samples were obtained from 611 volunteers at the Radboud University Nijmegen Medi­
cal Centre in Nijmegen, the Netherlands. To confirm that all subjects were sampled from the 
same (Caucasian) population, principal component analysis was performed with founders 
from 3 HapMap populations (CEU, YRI, and CHB & JPN) using Eigenstrat [236], for which Af- 
fymetrix GeneChip SNP 6.0 arrays data are publically available. DNA was extracted using the 
Oragene® DNA sample collection kit, according to the manufacturer’s protocol.
Copy number analyses
DNA samples were hybridised on Affymetrix GeneChip SNP 6.0 arrays, as described 
elsewhere [39]. Briefly, DNA was treated by Nsp and Sty restriction enzymes, leading to frag­
ments of 200 - 1000 bp. These fragments were PCR-amplified, biotin-labelled, fragmented 
to ~180bp, and hybridised to arrays, which were then fluorescently labelled and scanned to 
yield a measurement of hybridisation intensity for each probe. The intensity measurement 
for each genomic locus is the median value of 3-4 probes for the same allele of the same SNP. 
In total, each sample was represented by 2.7 million measurements (corresponding to 940 
thousand individual copy-number probes, and 2 x 900 thousand SNP alleles), which were 
used for copy number analyses.
Copy number analysis was performed using Affymetrix Genotyping Console Version 2.1 
software. Each sample was compared to a reference pool of 47 samples, which all had been 
hybridised in the same run. Based on Affymetrix quality control thresholds for sample quality 
(Contrast OC < .4) and copy number quality (MAPD < .4), we removed 6 samples. In addition 
we removed 8 samples with extraordinarily high numbers of copy number variants (>100 per 
individual, representing approximately 2SD), as this indicates that there is too much varia­
tion in intensity values to allow reliable CNV calling. We obtained all regions for which the 
Hidden Markov Model indicated a copy number 0 from the remaining 597 samples, to which 
we applied further quality control steps. We removed all regions smaller than 10 kb in size, 
covered by fewer than 10 probes, or with an average distance between consecutive probes 
of more than 20kb. By applying these stringent quality criteria, we expected to obtain a set 
of high-quality, reliable homozygous deletions for independent validation experiments. We 
subsequently parsed overlapping individual homozygous deletions into distinct regions of 
homozygous deletions (HDRs) using an in-house JAVA-based software tool.
PCR Validation
PCR experiments were performed to validate the presence of homozygous deletions. We 
used the software package Primer3 to design primers for each region identified by the array 
analyses [108]. For each region, we developed three primers: one proximal to the deleted 
region, a second one in the deleted region, and a third one distal to the deleted region. We 
performed PCR experiments under standard conditions on all samples with homozygous
74
deletions, except for regions for which more than 30 samples indicated a homozygous dele­
tion. For the latter, we performed PCR experiments on 10 randomly selected samples, thereby 
validating homozygous deletion of the region but not for all individual samples. A region was 
confirmed if at least one sample in that region showed no PCR product in the region, while 
showing clear PCR products proximal and distal to the region. Positive control samples were 
included in each PCR experiment.
Content analyses
Segmental duplications, as identified using the method described by Bailey et al. [237], 
repeatmasked sequence, indel-purified regions, as identified using the method of Lunter et 
al. [214] and phastCons regions, as identified using the method of Siepel et al. [213], were all 
obtained from the University of California Santa-Cruz (UCSC) genome browser (hg18) [105]. 
Recombination rates across the human genome were obtained from Myers et al. [238] and 
recast to the NCBI36 assembly using the UCSC NCBI34 NCBI36 chained alignment. Rates 
were calculated as the average recombination rate per base pair. Protein-coding genes were 
assigned to CNVs according to Ensembl [239].
To test the null hypothesis that a property is higher, or lower, within a set of regions than 
elsewhere in the genome, we performed a randomisation test. For this, 500 sets of regions 
were sampled randomly from the genome assembly; these regions were matched in both 
number and size to the set of regions under consideration. We calculated the fraction p of 
such randomly chosen regions that contained higher, or lower, values of the property. Values 
of p > 0.025 were generally considered to indicate that the CNV data were not significantly 
different from the genome data taken as a whole.
Protein-coding gene functions were investigated using Gene Ontology annotations [240] 
obtained from Ensembl [239]. The significance of enrichments or deficits of genes associated 
with particular GO terms were evaluated using hypergeometric tests. As multiple tests were 
performed, a False Discovery Rate (FDR) multiple testing correction was applied [241].
We downloaded, from the UCSC Genome Browser Database, the genomic coordinates 
(hg18) of all human ESTs and RNAs (named ESTs for convenience) available from Genbank 
[242]. We considered only 384,861 ESTs that were longer than 500 bp and that mapped 
uniquely to regions outside of known protein-coding genes in the human genome (Ensembl 
v50) and their respective 1.5 kb flanking regions . These sequences formed 39,078 clusters of 
overlapping (by at least 1 nucleotide) transcripts, named intergenic loci.
We used CPC [243] and default parameters, to identify transcripts appearing to lack 
protein-coding potential. We identified 9,454 ncRNA loci, defined as intergenic loci with two 
or more overlapping ESTs and where over 50% of the transcripts within the locus were pre­
dicted by CPC to be noncoding. These 9,454 ncRNA loci were represented by 64,688 human 
transcripts.
The significance of genome-wide associations was determined using a randomisation 
procedure that accounts for G+C content and chromosome-specific biases [244]. Briefly, we 
compared the observed density of human ncRNA sequence within HDRs to what would be 
expected based on a random set of segments with a similar size and G+C content sampled 
from the human intergenic sequence (defined as sequence outside human ENSEMBL protein- 
coding gene annotations and 1.5 kb flanks); additional details on the method are provided 
[244]. Simulations were performed 10,000 times.
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a preferred approach 
to an idea or 
thought
Abstract
Recent developments in microarray technology have enabled large-scale genetic 
studies on schizophrenia, and have led to the discovery of m any risk alleles. This 
development has been accom panied by prom ising expectations regarding clinical 
applications. However, most of the known genetic variants meet neither validity 
nor utility requirements for application in clinical practice. Ongoing discussions are 
not only about when or under w hat conditions, but also if results from large-scale 
schizophrenia genetics studies are relevant for clinical use. Based on a literature 
review and in-depth interviews w ith experts, we explored the argum ents used in 
these discussions. We have identified four different lines of arguing, w hich state 
that high-throughput schizophrenia studies w ill: (1) eventually reveal clinically 
relevant data; (2) not reveal clinically relevant data directly; (3) only reveal clinically 
relevant data when combined w ith non-genetic (environmental) factors; or (4) 
eventually be translated into a clinical setting, irrespective of clinical relevance.
As we w ill show, experts' perception of the relevance of large-scale genetic data 
predom inantly depends on their conceptual fram ework of the relationship 
between genes and schizophrenia. This is exem plified by discussions around the 
development of direct-to-consum er (DTC) genetic tests. Furthermore, the experts' 
conceptual fram ew ork determ ines their perception of ‘schizophrenia' itself, which 
is partly reflected in recent discussions on the new edition of the D iagnostic and  
Statistical M a n u a l o f  M ental Disorders (DSM-V). The challenges resulting from large 
scale genetic research and the dem and from consumers and patients for genetic 
testing call for a solid infrastructural and translational strategy for schizophrenia 
genetic research.
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Introduction
The publication of the draft sequence of the hum an reference genome in 
2001 generated a w ealth of expectations concerning medical treatm ent, d iag­
nosis and disease prevention [7,72,245]. A nticipating the publication of the draft 
sequence, leader of the Hum an Genom e Project (HGP) Francis Collins presented a 
“hypothetical case for 2010” [246]. The case envisions John, a 23-year-old college 
graduate, w ho is referred to his physician for increased serum cholesterol level. Af­
ter considering his fa m ily history on m yocardial infarction, John “agrees (and signs 
informed consent) to undergo 15 genetic tests that provide risk inform ation for 
illnesses for w hich preventive strategies are available.” A week later John discusses 
the results w ith his physician and a genetic nurse specialist. The tests show he 
carries low -risk gene variants for prostate cancer and Alzheim er’s disease, reducing 
his risks for development of these diseases. However his risk on developing con­
tracting coronary artery disease, colon cancer, and lung cancer is h ighly elevated.
Some of the elem ents of Collins’ hypothetical case have become part of today’s 
reality. Diagnostic genetic tests are being w idely used in health care practice for 
~20 00  diseases, predom inantly M endelian disorders [247]. Patients have to be 
referred by their physician to undergo such a test, w hich is performed by certified 
clinical genetic centres equipped w ith resources for medical aftercare and counsel­
ling. The relevance of these genetic tests in clinical practice is unquestioned, as 
they provide a clear diagnosis to individual patients and their fam ilies, are sup­
ported by effective counselling, and are based on h ighly inform ative genetic vari­
ants [247,248]. However, this is not the case for (diagnostic or predictive) genetic 
testing for common variants contributing to the aetiology of complex disorders for 
w hich the evidence is sought in large scale genetic studies, such as genom e-w ide  
association  (GWA) studies. W hile these studies have identified num erous genetic 
variants associated w ith common complex disorders, they have so far resulted in 
reliable and valid tests for only a few  disorders.
Despite the lack of extensive evidence, a num ber of com panies in for example 
the US and the UK have started to offer so-called direct-to-consum er (DTC) genetic 
tests for various common disorders [249]. Such tests have been criticised by health 
care experts for their lack of validity, utility  and proper counselling when offer­
ing inform ation about serious disorders [250-252]. M any argue that no com pel­
ling evidence exists for a single common variant or a com bination of genetic risk 
factors to be highly predictive for complex disorders, w hich makes today’s DTC 
genetic tests at least non-inform ative and at worst m isleading. Yet w hile there 
is w idespread consensus about the lack of valid data to offer genetic testing for 
complex m ulti-factorial disorders, Collins’ “hypothetical case for 20 10 ” shows that 
(medical genetic) experts are not entirely innocent when it comes to the creation 
of bold claim s and high expectations about the value of genetic research. Scientific 
literature is full of claim s concerning the identification of relevant risk variants for 
complex disorders such as type 1 and type 2 diabetes, celiac disease, and breast 
cancer [18-22,253]. DTC genetic testing companies, w ithout hesitation, make use of 
these claim s to offer personalised genom ic profiles to individuals.
In this chapter we aim  to investigate how clinical experts perceive the use of 
genetic research data, and w hat argum ents they use when discussing clinical 
relevance. Although the main occasion for perform ing this study has been the rise 
of DTC genetic testing, our objective is not to discuss the statistical and clinical
7.1
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valid ity of currently available data or tests; these issues have been addressed 
extensively elsewhere [22,23,59]. Rather, we aim  to explore the various conceptual 
fram ew orks  that determ ine the view  of medical and genetic professionals on the 
clinical value of large-scale genetic data, taking the current availab ility of DTC 
genetic tests as a concrete example.
We thereby focus on schizophrenia genetics research, partly because it fits 
w ithin  the them e of th is thesis, but also because schizophrenia is an interesting 
example of a disorder for w hich the genetic model has been largely debated. Over 
the past decades, various new insights into the genetics of schizophrenia have 
emerged, but this has not resulted in reliable and valid clinical tools. Currently, 
schizophrenia is generally diagnosed as it w as fifty years ago, depending entirely 
on qualitative clinical interviews and the description of clinical sym ptom s [254]. 
Unlike common diseases like hereditary breast cancer, schizophrenia has yet hardly 
benefited from developments in genetics and is anything but incorporated in c lin i­
cal genetics practices [255].
Early psychiatric genetic studies in the late fifties and early sixties suggested 
that schizophrenia w as determ ined by a single partially dom inant gene w ith 25 %  
penetrance (the 'm onogenic’ theory) [55,56]. Yet it w as also clear that schizophre­
nia did not inherit in a sim ple M endelian fashion. Others, therefore, hypothesised 
that schizophrenia w as determ ined by m ultiple genes, w hich collectively should 
exceed a certain threshold to result in disease (the 'polygenic’ theory) [55,256]. 
Recent technological developments (e.g. microarrays, high-throughput re-sequenc­
ing) together w ith large-scale research collaborations have enabled the analysis 
of very large data sets for the identification of either common or rare variants for 
schizophrenia. As a result the polygenic theory evolved into the com m on disease- 
com m on variant  (CD-CV) hypothesis, w hich states that complex disorders like 
schizophrenia are the result of m any genetic variants, each w ith a m inor effect on 
disease development. The modern version of the m onogenic theory -  the com mon  
disease-rare variant  (CD-RV) hypothesis -  states that complex disorders like schizo­
phrenia are m ain ly due to a num ber of rare, heterogeneous genetic variants, each 
w ith a m ajor effect on disease development. Most DTC genetic tests -  including 
those for schizophrenia -  incorporate common variants, even though their contri­
bution to disease development in relation to rare variants and the environm ent is 
not entirely clear. The m ain criticism  from both the clinical and research com m u­
nity -  that it is too early to tell w hether diseases like schizophrenia are predom i­
nantly caused by common or rare variants -  seems to be justified. However, as we 
w ill illustrate by the argum ents that experts use, discussions on the clinical value 
of genetics go beyond common or rare variants, as various concepts of the relation­
ship between complex disorders and genetics can be envisioned.
7 2  MethodologyThe pros and cons of using genetic tests for complex diseases have 
been discussed on several occasions [250 -252,257-26 1]. Likewise, in relation to 
schizophrenia, geneticists and psychiatrists have published editorials, com m entar­
ies, and reviews about the validity, utility and potential im plications of research 
data on schizophrenia genetics. Through a literature search we have explored the 
argum ents and lines of reasoning concerning the question on w hat genetic vari­
ants cause schizophrenia, the im pact of non-genetic factors on schizophrenia and
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the clinical criteria for diagnosis of schizophrenia. Besides this literature search we 
have performed interviews with four experts (Box 7.1) that we considered each to be 
exemplary for a different set of arguments and a different line of reasoning (Box 7.2). 
These experts were selected based on their various backgrounds and experiences in 
psychiatry, genetics, epidemiology and/or genetic testing. We use the interviews with 
these experts to illustrate some of the most striking differences. We use their different 
views to illustrate four exemplary positions, hence four different lines of arguing.
Prof. Dr. M ichael Owen is a psychiatrist w ho has a long history in psychiatric ge­
netic research. He has developed a view  on the 'genetic deconstruction of schizophre­
nia’. Dr. Cecile Janssens is an epidemiologist experienced in genetic risk prediction and 
evaluation of the performance of predictive tests. Her main concern is that large-scale 
genetic studies -  predominantly genome-wide association studies -  will not yield suf­
ficient gene discoveries to be relevant for disease prediction. Prof. Dr. Durk W iersma is
genetic 
deconstruction 
of schizophrenia
proposal to define 
schizophrenia, its 
subtypes and its 
overlap with other 
psychiatric disorders 
according to their 
genetic cause
Box 7.1. Four experts interviewed
In order to gather insights and views on the current debate on the value of genetic research in schizophrenia 
health practice, we interviewed four experts with different backgrounds:
Prof. Dr. M ichael Owen -  Acting Dean of the Medical School at the University of Cardiff, UK. As former head of 
the Department of Psychiatry, Owen has an extensive track record in psychiatry genetics. He is currently member 
of the Psychosis Workgroup, which develops the 5th edition of the Diagnostic and Statistical Manual of Mental 
Disorders (DSM-V).
Dr. Cecile Janssens -  Clinical Epidemiologist at the Department of Epidemiology of the Erasmus Medical 
Centre in Rotterdam, the Netherlands. With a background in psychology, Janssens has become an expert in the 
evaluation of (genetic) tests and genetic risk prediction.
Prof.dr. Durk W iersm a -  Professor Clinical Epidemiology at the Centre for Psychiatry at the University of Gro­
ningen, the Netherlands. Wiersma is one of the leading scientists in the Genetic Risk and Outcome of Psychosis 
(GROUP) project, which collects extensive clinical information from 1000 patients and their relatives. Wiersma 
has been involved in numerous epidemiologic and intervention studies on schizophrenia.
Prof. dr. Nine Knoers -  Professor Clinical Genetics at the Department of Human Genetics of the Radboud Uni­
versity Nijmegen Medical Centre, the Netherlands. Knoers is chair of the Dutch Society for Clinical Genetics, and 
has participated in many debates on the use of genetic data in clinical practice.
a clinical epidemiologist who has been involved in numerous schizophrenia studies. 
To him the environment is an all-too-often forgotten factor in genetic studies. Finally, 
Prof. Dr. Nine Knoers is a clinical geneticist with experience in research and diagnostic 
applications for monogenic disorders. Her main concern is the interest and view of 
patients. She emphasises that genetic results should be brought to patients in an 
interpretable way.
80
Results
Our literature review and interviews w ith the four key-stakeholders have 
provided inform ation on both recent developments concerning schizophrenia 
genetics research and diagnosis, and the w ay in w hich these developments are 
being valued by medical experts. We have deduced four different lines of arguing 
(Box 7.2) that shape current debates on the clinical relevance of large-scale genetic 
studies am ong medical and health experts. W hile these do not necessarily exclude 
one another, they rather represent differences in background and perspective 
regarding the clinical relevance of genetic data.
Large-scale genetic studies for schizophrenia will eventually reveal 
clinically relevant data
One of the more prom inent supporters of large scale genetic studies is Michael 
Owen. He and his colleagues have put much effort in GW A studies to objectively 
detect common variants (predom inantly SNPs) on a genom e-w ide scale. They par­
ticipated in a num ber of large-scale GW A studies on schizophrenia [58,61,65,67­
70,262] w hich revealed only a few  SNP that were significantly associated to schizo­
phrenia occurrence. Collectively, these explain no more than 2 %  of total disease 
burden. Nevertheless Owen and colleagues are optim istic about the potential of 
GW A studies. They argue that GW A studies have revealed at least some common 
variants underlying schizophrenia, hence more of these variants must have been 
retained in the population [263-265]. Therefore, they expect GW A studies to reveal 
additional loci, provided that large-scale studies com prising thousands of samples 
are set up to ensure sufficient statistical power [264,266]. International consortia 
(e.g. the International Schizophrenia Consortium , SGENE and the M olecular Ge-
Box 7.2. The four perspectives. 
1. Large-scale genetic studies for schizophrenia will eventually reveal clinically relevant 
data;
either large-scale GWA studies, CNV studies or a combination of both will eventually reveal causal pathways for 
schizophrenia and related mental disorders (Owen);
2. Large-scale genetic studies for schizophrenia will not reveal sufficient discoveries to 
be clinically relevant;
the effect and predictive value of the variants that will be identified will always be limited, regardless of their 
occurrence in the population (Janssens);
3. Large-scale genetic studies for schizophrenia will only reveal clinically relevant data if 
non-genetic factors are considered;
rather than focusing on the genetics of schizophrenia per se, other factors should be taken into consideration, 
such as environmental factors and methods for clinical interviewing (Wiersmta);
4. Large-scale genetic studies for schizophrenia will eventually be translated to a clinical 
setting;
the issue is not so much whether tests are valid or have sufficient predictive value. The demand from consumers 
and patients will define if and how such tests, as we see today with DTC-tests, will be used (Knoers).
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netics of Schizophrenia consortium, MGS) enable the study of increasingly larger 
data-sets by collecting large patient and control cohorts [58,69,262]. Furthermore, 
the Psychiatric GWAS Consortium  (PGC) is currently perform ing m eta-analyses on 
9,500 schizophrenia patients and 13,500 controls from 11 GW A studies [267,268].
Not everybody agrees w ith the C D -C V  hypothesis as an argum ent for using ever 
larger am ounts of genetic data [269,270]. For example, it w as noted that the PGC 
Consortium , in defense of their strategy to use larger genetic data sets, has pro­
vided evidence that actually m ay not support the C D -C V  hypothesis [270]. The PGC 
has referred to several studies that identified rare copy num ber variants (CNVs), 
not common SNPs. W hile CNVs can occur both rarely and frequently in the general 
population, the studies that the PGC referred to identified rare CNVs w ith a con­
siderable effect, thus providing evidence for the CD -RV hypothesis [267,268,270]. 
These CNVs are rare either because they have occurred recently -  and have not 
been subject to selection over a long period of tim e -  or they have been selected 
against for their deleterious nature [16,17]. Advocates of the CD -RV hypothesis thus 
argue that rare genetic variants w ith m ajor effects do exist, but that early link­
age studies were not able to identify them  because of allelic heterogeneity and 
reduced penetrances [269].
W hile the C D -C V  and the CD -RV theses were considered as being entirely op- 
possing and in tough competition w ith each other, this is not the case anymore 
[17]. Owen, for example, is also aware of the “high risk that CNVs seem to give”.
In fact, he and his colleagues have been am ong the first to study the relation be­
tween deletions on chromosome 22q11 and schizophrenia [271,272]. Together with 
his collaborators in the SGENE consortium  he has performed both SNP and CNV 
analyses on the sam e large cohort, yie ld ing com plem entary results [262,273]. The 
PGC consortium  is p lanning to do the same, although their prim ary focus is on SNP 
analyses. The possibility to analyse both common and rare variants sim ultaneously 
in single m icroarray or re-sequencing experim ents thus m ay ultim ately settle the 
C D -C V  versus CD -RV debate.
The overall concept of the C D -C V  and CD -RV hypotheses is that genetic variants
-  either rare or common -  w ill eventually prove to be clin ically powerful, hence 
clin ically relevant. It has often been argued that the prim ary reason for identifying 
these variants is not to develop genetic profiles [274]. Instead, these variants may 
serve to reveal the complete causal m echanism , thus reaching an understanding 
that is sim ilar to that for m any monogenic disorders. Owen acknowledges that 
we still “know very little about the biology” of schizophrenia, and that elucidating 
biological pathways should be a priority, and provide a first step towards clinically 
relevant results.
Large-scale genetic studies for schizophrenia will not reveal 
clinically relevant data
A second group of experts is less optim istic about the power of large-scale genom ­
ic SNP- and CNV-based studies. According to this group, larger studies m ay reveal 
more candidate genes for complex disorders, but their direct contribution to c lin i­
cal or public health care applications w ill remain lim ited. Also, large-scale genomic 
studies and the data they produce w ill certainly not be very useful in complex dis­
ease prediction based on genetic profiles. The main criticism  of this group is that 
ever larger sam ple sizes w ill only result in the identification of genetic variants
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w ith sm aller effects on a population-w ide scale. In a series of theoretical analyses, 
Janssens et al. show that the prediction of complex diseases based on genetic fac­
tors is not feasible [250,259,260]. Janssens argues that the predictive value “always 
comes down to a com bination of effect size and frequency”, w hich are generally 
opposing forces. The effect sizes of individual SNPs are sm all, and thus m any are 
required in a risk model to lead to good prediction. On the other hand, despite 
their large effects, rare variants ind iv idually occur at too low a frequency to be rel­
evant on a population-w ide scale. Still, consortia like ISC and PGC dedicate much of 
their efforts and resources to large-scale GW A studies, w ith as m ain argum ent that 
larger sam ple sizes w ill provide sufficient power for the detection of significant 
genom e-w ide associations of common variants w ith sm all relative risks. Although 
the m ain objective of such consortia may be to understand the biological back­
ground of disease, their results are often presented w ith a suggestive predictive 
value.
Despite the smoke curtain of p-values and odds ratios, Janssens is aware of the 
prim ary objective of large-scale genom ic studies, w hich is to find biological clues 
for therapeutic targets, possibly leading to novel preventive approaches [22]. One 
of the m ajor promises concerning large-scale genom ic studies is the develop­
ment of personalised medicine, in w hich preventive and therapeutic interventions 
for complex diseases are tailored to ind ividuals based on their genetic profiles 
[275,276]. Janssens argues that this is m isleading, since such personalised ap­
proaches are by definition not evidence-based. Genetic profiles that m ay be identi­
fied in individual patients do not necessarily im p ly that they represent complete 
causal m echanism s. This is exem plified by the 'case of the m issing heritability’, 
w hich shows that the variants identified thus far explain only a sm all fraction 
of the total disease burden [26]. The com binations of risk factors are likely to be 
'unique’ for individual patients, and thus not applicable to other patients. Fur­
thermore, w ithout substantial functional evidence it is im possible to state with 
certainty that a genetic variant affects a specific pathway. Janssens, therefore, 
predicts that the scientific com m unity w ill eventually be less interested in “bigger 
and bigger”, but instead apply “more intelligent approaches”, such as functional 
studies. A llocating resources towards biological validation of the variants im p li­
cated -  via com putational methods, functional assays or model systems -  would 
bring the intention to find causal m echanism s more to the surface.
Does this im p ly that researchers like Janssens advocate a halt to further 
investm ents in genom ics research of complex diseases? Certainly not. Identifying 
pathways on a large scale w ill likely result in more effective and more efficient 
preventive and therapeutic strategies, such as the application of better doses of 
pharm acotherapy and earlier starting ages of screening programs. Also Janssens 
argues that such interventions w ill likely become available to at-risk populations 
based on traditional risk factors or (novel) biomarkers, perhaps complemented 
w ith very strong genetic risk factors. In this respect, Janssens and Owen do not 
differ very much in their assessm ent of the relevance of genetic data. Yet it is clear 
that the predictive value of genetic profiling alone w ill not be powerful enough for 
decision m aking about invasive, irreversible and expensive interventions.
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• Large-scale genetic studies for schizophrenia will only reveal 
clinically relevant data if non-genetic factors are considered
Besides the debate between those w ho are optim istic and those w ho are pessi­
m istic about the clinical relevance of large-scale genom ic studies, there is a third 
group of professionals w hich argue that this discussion sim ply does not address 
the proper question. W hether or not an evidence-based health care system can 
become reality is not determ ined by the statistical power of genetic variants, but 
rather by the im pact of alternative factors, such as the environm ent and the qual­
ity of diagnostic psychiatric methods [277-279]. The focus of genetic research is 
currently prim arily on genes and the genome w hile a much more fruitful approach 
w ould be to study the interaction between genes and environm ental factors or the 
standardisation of (new) diagnostic procedures.
W iersm a is am ong those w ho represent th is view. He argues that “it is a very 
long road” to obtain good insight in the complete causal pathways of schizophre­
nia. One of the challenges he sees is to assess the im pact of non-genetic factors in 
heritability estim ates and genetic analyses for schizophrenia. These non-genetic 
factors can generally be divided into tw o groups: those that interact w ith the 
genes underlying schizophrenia (e.g. environm ental factors) and those that af­
fect the analyses (e.g. diagnostic procedures). W ith respect to the aetiology of 
schizophrenia, W iersm a argues that “genes do not code for such a complex tra it”, 
at least not by them selves. The genome m ay provide the basis for susceptibility 
to disease, but the high heritability (8 0%) also reflects the im pact of the environ­
ment, not exclusively that of genes [278]. Gene-environm ent (GxE) interaction 
models may, therefore, increase the chances of reliably detecting candidate genes 
for schizophrenia [277,278]. Moreover, h ig h-quality m easurem ents of environm en­
tal risk factors w ould also allow  for a significant reduction in required sam ple sizes, 
as high-exposure groups could be easily selected. On the other hand, W iersma 
acknowledges that including currently known environm ental risk factors -  urba- 
nicity, migration, obstetric and perinatal complications, and cannabis use -  is chal­
lenging due to statistical constraints and low -quality trait estim ates [277,280-284]. 
Yet, w ithout including such factors, brute num erical forces w ill get us nowhere, 
W iersm a argues.
Apart from including environm ental factors in genetic studies, W iersm a argues 
that more attention should be given to factors that affect the set-up of genetic 
analyses. Achieving evidence-based treatm ent or m edicine for schizophrenia 
requires a good infrastructure w ith high-quality, standardised diagnostic instru­
ments to perform large-scale genetic studies. The Genetic Risk and Outcome in 
Psychosis (GROUP) Consortium  that W iersm a and others have set up specifically 
aim s to build such an infrastructure for psychiatric research. An im portant aspect 
of this infrastructure is the involvem ent and tra in ing of psychiatrists and other 
health professionals in non-academ ic mental health institutes to perform clinical 
research, using standardised diagnostic instrum ents. The Appraisal of Guidelines 
for Research & Evaluation Instrum ent provides a fram ew ork for assessing the 
quality of clinical practice guidelines on a European level. W iersm a argues that the 
experience and structure w ithin  the GROUP Consortium  have largely contributed 
to the development of such guidelines for schizophrenia in the Netherlands. How ­
ever, he realises all too well that “w riting som ething down does not mean that it 
w ill be im plem ented”. Efforts should, therefore, go into practical im plem entation 
of the guidelines, w hich should lead to a better coherence between those who
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see and treat the patients, and those w ho perform research on the resulting data. 
Im plem enting such European-based guidelines, complemented w ith national coor­
dination and organisation results in “much better insig ht” in diagnosis of patients, 
protocols for treatm ent, and lines of com m unication, says W iersm a [285].
In sum m ary, to allow  for a broader focus than genetic variants and genetic 
susceptibility alone, and to include the complex interaction between genes and 
environm ental factors in research, there is a clear need for the organisation and 
integration of the entire psychiatric field. In turn this should allow  for an evidence- 
based translation of insights from genom ics research on schizophrenia which, 
according to many, is urgently needed.
Large-scale genetic studies for schizophrenia will 
eventually be translated to clinical practice
The last argum ent comes from a different direction. Clinical relevance, health 
practitioners for example argue, does not depend only on the predictive value or 
the valid ity of genetic tests or data. Rather, i f  and when  genetic data are clinically 
relevant is predom inantly determ ined by patients and other consumers [276,286]. 
The introduction of DTC genetic tests for schizophrenia -  as w ell as for other com­
plex disorders -  exem plifies this tendency. Although the popularity of DTC genetic 
tests is currently unclear [287], their 'relevance’ has not been determined by clinical 
valid ity or utility, but by the dem and for these tests from users such as patients 
and their fa m ily  members. C lin icians and clinical geneticists, according to some, 
can best operate under the motto “if you cannot beat them , jo in  them ”.
Nine Knoers, a clinical geneticist w ho is both sceptical and reluctant to promote 
DTC testing, is one am ong m any w ho argue that the clinical relevance of current 
genetic data is questionable. Despite this objection, however, Knoers expects that 
genetic tests for complex disorders like schizophrenia w ill become reality at some 
point in the future, at least for diagnostic purposes. Patients -  especially those 
participating in research projects -  are generally curious to learn about the results, 
and w hether these w ill lead to clinical application. Knoers can often not be certain 
about the potential outcome of research projects. Still, it is often a m atter of te ll­
ing patients “w ithout batting an eyelid” that research w ill likely result in preven­
tive m easures. The increased dem and of patients for clinical solutions w ill certainly 
make it w orthw hile for some diagnostic laboratories to develop diagnostic tests 
for complex disorders. Such tests, Knoers argues, ideally should only be applied in 
diagnostics “if there is a substantial added value for the patient”. But, even though 
she w ould preferably apply genetic tests only after thorough evaluation, Kno­
ers realises these th ings “som etim es ju st happen”. The em erging genom e-based 
knowledge is expected to lead to a conceptual shift in both public health care and 
m edicine [276,286]. If the psychiatric genom ic field does not prepare accordingly, 
it m ay end up in a difficult dichotomy: genom ics m ay advance and create sign ifi­
cant health opportunities w hich attracts potential users, but at the sam e tim e it 
puts restrictions to actual applications based on valid ity and utility  argum ents 
[286]. There is a clear opportunity and responsibility to develop an interdisciplinary 
strategy to assess and translate genom ic knowledge into evidence-based applica­
tions [276]. The integration of psychiatric health programs and the education of 
psychiatrists in genom ics should support evidence-based policy m aking [276]. 
Obviously, policy makers often find them selves in an 'evidence d ilem m a’ [248,288];
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when is there enough evidence for genom ics results to be im plem ented into c lin i­
cal practice?
In the Netherlands, any plan to introduce a DNA-based diagnostic test for a 
certain disease is to be discussed w ithin  the National Board for DNA Diagnostics 
(http://w w w .dnadiagnostiek.nl/index.php). Issues like disease frequency, d iag­
nostic quality, and interpretability of test results are all carefully considered before 
im plem entation. Still Knoers argues that it m ay be hard for the board to say: “we 
are not going to do th is’”. Her hope is that the genetics com m unity can help in re­
ducing both too high expectations and fear am ong consumers, by explaining that 
“a risk on disease tw o tim es higher than a low population risk is still not a high 
risk”. In order to do this, genetic counsellors w ould have to learn much more about 
issues like genetic risk predictions and uncertainties. A significant increase in the 
popularity of DTC genetic tests would certainly put a great burden on the clinical 
genetics com m unity. Extensive counselling w ould not be feasible in the present 
setting; “we sim ply cannot cope w ith it”. In order to be prepared, the (psychiatric) 
genetics field thus needs to reconsider its strategy and organisation.
4 Discussion and conclusionThe clinical relevance of large-scale genetic studies and DTC genetic 
tests for complex disorders has been frequently debated [23,26,59,289,290]. W hile 
the success and popularity of DTC genetic tests m ay be lim ited (DecodeMe has 
filed bankruptcy, but was rescued, and 23andM e has gone through two rounds 
of lay-offs), their appearance has raised questions about the clinical relevance of 
large-scale production of genetic data in general [291,292]. Our study shows that 
assessing this clinical relevance is not straightforward, as it is determ ined by the 
conceptual scheme w hich is applied, or the “glasses” through w hich one looks. As 
we have illustrated, evaluating genetic research results not only depends on the 
faith people have in large-scale genom ic studies, but also on their underlying con­
ceptual fram ework concerning the relationship between genes and disease sym p­
tom s. Those who, like Owen, support the idea that schizophrenia is predom inantly 
caused by a com bination of common and rare variants in the hum an genome, 
believe that large-scale genom ic studies have the potential both to reveal causal 
m echanism s and to result in genetic (diagnostic) tests. W hile Janssens agrees that 
large-scale genetic data m ay indeed be useful for understanding causal m echa­
nisms, she argues that they are probably not useful for predictive or diagnostic 
tests. The m ain argum ents of Owen and Janssens can be directly weighed against 
one another, as they both address the sam e issue in the debate -  the predictive 
or diagnostic value of common and/or rare genetic variants. W hile they m ay not 
agree on all issues, the individual conceptual fram eworks of Owen and Janssens 
show considerable overlap. Conversely, when W iersm a argues that we m ay be 
on the w rong track if  we focus prim arily on the genome, he addresses a different 
issue. As a result, the views of Owen and Janssens on this issue are not necessar­
ily opposing to that of W iersm a; in fact, both Owen and Janssens acknowledge 
the im portance of environm ental factors. Yet their prim ary concern in the debate 
is w ith the effect of genetic variants on disease development, w hich m ay in part 
reflect their conceptual fram ework. Likewise, Knoers approaches the debate from a 
more pragm atic view ; she argues that genetic tests for schizophrenia w ill eventu­
ally enter the health care system, regardless of their analytic or clinical validity. Our
Kraepelinean
dichotomy
classification of 
psychosis based on 
a strict distinction 
between manic 
depression and 
dementia praecox 
(premature 
dementia)
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study thus illustrates a major challenge in the assessm ent of the clinical value of 
large-scale genetic data; it largely depends on the individual conceptual fram e­
works of its assessors. W hen considering genetic testing for psychiatric disorders 
like schizophrenia, both those in favour and those against m ay propose valid argu­
ments. However, if  these argum ents address different issues of the debate -  and 
are thus not necessarily opposing -  find ing a solution m ay be challenging. It is 
therefore essential to clearly describe individual conceptual fram eworks w ithin the 
discussion, and to develop a conceptual scheme for w hich the individual perspec­
tives overlap.
Conceptual fram eworks do not only determ ine the view  on w hether or under 
w hat circum stances large scale genetic data are useful for clinical applications; 
they also shape the concept of “schizophrenia” itself [43,293-299]. To gather 
knowledge about a particular disease leads to a better understanding of its 
sym ptom s and the w ay in w hich these are best measured, w hich in turn may 
change the concept of the disease. W hat we consider schizophrenia to be, in other 
words, is closely related to the concepts we use to understand the relationship 
between a particular set of sym ptom s and, in th is particular case, genes. It is thus 
not surprising that recent genetic studies -  in particular SNP- or CNV-based GWA 
studies -  have caused experts to question the diagnostic definition of schizo­
phrenia [254,272,299,300]. Discussions about the concept of schizophrenia are 
not new; the prim ary m otivation for the Am erican Psychiatric Association (APA) 
to publish the first edition of the Diagnostic and Statistical M anual of Mental 
Disorders (DSM) in 1953 was the extensive debate on nom enclature and organi­
sation of mental disorders before and shortly after World W ar II [301]. Today the 
DSM -  now at its fourth revised edition (DSM-IV-TR) -  provides the main guidelines 
for general practitioners and psychiatrists to perform diagnosis [119]. It strictly 
categorises schizophrenia, bipolar disorder, and schizoaffective disorder as distinct 
entities, follow ing the dichotom ous model of Emile Kraepelin [302]. Yet there is no 
objective and/or quantifiable biochemical or physiological tests (e.g. glucose level 
m easurem ents in type 2 diabetes) available to clearly distinguish schizophrenia 
from other psychosis-related disorders. As a result, boundaries between the diag­
nostic categories are often arbitrary and require substantial subjective judgm ent 
by clinicians, w ho m ay find it difficult to discern distinctive clinical features for 
either schizophrenia or bipolar disorder [303]. M any -  including Kraepelin h im se lf- 
have questioned the relevance of this model, as it m ay not represent true nosol­
ogy [279,297,298,304-306]. There is general consensus that shortcom ings exist 
in the diagnostic classification system for psychiatry, despite the developments 
since DSM -I. Owen therefore argues for a “genetic deconstruction of psychosis”; 
a re-categorisation of psychosis-related disorders based on their genetic back­
ground. Others are less convinced that genetic studies have provided com pelling 
evidence for the overlap between e.g. schizophrenia and bipolar disorder [110,296], 
and either propose alternative classification criteria, or argue that practical issues 
resulting from a re-categorisation w arrant keeping current diagnostic boundaries 
[293,297,298]. Keeping diagnostic criteria as they are now w ould enable clinicians 
to decide how best to initiate treatm ent, and keep them  sim ple and measurable. 
Not only does this controversy show that there are different view s on the w ay for­
ward for psychiatric diagnosis, it also shows that experts propose solutions based 
on their individual perspective.
W hat can be learned from the different perspectives that we have encountered
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and the w ay in w hich these differences are being portrayed? As noted above, 
experts generally agree about the lim itations to clinical applicability of large 
scale genetic research data, but the perspective or conceptual fram ew ork shapes 
one’s argum entation, and also w hat one considers schizophrenia to be. The first 
challenge is thus to identify the perspectives at stake in both the 'large-scale 
data’ and the 'schizophrenia entity’ discussions, of w hich exam ples have been 
presented here. Identifying and channelling the positions of relevant stakehold­
ers is a prim ary requirement to generate shared understanding and a common 
conceptual fram ework for policy decision m aking. The increased desire of consum ­
ers and patients to find out more about their prospective future by genetic testing, 
in conjunction w ith the increased assertiveness of (prospective) patients, warrants 
the development of such common strategy. This was also illustrated by the view  of 
Knoers. She does not disagree w ith any of the colleagues that feature in this chap­
ter; she is aware of the value of GW A studies, she doubts the ultim ate predictive 
value of these studies for every complex disorder and she realises that the role of 
the environm ent m ay be more im portant than geneticists tend to think. However, 
she is also pragm atic about the issue. Despite the lack of evidence for the valid ity 
and clinical utility, DTC genetic tests for psychiatric disorders are a current reality. It 
lies outside the power of m edical professionals to (re)define this reality. The mere 
publication of p-values and odds ratios as a scientific argum ent for the relevance of 
genetic findings w ill continue to result in the development of controversial genetic 
profiles and tests, thereby reinforcing speculations. In addition to a quantitative 
assessm ent of the analytic and clinical valid ity of genetic testing for schizophre­
nia, it is im portant to also provide a common fram ework in w hich such criteria
-  including ethical, legal and social issues -  should be discussed. Identifying and 
clarifying individual conceptual fram eworks m ay be a first step towards solutions 
for issues like the use of (unverified) genetic data or regulation of genetic testing 
[307,308]. Recently, integrative conceptual fram eworks for large-scale genetic data 
generation and translation into genetic tests have been proposed, h ighlighting 
the m ultiple components of genetic research and policy-m aking [309-311]. Instead 
of strong opposition to the use of large-scale genetic research for schizophrenia 
now, it is essential to use such shared conceptual fram eworks to initiate trans- 
disciplinary coordination and to develop future policy m aking strategies. More 
transparency about the positions of various professionals w ould help both science 
and the public in coping w ith the com plexities of genetic and psychiatric research. 
A cknow ledging the existing differences w ill show us w hat genetics is about: a 
complex research field that does not provide the ultim ate solution for disease, 
but helps shape disease entities, and identifies their prim ary causes. Explicit use 
of these differences w ithin a common conceptual fram ew ork for schizophrenia 
genetics w ill facilitate the dialogue between policy-m akers and the m any different 
stakeholders involved.
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8 . General discussion
8 1  LADN fait n'importe quoiIn the introduction of this thesis we alluded to the incredible richness 
of DNA, w hich provides unlim ited possibilities for diagnosis and treatm ent. At 
the sam e tim e, researchers face m any challenges when trying to fu lly  compre­
hend genetic variation, and unravel the exact w orkings of our DNA. In order to 
understand the genetic basis for complex disorders, geneticists have predom i­
nantly been searching for common genetic variants (e.g. SNPs) [22,23,290,292]; 
genom ic deletions, duplications, and other rare genom ic variants were thought to 
play a role in rare diseases only. Yet the introduction of high-resolution microar­
rays -  and more recently high-throughput sequencing -  has revealed numerous 
rare variants that m ay be equally im portant in the aetiology of complex disease 
[16,17,30,189,190,312,313]. W ith the identification of six novel rare genom ic deletions 
and duplications in patients w ith various psychosis-related phenotypes, the results 
described in this thesis have provided evidence for a significant role of rare copy 
num ber variation (CNV) in the development of schizophrenia. These and other 
findings w arrant a broad discussion on the future direction of genetic studies on 
schizophrenia, w hich today are generally based on hypothesis-free and hypothe­
sis-generating -  not hypothesis-driven -  approaches. Here we relate the develop­
ments in genetic research on schizophrenia to the past experience w ith another 
complex psychiatric disorder -  mental retardation -  and propose to initiate the 
incorporation of high-throughput genom ics technologies in the standard diagnos­
tic w orkflow  for patients suffering from schizophrenia.
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8 2  Identification and interpretation of novel CNVs• ^  in schizophrenia patients
The first three chapters o f th is thesis describe the identification o f CNV in pa­
tients w ith  schizophrenia, using a genom e-w ide profiling approach w hich has 
also been successfully  applied in other psychiatric disorders, such as autism , 
m ental retardation, schizophrenia, and A lzheim er’s and Parkinson’s disease 
[49,50,52,53,66,85,115,129,138,168-172,174]. W e identified six relatively large CNVs in 
carefully  selected cohorts o f schizophrenia patients for w hom  extensive phenotyp­
ic inform ation w as available [83,173]. Clinical assessm ent based on the Diagnostic 
and Statistic M anual of M ental Disorders (DSM-IV-TR) [119] indicated the presence 
of either a specific subtype o f schizophrenia (e.g. deficit schizophrenia), or of a 
syndrom al form  of schizophrenia, inclu din g  ad ditional characteristics like m ental 
retardation or dysm orphic facial features. The CNVs identified neither occurred 
as com m on events in the general population, nor w ere located in highly variable 
genom ic regions, thu s providing a first indication for their involvem ent in the 
patients’ clinical phenotype. In Chapter 2 w e identified tw o overlapping deletions 
on chrom osom e 7q35, affecting several genes, am ong w hich contactin associated 
protein-like 2 (CNTNAP2). Targeted follo w -up screening o f a large cohort of patients 
w ith  general schizophrenia revealed an additional deletion that only affected the 
CNTNAP2 gene, providing fu rth e r support for a role o f th is gene in schizophrenia 
developm ent. In Chapter 3 w e detected rare CNVs affecting the neurexin-1 (NRXN1), 
astrotactin-2 (ASTN2), m yelin transcription factor 1-like (MYT1L) and delta-catenin 
(CTNND2) genes in patients w ith  deficit schizophrenia. These CNVs w ere further 
studied in a larger cohort o f 752 patients w ith  various subtypes of schizophrenia, as 
w ell as 70 6  control ind ivid uals. Recurrent CNVs w ere found affecting the coding re­
gions o f NRXN1, ASTN2 and MYTL1, w hereas only one (intronic) CNV w as observed in 
NRXN1 in one of the control ind ivid uals. In chapter 4  w e describe the detection of 
a d uplication in the retinoid-related orphan receptor alpha (RORa) gene in a single 
patient w ith  a com plex phenotype, w hich included schizoaffective disorder, seizure 
disorder, m ental retardation, and dysm orphic facial features. A nalysis of avail­
able fam ily  m em bers revealed no direct relation o f th is duplication w ith  a specific 
phenotype. However, detailed brain analysis using m agnetic resonance im aging 
(MRI) and positron em ission tom ography (PET) show ed that the duplication did 
segregate w ith  abno rm alities in brain structure and fu nction ing.
Interestingly, the affected genes all play a role in neurobiological processes; 
som e have even been previously im plicated in psychiatric disease. The gene 
affected by deletions identified in Chapter 2 -  CNTNAP2 -  is a m em ber o f the 
neurexin gene fam ily, o f w hich the m em bers are known transm em brane presyn- 
aptic proteins. D isruption of CNTNAP2 w as in itia lly  observed in a fam ily  w ith  Gilles 
de la Tourette syndrom e and obsessive com pulsive disorder [79]. M ore recently, 
m utations in th is gene w ere associated w ith  cortical dysp lasia-focal epilepsy 
(CDFE) syndrom e in Old Order Am ish fam ilies [90]. Follow ing the publication of 
our results [83], various disruptio ns o f CNTNAP2 have been reported in patients 
w ith  autism  spectrum  disorder, attention-deficit hyperactivity disorder, language 
im pairm ent, m ental retardation and schizophrenia [82,113,314-316]. CNTNAP2 is 
essential in stabilizing axon conduction and in m ain tain in g  the inter-nodal resting 
potential [91], and its disruption m ay result in a destabilised axon potential, w ith 
m any possible effects on brain fu n ctio n in g  [317]. W hile  there is no direct evidence
9 0
for the effect of disruption of CNTNAP2 in the brains of patients w ith  schizo­
phrenia, these results collectively show  that CNTNAP2 plays an im portant role in 
general neurological function ing.
M ost o f the CNVs presented in Chapter 3 affected the NRXN1 gene, w hich is -  
like CNTNAP2 -  also a m em ber of the neurexin gene fam ily. D isruption o f NRXN1 
w as first observed in patients w ith  autism  spectrum  disorder [111], and has later 
also been associated w ith e.g. autism , m ental retardation and schizophrenia 
[49-51,65,66,82,168]. W hile  CNVs in the CNTNAP2 gene have th us far been exclu­
sively observed in psychiatric patients, w e also identified a deletion in NRXN1 in 
one out o f 7 0 6  control individuals. This deletion affected only intronic sequences, 
as w as also the case for duplications in tw o  o f the patients. Such CNVs are unlikely 
to have m ajor phenotypic effects, even though they m ay affect regulatory ele­
m ents. These observations indicate that correct interpretation o f the clinical effect 
o f CNVs requires careful consideration o f their genom ic location and the type of 
sequence (coding or non-coding) they affect, instead o f focu sing on num bers only 
[173]. This w as fu rth e r supported by a more recent study, in w hich 14 CNVs affect­
ing NRXN1 w ere identified in 2,977 schizophrenia cases (0.47%) versus 52 in 33,746 
controls (0.15%) [66]. W hile the percentage of CNVs affecting N R X N  in patients 
and controls did not differ significantly, the authors did show  that the percentage 
o f CNVs sp ecifically d isru ptin g  exons w as sig nificantly larger in patients than in 
controls [6 6 ]. A com plicating factor in the interpretation o f CNVs in NRXN1 is the 
existence o f m ultiple splice form s generated from  tw o m ajor transcripts -  NRXN1a 
and NRXNip. D isruption o f the prom oter region and proxim al exons of the longer 
NRXN1a transcript by either CNVs or point m utations m ay reduce transcription fa c­
tor b ind ing  capacity, thereby possibly affecting schizophrenia pathogenesis [172].
In Chapter 3 w e identified deletions affecting the prom oter region and the first 
tw o  exons o f NRXN1a in tw o patients w ith  schizophrenia, w hich is in line w ith  this 
hypothesis. However, clinical interpretation o f the deletion identified in another 
patient, affecting exons 8-12 o f NRXN1, rem ains elusive, and requires functional 
fo llo w -u p studies.
Both CNTNAP2 and NRXN1 are im portant factors in the developm ent of the ner­
vous system, w here they act as cell-adhesion m olecules to cluster voltage-gated 
potassium  channels (Kv1.1) at the nodes o f Ranvier, and form  synaptic contacts, 
respectively. In chapter 3 w e identified CNVs affecting three other genes that have 
been less extensively studied, but are nevertheless known to play a role in the de­
velopm ent o f the nervous system . Two rare CNVs affected astrotactin-2 (ASTN2), a 
neuronal cell-adhesion m olecule that is thought to be involved in neuronal m igra­
tion [49]. ASTN2 is highly expressed in the brain, and rare deletions affecting ASTN2 
have recently been im plicated in autism  [49]. W hile ASTN2 itse lf has not been 
extensively studied, its hom olog astrotactin (ASTN1) is known to support neuronal 
m igration by e stab lishing  interactions betw een neuronal and glial cells [126,318]. 
Likewise, putative effects of recurrent CNVs affecting m yelin transcription factor 
1-like (MYT1L) as identified in Chapter 3, can be deduced from  the fam ily  of myelin 
transcription factors 1 (MYT1) it belongs to. MYT1 genes are expressed in early neu­
ronal developm ent, and regulate proliferation and differentiation o f oligodendro­
cytes in the central nervous system  [127,132,319]. Furtherm ore, deletions in MYT1L 
have recently been observed in patients w ith  childhood-onset schizophrenia (COS), 
w hich fu rth e r supports its role in neuronal developm ent [319]. Finally, in Chapter 3 
w e identified a single deletion in catenin delta 2 (CTNND2) -  another cell-adhesion
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m olecule -  w hich is essential for norm al synaptic function [320,321]. It acts in the 
adherens ju n ctio n s of neurons, w here it binds to cadherins to regulate adhesion 
and to initiate dendritic b ranching [321]. Knocking out o f CTNND2 in mice leads to 
severe neurological im pairm ent [322]. Despite its im portant function in early brain 
developm ent, CTNND2 has not been previously im plicated in psychiatric disorders, 
except for severe m ental retardation as part o f Cri du Chat syndrom e [139]. As we 
only identified a single CNV affecting CTNND2, it is likely that variation in this gene 
is rare.
Similarly, in Chapter 4  w e identified a CNV affecting retinoid-related orphan re­
ceptor alpha (RORa) occurring in a single fam ily  only. The RORa gene also exhibits 
im portant neurological functions, but has not been directly im plicated in a specific 
psychiatric disorder previously. It is expressed in Purkinje cells of the cerebellum , 
and is involved in m ain tain in g  circadian rhythm s [147,153,158]. Staggerer mice -  
w hich lack fu nction al RORa protein -  exhibit severe ataxia due to m assive cerebel­
lar neurodegeneration [158]. W hile  these specific effects o f RORa d isruption have 
not been dem onstrated in hum an brains, the results from  studies in mice could 
im ply a role for th is gene in the developm ent of psychiatric disease.
Implications for schizophrenia genetics
The results from  Chapters 2, 3 and 4  have three m ajor im plications, 
w hich w ill be discussed below.
Rare CNVs play a role in schizophrenia development
We have show n that the role of rare CNVs in schizophrenia developm ent m ay be 
larger than previously thought. This notion is fu rth e r supported by other recent 
studies, in w hich researchers have consistently identified rare an d/o r de novo  CNVs 
that increase the risk to develop schizophrenia, especially w hen th ey disrupt gene 
fu nction s [50,65,83,114-116,121,169,170,173,273,323,324]. It is estim ated that CNVs 
currently explain 2-4% of the total schizophrenia burden, and this num ber may 
increase to 10-20%  as results from  novel ultra high-resolution array and high- 
th ro ug h pu t re-sequencing platform s becom e available [325]. Im portantly, m any 
of the schizophrenia-related CNVs have been repeated ind ependently in one or 
more different studies, e.g. those affecting the 1q21 deletion region, or the NRXN1, 
CNTNAP2, and APBA2 genes [50,83,114,121,173]. Such consistency has not been 
observed in linkage and (genom e-w ide) association studies, w hich has ham pered 
the identification o f unequivocal candidate loci, despite substantial increase in 
sam ple size [268,270]. As w as m entioned in Chapter 1 and fu rth e r discussed in 
Chapter 7, the increasing num ber of rare CNVs linked to psychiatric disease have 
refuelled the debate on the genetic m odels (com m on d isease-com m on vari­
ant  -  CD-CV -  or com m on disease-rare variant  -  CD-RV) underlying schizophrenia 
[16,17,30,59,60,325,326]. W hile m any geneticists have a strong preference for either 
the CD-CV or the CD-RV hypothesis as the prim ary disease model, all agree that 
neither of the hypotheses exp lains all of disease burden. Concordantly, w hile  
heritab ility  of schizophrenia is high (~80% ), the m ajority o f disease burden has not 
been explained by either of the tw o  m odels. Some hypothesise that the 'm issing 
heritab ility’ that geneticists observe is not only due to variation s in the DNA, but 
m ay also be sought in epigenetic variation, environm ental factors or even fac-
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Figure 8.1. Gene 
enrichment in 
candidate CNVs. The 
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tors that have not yet been considered [26,264].The identification of rare CNVs as 
causal or su scep tibility  factors for schizophrenia and other com plex diseases not 
only show s that rare genetic variants play a more prom inent role in disease de­
velopm ent than previously thought; it has also broadened the vie w  on the entire 
spectrum  of possible causal factors for com plex disease [17,23,30,59].
Disruption of neurodevelopmental genes plays a critical role in 
schizophrenia development
W hile  w e detected schizophrenia-associated CNVs using an unbiased genom e- 
w id e  approach, all affected genes exhibit im portant neurological functions, 
strongly suggesting that th eir disruption m ay have psychiatric consequences. 
Some CNVs affect m ultiple genes w ith in  a region, but w e considered that the most 
likely candidate gene w as either entirely deleted or disrupted by a partial dele­
tion or duplication. It is generally challenging to directly test w h e th e r a (partial) 
deletion or duplication actu ally  has a d isruptive effect on the brain, and due to 
lack of suitable tissue  m aterial w e w ere not able to perform  such fu nction al stud ­
ies. Instead, w e here provide fu rth e r support from  bioinform atic analyses for the 
d isruption-hypothesis, using an approach recently developed by our group [327]. 
This approach b asically identifies enrichm ents or depletions o f genes that result in 
a phenotype in ~ 5,o o o  publicly available m ouse knockout experim ents. We applied 
th is approach to 36 candidate CNVs w hich have been identified in patients w ith 
schizophrenia, am ong w hich the 6 candidate CNVs from  our studies [60,83,173]. 
A nalysis o f these regions (1,000 perm utations) show s that these are significantly 
enriched for genes that -  w hen disrupted in mice -  result in abnorm al behav­
ioural/n eu rological (+100%  enrichm ent; p  = ix i0 -4) or nervous system  (+99.9%  
enrichm ent; p  < 1x10-5) phenotypes (Figure 8.1). It w as previously show n that CNVs 
occurring in the general population are not sig nificantly enriched for such genes 
[327], ind icatin g that the enrichm ents observed here m ay be specific for schizo-
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phrenia. Furtherm ore, GO-term analysis o f the schizophrenia-related CNV genes 
revealed a 1.77-fold enrichm ent for developm ental processes (p = 2x10-3; Figure 8.1). 
Based on these data, w e argue that a bioinform atic analysis o f fu nction al biases 
for schizo ph renia-associated  CNV genes can be exploited to prioritise genes for 
fu rth e r investigation in schizophrenia ind ivid u als [327].
Our results support the hypothesis that aberration of neurodevelopm ental genes 
m ay constitute a prim ary cause for schizophrenia. It w as previously suggested that 
arrayCGH w ould  be a prom ising approach to provide fu rth e r insight in the effect 
of genetic factors in different neuronal developm ental stages [94]. The six novel 
candidate genes for schizophrenia identified in our studies all have im portant 
fu nction s in the developm ent o f neurons. Com bined w ith the high heritability, 
the variety o f m ild psychiatric sym ptom s often seen prior to schizophrenia onset, 
and the identification of CNVs that m ay be specific for p articular schizophrenia 
subtypes (e.g. COS), w e conclude that rare CNVs w ith  disruptive effects on genes 
w hich are essential for neurodevelopm ent m ay contribute to schizophrenia.
Genetic overlap exists between various psychiatric disorders
Four of the novel candidate genes for schizophrenia reported here have been previ­
ously im plicated in other psychiatric disorders, im plying the existence o f genetic 
overlap betw een these psychiatric disorders. O f note, 29 of 36 schizophrenia-relat­
ed CNV regions described above w ere also identified in patients w ith  m ental retar­
dation (Hehir-Kwa, p erson a l co m m u n ica tio n ).T his overlap indicates that common 
disease pathw ays m ay underlie various psychiatric disorders. On the other hand, 
as discussed in Chapter 7, genetic overlap m ay partly  reflect the challenges faced 
in psychiatric diagnosis. W ithin the group o f psychosis-related disorders (am ong 
w hich schizophrenia) there is a lack of d istinctive clinical features (“point of rar­
ity”) to establish a clear disease categorisation [328]. D iagnosis of schizophrenia 
depends entirely on clinical exam ination, using diagnostic criteria described in the 
revised Fourth Edition o f the D iagnostic and Statistical M anual o f M ental disorders 
(DSM-IV-TR) [119]. The DSM-IV-TR assum es a strict dichotom y betw een e.g. schizo­
phrenia and bipolar disorder, w hich m ay not represent true nosology. Preparations 
for the fifth edition of DSM (DSM-V) have raised an extensive debate about the 
valid ity of schizophrenia as a clinical entity, and about alternative approaches that 
should be considered to classify  psychosis-related disorders [254,293,297-299].
An increasing num ber o f studies show  that m any genetic varian ts m ay increase 
susceptibility  to both schizophrenia and bipolar disorder [62,329,330]. Owen and 
colleagues have therefore proposed to apply a 'genetic deconstruction’ to psycho­
sis [299], w hich m ay result in a genetics-based re-categorisation o f m ajor psychi­
atric classes. Owen and colleagues acknow ledge that interpretation of relations 
between gene actions and brain m echanism s rem ains largely speculative (see also 
Chapter 5). Yet, they also expect that m olecular genetic analyses m ay significantly 
contribute to our u nd erstand ing  of the pathophysiology o f psychiatric disease. The 
'genetic deconstruction’ proposal w as o rig inally  developed based on results from  
linkage and (genom e-w ide) association studies -  of w hich the clinical value w as 
largely questioned [60,110,297,306]. We now  hypothesise that detailed analysis of 
rare CNVs at the level of the individual patient m ay sig nificantly  increase insight in 
the extent to w hich various psychiatric phenotypes overlap.
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8 4  Towards diagnostic application of CNV• ^  profiling for schizophrenia
W ith the identification of rare CNVs by us and others, know ledge on the role of 
genom ic variation in the developm ent o f schizophrenia is now  at a sim ilar stage 
as for m ental retardation (another com m on psychiatric disorder) a few  years ago. 
The identification o f rare de novo  CNVs in patients w ith  unexplained m ental re­
tardation [34,35,37,88,331-333] initiated an extensive debate about the diagnostic 
application of arrayCGH [334 -337]. Genetic diagnosis for m ental retardation has 
for long depended on cytogenetic technologies w hich provide insight in genom ic 
aberrations either on a genom e-w ide scale, but w ith a low  resolution (by chrom o­
som e banding), or on specific regions of the genom e w ith  a high resolution (by 
FISH) [31]. The advent o f the significantly  increased genom e-w ide resolution of 
arrayCGH did not raise the question w h eth er  th is techn olo gy should be applied in 
diagnostics; it w as rather a question o f w hen  and how. Some argued that the high 
diagnostic yield o f w hole-genom e arrays w o u ld  outw eigh the risk o f fin d in g  am ­
biguous results [37,336-338]. Others argued that the yield o f w hole-genom e arrays 
w o u ld  not be much higher than that o f arrays targeted at known d isease-causing 
genom ic regions, and should therefore not be applied w ith o u t fu rth e r consider­
ation [88,335]. N ow -  less than five years later -  genom e-w ide copy num ber profil­
ing  is a standard procedure in the diagnostic w o rk flo w  of m ental retardation and 
has revealed m any causative genom ic aberrations in previously unexplained cases 
[37,38,339-341]. Despite the lack of full penetrance and som etim es am b iguo us test 
results, genom e profiling technologies have greatly advanced diagnosis in m ental 
retardation, and have provided im portant inform ation to m any patients and their 
fam ilies. We hypothesise that application o f genom e-w ide profiling as a standard 
procedure in the d iagnosis of schizophrenia m ay yield a sim ilar benefit.
Fast and affordable detection o f CNVs using high-resolution genom e-w ide 
m icroarrays fo llo w in g  an hypothesis-free approach can now  readily be perform ed 
in schizophrenia. A practical w o rkflo w  for diagnostic application of genom ic profil­
ing  in m ental retardation [38] has been w id ely  used, and requires little adaptation 
for the application to schizophrenia. As w e show ed in Chapter 5, the high resolu­
tion o f current genom ic m icroarrays reveals on average - 3 0  CNVs per individual, 
and the new est generation o f m icroarrays m ay even reveal up to 50 CNVs [43]. An 
essential first diagnostic step is to d iscrim inate betw een com m on CNVs that occur 
fre q u en tly  in the general population, and rare CNVs that m ay be patient-specific. 
CNVs identified in healthy ind ivid uals have been docum ented in the publicly avail­
able Database o f G enom ic Variants [28]. Still clinical interpretation based on this 
database rem ains challenging, as the results in th is database are not curated and 
often not validated by independent technologies. Furtherm ore, inclusion o f results 
from  m icroarray platform s of various resolution m akes it d ifficult to com pare 
genom ic sizes, breakpoints and absolute copy num ber types (e.g. heterozygous 
versus hom ozygous deletions). Therefore it is im portant to com pare the identified 
CNVs w ith  those identified in healthy ind ivid uals on a m icroarray platform  of sim i­
lar resolution. In Chapters 2 to 4  w e used an in-house control population that w as 
either hybridised on a com parable m icroarray platform  or screened by the sam e 
targeted approach as the patients. This allow ed for a clear d istinction between 
norm al and disease-related genom ic variation.
CNVs detected for diagnostic purposes require independent validation, especial­
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ly those in the lower size range. W e generally used m ultip lex ligation-dependent 
probe am plification (MLPA) for validation, w hich can also be easily used for estim a­
tion o f recurrent risk in healthy individuals, as w ell as for parental testing . The 
latter is often crucial in determ inin g  the relation to disease, either by revealing de 
novo  occurrence of the CNV in the patient, or by show in g segregation w ith in  the 
fam ily. De novo  occurrence of a CNV w ith o u t phenotypic effect is rare (especially 
outside o f CNV hotspots), and th u s its occurrence in a patient strongly indicates 
causality [39,41,43]. On the other hand, clear segregation o f a rare CNV w ith d is­
ease in a fam ily  m ay also indicate causality, as w as previously show n for disruption 
of DISC1 in a single fam ily  w ith  schizophrenia [74]. However, clinical interpreta­
tion o f rare inherited CNVs in a fam ily  w ith  various psychiatric phenotypes -  such 
as the d uplication in RORa described in Chapter 4  -  rem ains challenging, as w as 
also show n for m ental retardation [38,342,343]. It w o u ld  th us be recom m ended 
to in itia lly  focus on de novo  CNVs for diagnostic purposes. Yet ob taining parental 
sam ples is generally more challenging for schizophrenia than it is e.g. for m ental 
retardation, as the age of onset for schizophrenia is usually  m uch higher (between 
18 and 35 years of age). Still onset does occur between age 6 and 12 for a specific 
subtype o f schizophrenia (childhood-onset schizophrenia or COS). Two recent stu d ­
ies have show n that rare CNVs m ay explain aetiology in up to 40%  of the patients 
w ith  COS [115,319]. In case parents o f patients w ith schizophrenia are not available 
for genom ic profiling, correct clinical interpretation of CNVs requires additional 
evidence. An em erging approach is the use o f bioinform atics-based classification 
tools to discern disease-related CNVs. A w ide range of m ethods is available to pre­
dict the role of CNVs in disease [34 4-34 7]. These include pathway, gene network, 
and gene ontology analyses, repository searches, and gene classification. Hehir- 
Kwa et al. recently developed a bioinform atics tool specifically for CNV data, w hich 
allow ed a classification of disease-related CNVs in m ental retardation w ith  94%  ac­
curacy [348]. Our prelim inary results described in paragraph 8.3 indicate that such 
b ioinform atic approaches m ay also be of significant value in the interpretation of 
the effect o f CNVs on schizophrenia developm ent.
Advantages of applying diagnostic CNV profiling for 
schizophrenia
It is expected that diagnostic CNV profiling for schizophrenia w ill result in the 
identification o f m any rare CNVs related to specific psychosis-related pheno­
types. In th is way, diagnostic application can help in “deconstructing psychosis”.
In Chapter 7 w e alluded to the divide in the v ie w  am ong experts involved in 
the preparations for DSM-V [297,298]. Several approaches have been proposed, 
w hich are generally directed tow ards either a dim ensional or a categorical model 
[297,299,349]. The form er assum es the existence o f a spectrum  o f neurobiological 
and cognitive dim ensions, in w hich psychiatric disorders represent a continuum  
of phenotypic variation. Possible applications w ith in  th is dim ensional m odel are a 
“genetic deconstruction” of psychosis [299] or a factorial clustering o f psychiatric 
sym ptom s [297]. The categorical model assum es the existence o f a num ber of 
distinct categories w ith in  the general schizophrenia entity, e.g. deficit schizophre­
nia [140] or childhood-onset schizophrenia [319]. M any of the recently identified 
CNVs have not only been im plicated in schizophrenia, but also in other psychiatric 
disorders, w hich w ould  support a m ulti-dim ensional m odel. The identification
9 6
o f phenotypically distinct m ental retardation subtypes characterised by distinct 
m icrodeletions or -duplications indicate that genom ic profiling can be useful 
in id entifying specific disease categories. An exam ple of such a specific m ental 
retardation subtype is the 17q21 m icrodeletion syndrom e w hich has, since its 
discovery, been characterised in m uch m ore detail at the phenotypic level (“reverse 
phenotyping ”) [35,333,350]. In th is thesis w e have provided exam ples of CNVs that 
occur only in specific fam ilie s (RORa in Chapter 4) or subgroups (MYT1L in Chapter 
3), as w ell as those w hich m ay result in various psychiatric disorders. In either case, 
genom ic profiling w ould  strengthen current diagnosis, as it has the potential to 
reveal subtypes or extra dim ensions that w o u ld  rem ain undetected by clinical 
in te rvie w in g  alone.
One of the m ajor objections o f applying genom e-w ide approaches in d iagno s­
tics is its potential to create unnecessary an xiety am ong patients and th eir fa m i­
lies [351]. However, most clinical geneticists and paediatricians are w ell-trained 
in counselling th eir patients. In addition, providing a clearly identifiable cause for 
apparent phenotypic and behavioural features generally reassures the patients 
and their fam ilies, and grants them  access to h igh-qu ality  health care.
Im plem enting genom ic profiling in schizophrenia m ay not only im prove d iag ­
nosis; it m ay also be beneficial for und erstand ing the biological underpin nings of 
schizophrenia and, as such, m ay aid in the identification of new  drug targets. As 
w as suggested in Chapter 7, elucidating the full genetic background of schizophre­
nia requires large sam ple sizes w ith  w ell-d efin ed  phenotypes. At present, patients 
are diagnosed based on a subset of qualitative sym ptom s -  none o f w hich is m in i­
m ally necessary -  leading to substantial phenotypic variab ility  w ith in  the d iag no s­
tic category of schizophrenia. This leaves geneticists w ith  highly heterogeneous 
stud y cohorts, w hich ham pers the detection o f shared genetic factors [297,298]. 
Genetic heterogeneity m ay be su b sta n tially  reduced by genom ic profiling, as it 
allow s researchers to collect patients based on specific deletions or duplications.
As a direct result, genetic research leads to patient cohorts that are not only more 
hom ogeneous, but also larger in size. G enom ic profiling in a diagnostic setting 
th u s provides an efficient and effective w ay o f collecting the required sam ple sizes 
for pow erful genetic studies, e.g. to elucidate the m echanistic and architectural 
features o f particular CNVs, or the pathw ays they affect. Moreover, the collection 
o f larger cohorts allow s for m oving from  a hypothesis-driven approach tow ards a 
m ore hypothesis-free or hypothesis-generating approach. As a result o f the recent 
technological advancem ents (e.g. m icroarrays and high-throughput re-sequenc­
ing) th is transitio n is already tak in g  place. By using a hypothesis-free approach, 
w e and others have confirm ed known candidate genes and, in addition, have 
identified new  ones [352-357]. This approach can be extended tow ards searching 
for overlapping CNVs prior to extensive phenotypic diagnosis as exem plified by 
the 17q21 m icrodeletion syndrom e (see above), resulting in the generation o f novel 
hypotheses.
The collection of large cohorts w ith  w ell-d efin ed  phenotypes could be further 
im proved by the developm ent o f so-called endophenotypes. In chapter 5 w e have 
provided som e prelim inary evidence for a relation betw een CNVs and structural 
brain volum es, w hich could serve as endophenotypes for a num ber o f psychiatric 
disorders, inclu din g schizophrenia. M any anatom ical, electrophysiological, sensory 
and psychiatric endophenotypes have been proposed for schizophrenia [358]. 
Structural brain m easurem ents by m agnetic resonance im aging (MRI) are am ong
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the m ost prom ising, as they are h ighly reliable, heritable, robustly correlated 
w ith  phenom enological features of psychiatric disorders, and non-invasive [359]. 
A lthough this pilot study already yielded a num ber of interesting CNV regions 
that m ay be linked to specific brain volum es, larger cohorts w ill be crucial for the 
identification o f significant associations. In addition, the detection of biologically 
m eaningful results w ould  require independent replication cohorts, as w ell as ad ­
ditional fu nction al studies.
8  — Challenges ahead
•  j  From the above it m ay be clear that the application o f high-througput 
genom ics technologies has advanced psychiatric genetics in m any w ays. Yet it is 
clear that the best is still to come. Already in 2006, w hen the m icroarray tech n o l­
ogy began to provide results en masse, it w as predicted that the “w ild  w orld  of 
sequencing DNA w as ju s t  b eg in n n in g ” [360]. Indeed, tim e and costs o f DNA se­
quencing have been reduced to a level that make it suitable for clinical application. 
The first published personal w hole-genom e sequences offer insight in its future 
possibilities, and also in the challenges that com e w ith it.
Next-generation sequen cing allow s for the sim u ltan eo us detection of all ge­
netic variation, i.e. rare and com m on variants, single nucleotide varian ts and CNVs, 
and even balanced genom ic abnorm alities, at u ltim ate resolution. The technology 
is thus expected to sig nificantly advance disease gene identification, thereby rap­
idly resolving the genetic factors underlying m any (M endelian) disorders. A m ajor 
advantage o f next-generation sequen cing  for CNV studies is the possibility to 
detect true -  not relative -  copy num bers. Furtherm ore, next-generation sequenc­
ing allow s for more accurate breakpoint detection, w hich is of m ajor im portance in 
disease studies, as the phenotypic effect largely depends on the genom ic content 
being affected and the genes being disrupted.
These developm ents are o f im portance for diagnostic genom ic profiling in the 
near fu tu re  since (i) they are likely to settle the debate for either com m on or rare 
variants as prim ary cause for m any unresolved disorders [361], (ii) they m ay lead 
to a genetic confirm ation of clinical diagnoses previously anticipated but not 
confirm ed [362] or (iii) they m ay lead to a correction o f earlier m isdiagnosis. These 
assum ptions pose additional challenges to the interpretation o f genom ic variants, 
w hich should be considered and dealt w ith  at an early stage [338].
In addition to rew ritin g diagnostic m anuals, one hope is that extensive genom ic 
profiling by high-throughput sequen cing  w ill lead to the id entification o f novel 
biological pathw ays involved in the aetiology of schizophrenia, w hich in turn will 
help in the developm ent of new  therapies and in the developm ent o f personalised 
treatm ent. Even though l ’A D N  f a it  n ’im p o rte  quoi, w ith  the help o f advanced 
genom ic technologies, an open m ind to new  developm ents, and strong integra­
tion betw een research and clinical practice, w e w ill eventually  be able to reveal its 
secrets.
next-generation (or
high-throughput)
sequencing
new technology 
that allows fast 
and affordable 
sequencing o f entire 
(human) genomes
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Summary
For more than a century -  since Darwin's and Mendel's discoveries of species variation and 
inheritance laws, respectively -  geneticists have been studying genetic variability that distin­
guishes one species from another, one trait from another, and health from disease. Genetic 
research has revealed many secrets, and has resulted in many applications for the diagnosis, 
prevention and treatment of disease. At the same time, each step closer to unravelling the 
mechanisms underlying genetic variation opens up new areas of research with unforeseen 
questions, resetting hypotheses on the architecture, content and function of our genome. 
Hence, l'ADN fait n'importe quoi -  DNA does whatever -  which reflects the complexity of DNA 
and at the same time points at its potential to do almost anything.
The quest for genetic variation underlying schizophrenia set out in this thesis is characterised 
by a coherent strategy to identify rare genetic variants with a substantial impact on schizo­
phrenia development. It started off with the identification of hemizygous deletions in three 
patients with phenotypes of various complexities, ranging from a severe cognitive impairment 
combined with epileptic seizures to a mild form of schizophrenia (Chapter 2). The deletions 
varied in size, but all affected the contactin-associated protein-like 2 (CNTNAP2) gene on chro­
mosome 7q35. This gene had been previously associated to a syndrome comprising focal epi­
lepsy in Old Order Amish people. We here establish the association of variation in CNTNAP2 
to epilepsy outside the Old Order Amish community. Moreover our data suggest that dosage 
alteration of this gene may lead to a complex phenotype of schizophrenia, epilepsy and cogni­
tive impairment.
The patients with a CNTNAP2 deletion generally possessed a broad range of diagnostic features, 
resulting in a complex phenotype. The patient with the smallest deletion (200kb) showed the 
least severe phenotype, while the patient with the largest deletion had the most severe and 
most complex phenotype. This notion prompted us to continue our search in patients with a 
specific well-described phenotype. To this end, we screened 54 patients with deficit schizophre-
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nia, a subtype that is characterised by enduring negative symptoms, and severe hallucinations 
and delusions. In these patients, we identified a total of ninety CNVs, 77 of which had been 
reported previously in unaffected control cohorts. Among the genes disrupted by the other 
rare CNVs were myelin transcription factor 1-like (MYT1L), catenin delta 2 (CTNND2), neurexin-1 
(NRXN1) and astrotactin-2 (ASTN2). All four genes play an important role in neuronal function­
ing, but -  except for NRXN1 -  have not been associated with schizophrenia before. The second 
phase of this study consisted of an analysis of the occurrence of CNV at these 4 loci in a larger 
cohort of 752 patients with a general schizophrenia diagnosis, and 706 normal controls. By 
doing so, we identified 8 additional CNVs of which the 4 that affected coding sequences were 
only found in the patient cohort. The results in Chapter 3 thus show that rare copy number 
variants play a significant role in schizophrenia development, and that an effective strategy 
to identify these variants is to first identify them in a small well-characterised patient cohort 
(discovery cohort), and to subsequently look for their occurrence in a larger cohorts.
It is clear that the approaches used in Chapter 2 and 3 do not resolve all cases of schizophrenia. 
Certain CNVs may be extremely rare or occur in a single family only. The latter was the case 
for a partial duplication of the RORa1 (retinoid-related orphan receptor alpha 1) gene that we 
identified in a patient with a complex phenotype comprising schizoaffective disorder, seizure 
disorder, mental retardation, and dysmorphic facial features (Chapter 4). We failed to detect 
this duplication in any of the other patient cohorts that we studied. However, we did identify 
the partial duplication in the patients' sister with schizophrenia and its mother with major 
depression. The three family members with the duplication were diagnosed differently accord­
ing to a standard psychiatric classification. Yet detailed magnetic resonance imaging (MRI) and 
positron emission technology (PET) analyses showed their underlying brain morphology to be 
clearly associated with the RORa1 duplication. Chapter 4 thus demonstrates the importance of 
detailed clinical and imaging analyses for the interpretation of rare CNVs.
A very pressing question - what is normal? -  has emerged from studies on patients with schizo­
phrenia. Several extensive studies have been performed on CNV in large cohorts of apparently 
healthy individuals, some of which we have used as controls for our studies on schizophrenia. 
Yet it remained unclear whether these individuals were truly healthy or, alternatively, were 
simply not diagnosed for a particular disease. Moreover, the effect of CNV on normal brain 
morphology in these individuals has remained elusive, thus further complicating the inter­
pretation of psychiatric effects. By participating in the Brain Imaging Genetics (BIG) project 
we got the opportunity to gain preliminary insight in the effect of rare CNVs on brain mor­
phology (Chapter 5). We obtained high-resolution CNV profiles as well as structural magnetic 
resonance imaging (sMRI) scans from 601 healthy, right-handed Caucasians between 18 and 35 
years of age. Individual t-tests for association between each of 9 regional brain volumes and 
CNV in 614 genomic regions revealed five regions with putative effects on whole brain, white 
and grey matter, globus pallidus, caudate nucleus, amygdala and hippocampus volumes. Most 
interesting were overlapping CNVs on chromosome ^ 1 3 .4 2  seen in 23 individuals, which may 
affect white and grey matter volumes; deletions occurred in individuals with lower white mat­
ter (and higher grey matter) volumes, while the reverse was true for duplications. These results 
provide a first indication that rare CNVs may affect brain morphology in healthy individuals, 
and indicate that this approach may be instrumental in unravelling the complex relation be­
tween CNVs and psychiatric disease.
Surprisingly, we also identified several regions that appeared to be dispensable in a normal hu­
man genome. The high-resolution microarrays that we used throughout this thesis allowed us 
to identify homozygous deletions, each corresponding to a complete DNA loss. In a sample of 
597 healthy Caucasian individuals we detected 2050 homozygous micro-deletions larger than 
10kb in size. Together, these micro-deletions encompass 90 distinct regions of homozygous
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deletions (HDRs), 58 of which were confirmed by PCR. The confirmed HDRs together represent 
2.8 Mb of human sequence whose complete loss is not accompanied by an overt phenotype. 
We also showed that most confirmed HDRs are relatively low in functional sequences, pre­
sumably because their removal causes little change in fitness. In addition, the HDRs showed 
significant reductions in conserved sequences and non-coding RNA loci, as well as a significant 
increase in pseudogenes, as compared to the overall human genome. The latter indicates that 
deletions constitute a mechanism for removing pseudogenes from the human genome. The 
number of protein-coding genes affected by HDRs on the other hand was not significantly 
lower compared to random genomic regions of similar size. Among the 36 protein-coding 
genes in HDRs were some with known and seemingly important functions, such as the LCE3 
cluster (implicated in psoriasis), ADAM3A (male murine infertility), and MGAM (digestion of 
malted dietary oligosaccharides). Chapter 6 thus provides an initial map of relatively large and 
validated HDRs in Caucasian genomes, thereby revealing a first glimpse on the evolutionary 
mechanisms that may act to retain and discard essential and non-essential regions of the hu­
man genome, respectively.
The first six chapters in this thesis -  as well as studies by others -  illustrate the fast develop­
ment in genomics technology, and the potential it may have for clinical practice. In fact, some 
of the findings by us and others have already found their way to the clinic. Yet most of the 
known genetic variants for schizophrenia meet neither validity nor utility requirements for di­
rect application in clinical practice. We used Chapter 7 to reflect on ongoing discussions about 
if, when and under what conditions results from large-scale schizophrenia genetics studies 
are relevant for clinical use. Based on a literature survey and in-depth interviews with experts, 
we explored the arguments used in these discussions. By doing so, we identified four differ­
ent lines of arguing stating that high-throughput studies on schizophrenia genetics will: (1) 
eventually reveal clinically relevant data; (2) not reveal clinically relevant data directly; (3) only 
reveal clinically relevant data when combined with non-genetic (environmental) factors; or (4) 
eventually be translated into a clinical setting, irrespective of clinical relevance. We observed 
that the experts' perception of the relevance of large-scale genetic data predominantly de­
pends on their conceptual framework of the relationship between genes and schizophrenia, 
which is also exemplified by discussions around direct-to-consumer (DTC) genetic tests. Fur­
thermore, the experts' conceptual framework determines their perception of ‘schizophrenia’ 
itself, which is partly reflected in recent discussions on the new edition of the Diagnostic and 
Statistical Manual of Mental Disorders (DSM-V). The challenges resulting from large scale ge­
netic research and the demand from consumers and patients for genetic testing, therefore, 
call for a solid infrastructural and translational strategy for schizophrenia genetic research.
To finish this thesis with a prospect for the future, we summarised and discussed our results 
in Chapter 8. In this closing chapter we also argue that schizophrenia diagnosis may benefit 
from application of CNV profiling as a diagnostic tool. Novel technologies -  predominantly 
next-generation sequencing -  offer further opportunities for improved diagnosis. And while 
DNA may still do whatever, with the help of advanced genomic technologies, an open mind 
to new developments, and a strong integration between research and clinical practice, we will 
eventually be able to reveal its secrets. This may significantly advance patient diagnosis, and 
may even provide possibilities for disease prevention.
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Samenvatting
Al meer dan honderd jaar bestudeert de genetica erfelijke variatie die ervoor zorgt dat de 
ene soort de andere niet is, het ene kenmerk het andere niet is, en de één gezond en de ander 
ziek is. Ontdekkingen van Darwin -  over de oorsprong van soorten -  en van Mendel -  de 
wetten van overerving -  hebben aan de basis gestaan van de moderne genetica. Genetisch 
onderzoek heeft veel geheimen rondom DNA onthuld, waarmee een wezenlijke bijdrage is 
geleverd aan toepassingen in de diagnose, preventie en behandeling van ziekten. Toch heeft 
het DNA ook nog veel geheimen, en roept iedere ontdekking weer nieuwe vragen op over de 
architectuur, de inhoud en de werking van ons DNA. Daarom opent dit proefschrift met de 
frase l'ADN fait n'importe quoi -  DNA doet van alles -  waarmee wordt aangegeven dat het 
DNA weliswaar complex en moeilijk te ontrafelen is, maar tegelijkertijd de potentie heeft om 
alles te kunnen.
De zoektocht naar de genetische achtergrond van schizofrenie die we beschrijven in dit 
proefschrift kenmerkt zich door een logische opeenvolging van wetenschappelijke studies.
De strategie binnen deze studies is gericht op het identificeren en interpreteren van genomi- 
sche deleties en duplicaties -  gezamenlijk copy number variation of CNV genoemd -  die een 
rol kunnen spelen bij schizofrenie.
De zoektocht begon met de identificatie van een hemizygote deletie in drie patiënten met 
verschillende complexe ziektebeelden, uiteenlopend van ernstige verstandelijke handicap 
met epileptische aanvallen tot een milde vorm van schizofrenie (Hoofdstuk 2). De deleties 
variëerden in lengte van 200kb tot 10,7Mb. In alle gevallen was het gen contactin associated 
protein-like 2 (CNTNAP2) op chromosoom 7q35 aangedaan. Dit gen was eerder gevonden als 
oorzaak van een syndromale vorm van focale epilepsie in de Old Order Amish gemeenschap. 
Wij hebben laten zien dat dit gen ook buiten deze gemeenschap is betrokken bij epilepsie. 
Daarnaast geven onze data aan dat dosisveranderingen in dit gen als gevolg van CNV kun-
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nen leiden tot een complex ziektebeeld dat schizofrenie, epilepsie en verstandelijke handicap 
omvat.
De patiënten met een deletie in CNTNAP2 vertoonden in het algemeen een breed spectrum 
van klinische kenmerken, resulterend in een complex fenotype. De patient met de kleinste 
deletie (22okb) vertoonde het minst complexe fenotype, terwijl die met de grootste deletie 
(10Mb) de meest ernsige en complexe kenmerken had. Gebaseerd op deze bevindingen 
hebben we onze zoektocht voortgezet in patiënten met een specifiek en goed gekarakteri­
seerd fenotype. We analyseerden 54 patiënten met deficit schizophrenia, een subtype dat 
gekenmerkt wordt door langdurige, negatieve symptomen, evenals ernstige hallucinaties 
en waanbeelden. We ontdekten negentig CNVs, waarvan er 77 eerder gevonden waren in 
gezonde personen. Onder de genen die betrokken waren bij de overige CNVs waren myelin 
transcription factor 1-like (MYTiL), catenin delta 2 (CTNND2), neurexin-1 (NRXNi) en astrotac- 
tin-2 (ASTN2). Deze vier genen spelen een belangrijke rol in het functioneren van de hersenen, 
maar zijn (behalve NRXNi) niet eerder met schizofrenie in verband gebracht. Vervolgens be­
studeerden we het DNA van een uitgebreid cohort van 752 andere patiënten en 706 gezonde 
personen op de aanwezigheid van CNV in deze specifieke genen. We vonden 8 additionele 
deleties en duplicaties, waarbij afwijkingen in de vier genoemde genen alleen bij patiënten 
voorkwamen. Uit de resultaten beschreven in Hoofdstuk 3 blijkt dus dat zeldzame CNVs een 
significante rol kunnen spelen bij de ontwikkeling van schizofrenie. Bovendien laten we zien 
dat het eerst genomisch profileren van een kleine, goed gekarakteriseerde patiënten cohort, 
en het vervolgens gericht screenen van een grotere populatie een effectieve strategie is om 
causatieve CNVs te vinden.
Hoofdstukken 2 en 3 laten bovendien zien dat de gebruikte strategie niet alle gevallen van 
schizofrenie verklaart. Soms is een deletie of duplicatie zo zeldzaam, of komt deze alleen 
voor dat hij slechts in één specifieke familie. Een voorbeeld hiervan is wordt gevonden. Dat 
was bijvoorbeeld het geval voor een gedeeltelijke duplicatie van het retinoid-related orphan 
receptor alpha 1 (RORai) gen die we in eerste instantie vonden in een patiënt met een com­
plex ziektebeeld, bestaande uit onder andere schizoaffectieve stoornis, epilepsie, verstande­
lijke handicap en faciale afwijkingen (Hoofdstuk 4). We vonden deze duplicatie in geen van 
de andere patiëntcohorten die we eerder bestudeerd hadden. We vonden de duplicatie echter 
wel in de zus en de moeder van de patiënt, die respectievelijk schizofrenie en zware depressie 
hadden. Hoewel de ziektebeelden niet geheel overeenkwamen, lieten gedetailleerde scans 
van magnetic resonance imaging (MRI) en positron emission technology (PET) zien dat hun 
hersenmorfologie duidelijk gerelateerd was aan de duplicatie in RORai. Hiermee leveren 
we niet alleen een extra argument voor de oorzakelijkheid van de duplicatie in RORai, maar 
laten we ook zien dat de functionele interpretatie verbeterd kan worden door gedetailleerde 
klinische analyses.
De eerste studies met patiënten met schizofrenie laten zien hoe complex de analyse en 
interpretatie van CNV is. Uit onze resultaten kwam een prangende vraag naar voren: wat is 
normaal? Meerdere studies hadden inmiddels het veelvuldig voorkomen van CNVs in ogen­
schijnlijk gezonde individuen aangetoond. Het blijft echter onduidelijk of deze individuen 
ook echt gezond zijn, of simpelweg niet als zodanig zijn gediagnosticeerd. Daarnaast is het 
effect van CNV op het brein volstrekt onbekend, wat op zijn beurt weer een weerslag heeft 
op de interpretatie van psychiatrische effecten. In kader van het Brain Imaging Genetics (BIG) 
project verzamelden wij MRI scans en hoge resolutie CNV en SNP-profielen van 601 gezonde, 
rechtshandige, West-Europese vrijwilligers in de leeftijd van 18 tot 35 jaar (Hoofdstuk 5). 
Middels individuele t-tests hebben we getracht een verband te vinden tussen ieder van de 
9 geanalyseerde hersenregio's en de aanwezigheid van CNV in specifieke chromosomale re­
gio's. Het meest in het oog springend was een CNV op chromosoom ^ 1 3 .4 2 ; individuen met
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een deletie in dit locus hadden een kleiner volume aan witte massa dan gemiddeld. Hoewel 
de bewijzen voor een link tussen CNV en hersenmorfologie gerepliceerd dienen te worden, 
geeft deze studie een eerste indicatie dat een dergelijke aanpak kan helpen bij het ontrafelen 
van de complexe relatie tussen het genoom en het brein.
Als onderdeel van de vraag wat normaal is waren we geïnteresseerd in het aantal en type 
regio's van het genoom die we geheel zouden kunnen missen zonder ernstige consequenties. 
De hoge resolutie microarrays die we gebruikt hebben voor bijna al het werk dat beschreven 
is in dit proefschrift maken dit mogelijk, door genoomwijde detectie van zogenaamde 
homozygote deleties die corresponderen met een volledig verlies van DNA. In 597 gezonde 
personen vonden we 2050 homozygote microdeleties groter dan 10kb. Deze microdeleties 
lagen in 90 verschillende overlappende chromosomale regio's, waarvan we er 58 hebben 
bevestigd met PCR. De bevestigde regio's vertegenwoordigen in totaal 2,8Mb aan genoom- 
sequentie welke bij verlies geen duidelijk fenotype oplevert. Deze regio's bevatten minder 
functionele en geconserveerde sequenties en meer pseudogenen dan gemiddeld over het 
genoom, hetgeen mogelijk het geringe fenotypische effect . Dit verklaart waarom verlies van 
deze regio's geen of weinig effect zal hebben op de algemene gezondheid. Toch zijn er onder 
de 36 coderende genen wel een aantal met een duidelijke functie, zoals het LCE3 cluster (in 
verband gebracht met psioriasis), ADAM3 (mannelijke vruchtbaarheid) en MGAM (vertering 
van mout). Hoofdstuk 6 laat dus een initiële kaart zien van relatief grote en gevalideerde 
regio's met homozygote deleties, hetgeen een eerste blik werpt op mogelijke evolution­
aire strategieën voor het behoud en verlies van essentiële en niet-essentiële regio's in het 
humane genoom.
De eerste zes hoofdstukken van dit proefschrift leverden resultaten op die een bijdrage heb­
ben geleverd aan de wetenschappelijke kennis over de genetische achtergrond van schizof­
renie. Om de relevantie van deze resultaten -  en van resultaten van grootschalig genetisch 
onderzoek in het algemeen -  te plaatsen in de context van klinische relevantie, hebben we 
ons in hoofdstuk 7 de vraag gesteld of dergelijke resultaten een wezenlijke bijdrage kunnen 
leveren aan de klinische praktijk. We hebben deze vraag voorgelegd aan vier experts, die ieder 
antwoordden vanuit hun eigen expertise en medische wetenschappelijke achtergrond (con­
ceptuele kader). De perceptie van de experts over de relevantie van grootschalige genetische 
studies voor de klinische praktijk -  in het bijzonder voor de diagnose van schizofrenie -  hangt 
in grote mate samen met hun visie op de relatie tussen genen en het ontstaan van schizof­
renie. Daarnaast bepaalt het conceptuele kader ook hoe de experts 'schizofrenie' zelf zien, 
wat onder meer tot uitdrukking komt in de discussie rondom de nieuwe (vijfde) editie van de 
Diagnostic and Statistic Manual on Mental Disorders (DSM-V). Met een toenemende rol van 
de genetica in de gezondheidszorg en de toenemende vraag naar genetische testen is het 
van groot belang een solide infrastructuur te ontwikkelen voor de toepassing van genetica in 
de diagnose en behandeling van schizofrenie.
Om dit proefschrift te besluiten met een blik naar de toekomst pleiten we in het laatste 
hoofdstuk -  na een korte samenvatting en discussie van de resultaten -  voor toepassing van 
genoomwijde CNV profilering in de diagnostiek van schizofrenie. Nieuwe technologieën 
-  met name next-generation sequencing -  bieden grote mogelijkheden voor verbeterde 
diagnose. En hoewel het DNA nog steeds doet wat het wil, zullen we met behulp van nieuwe 
technologie, een open houding ten opzichte van nieuwe ontwikkelingen en sterke integratie 
van onderzoek en kliniek, zijn geheimen uiteindelijk kunnen onthullen. Dit kan op de lange 
termijn leiden tot verbeterde, op de patiënt afgestemde behandeling en waar mogelijk 
preventie.
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• Rare copy number variants and their effect on schizophrenia - taking the genome out of the brain •

